#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Time‐dependent neuronal changes associated with craving in opioid dependence: an fMRI study
#Text=Abstract
#Text=Relapse after initially successful treatment is a significant problem facing the treatment of opioid dependence.
1-1	0-14	Time‐dependent	_	
1-2	15-23	neuronal	_	
1-3	24-31	changes	_	
1-4	32-42	associated	_	
1-5	43-47	with	_	
1-6	48-55	craving	_	
1-7	56-58	in	_	
1-8	59-65	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-9	66-76	dependence	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[1]	
1-10	76-77	:	_	
1-11	78-80	an	_	
1-12	81-85	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
1-13	86-91	study	_	
1-14	92-100	Abstract	_	
1-15	101-108	Relapse	_	
1-16	109-114	after	_	
1-17	115-124	initially	_	
1-18	125-135	successful	_	
1-19	136-145	treatment	_	
1-20	146-148	is	_	
1-21	149-150	a	_	
1-22	151-162	significant	_	
1-23	163-170	problem	_	
1-24	171-177	facing	_	
1-25	178-181	the	_	
1-26	182-191	treatment	_	
1-27	192-194	of	_	
1-28	195-201	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[2]	
1-29	202-212	dependence	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[2]	
1-30	212-213	.	_	

#Text=Evidence suggests craving elicited by re‐exposure to drug cues may precipitate relapse.
2-1	214-222	Evidence	_	
2-2	223-231	suggests	_	
2-3	232-239	craving	_	
2-4	240-248	elicited	_	
2-5	249-251	by	_	
2-6	252-263	re‐exposure	_	
2-7	264-266	to	_	
2-8	267-271	drug	_	
2-9	272-276	cues	_	
2-10	277-280	may	_	
2-11	281-292	precipitate	_	
2-12	293-300	relapse	_	
2-13	300-301	.	_	

#Text=Attempts to identify neural biomarkers of cue‐elicited craving have yielded inconsistent findings.
3-1	302-310	Attempts	_	
3-2	311-313	to	_	
3-3	314-322	identify	_	
3-4	323-329	neural	_	
3-5	330-340	biomarkers	_	
3-6	341-343	of	_	
3-7	344-356	cue‐elicited	_	
3-8	357-364	craving	_	
3-9	365-369	have	_	
3-10	370-377	yielded	_	
3-11	378-390	inconsistent	_	
3-12	391-399	findings	_	
3-13	399-400	.	_	

#Text=We aimed to apply a novel continuous functional magnetic resonance imaging technique to follow the minute‐to‐minute evolution of brain responses, which correlate with the waxing and waning of craving.
4-1	401-403	We	_	
4-2	404-409	aimed	_	
4-3	410-412	to	_	
4-4	413-418	apply	_	
4-5	419-420	a	_	
4-6	421-426	novel	_	
4-7	427-437	continuous	_	
4-8	438-448	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-9	449-457	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-10	458-467	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-11	468-475	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-12	476-485	technique	_	
4-13	486-488	to	_	
4-14	489-495	follow	_	
4-15	496-499	the	_	
4-16	500-516	minute‐to‐minute	_	
4-17	517-526	evolution	_	
4-18	527-529	of	_	
4-19	530-535	brain	_	
4-20	536-545	responses	_	
4-21	545-546	,	_	
4-22	547-552	which	_	
4-23	553-562	correlate	_	
4-24	563-567	with	_	
4-25	568-571	the	_	
4-26	572-578	waxing	_	
4-27	579-582	and	_	
4-28	583-589	waning	_	
4-29	590-592	of	_	
4-30	593-600	craving	_	
4-31	600-601	.	_	

#Text=Newly detoxified male opioid‐dependent patients and healthy control participants attended two separate, counterbalanced, functional magnetic resonance imaging scanning sessions during which they viewed a 10‐minute video (drug cue or neutral cue) followed by 5 minutes of fixation.
5-1	602-607	Newly	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
5-2	608-618	detoxified	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
5-3	619-623	male	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
5-4	624-640	opioid‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
5-5	641-649	patients	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[4]	
5-6	650-653	and	_	
5-7	654-661	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-8	662-669	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-9	670-682	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-10	683-691	attended	_	
5-11	692-695	two	_	
5-12	696-704	separate	_	
5-13	704-705	,	_	
5-14	706-721	counterbalanced	_	
5-15	721-722	,	_	
5-16	723-733	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
5-17	734-742	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
5-18	743-752	resonance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
5-19	753-760	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
5-20	761-769	scanning	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-21	770-778	sessions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-22	779-785	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-23	786-791	which	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-24	792-796	they	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-25	797-803	viewed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-26	804-805	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-27	806-808	10	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-28	808-809	‐	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-29	809-815	minute	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-30	816-821	video	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-31	822-823	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-32	823-827	drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-33	828-831	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-34	832-834	or	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-35	835-842	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-36	843-846	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-37	846-847	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-38	848-856	followed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-39	857-859	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-40	860-861	5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-41	861-862	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-42	862-869	minutes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-43	870-872	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-44	873-881	fixation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
5-45	881-882	.	_	

#Text=Participants rated the intensity of their craving throughout each session.
6-1	883-895	Participants	_	
6-2	896-901	rated	_	
6-3	902-905	the	_	
6-4	906-915	intensity	_	
6-5	916-918	of	_	
6-6	919-924	their	_	
6-7	925-932	craving	_	
6-8	933-943	throughout	_	
6-9	944-948	each	_	
6-10	949-956	session	_	
6-11	956-957	.	_	

#Text=We hypothesized that subcortical/ventral prefrontal cortex (PFC) regions and dorsal PFC regions would show different associations with craving reflecting their putative roles in appetitive processing versus cognitive control.
7-1	958-960	We	_	
7-2	961-973	hypothesized	_	
7-3	974-978	that	_	
7-4	979-990	subcortical	_	
7-5	990-991	/	_	
7-6	991-998	ventral	_	
7-7	999-1009	prefrontal	_	
7-8	1010-1016	cortex	_	
7-9	1017-1018	(	_	
7-10	1018-1021	PFC	_	
7-11	1021-1022	)	_	
7-12	1023-1030	regions	_	
7-13	1031-1034	and	_	
7-14	1035-1041	dorsal	_	
7-15	1042-1045	PFC	_	
7-16	1046-1053	regions	_	
7-17	1054-1059	would	_	
7-18	1060-1064	show	_	
7-19	1065-1074	different	_	
7-20	1075-1087	associations	_	
7-21	1088-1092	with	_	
7-22	1093-1100	craving	_	
7-23	1101-1111	reflecting	_	
7-24	1112-1117	their	_	
7-25	1118-1126	putative	_	
7-26	1127-1132	roles	_	
7-27	1133-1135	in	_	
7-28	1136-1146	appetitive	_	
7-29	1147-1157	processing	_	
7-30	1158-1164	versus	_	
7-31	1165-1174	cognitive	_	
7-32	1175-1182	control	_	
7-33	1182-1183	.	_	

#Text=Compared with controls, drug cue (minus neutral cue) video recruited the left amygdala and was temporally correlated with craving.
8-1	1184-1192	Compared	_	
8-2	1193-1197	with	_	
8-3	1198-1206	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
8-4	1206-1207	,	_	
8-5	1208-1212	drug	_	
8-6	1213-1216	cue	_	
8-7	1217-1218	(	_	
8-8	1218-1223	minus	_	
8-9	1224-1231	neutral	_	
8-10	1232-1235	cue	_	
8-11	1235-1236	)	_	
8-12	1237-1242	video	_	
8-13	1243-1252	recruited	_	
8-14	1253-1256	the	_	
8-15	1257-1261	left	_	
8-16	1262-1270	amygdala	_	
8-17	1271-1274	and	_	
8-18	1275-1278	was	_	
8-19	1279-1289	temporally	_	
8-20	1290-1300	correlated	_	
8-21	1301-1305	with	_	
8-22	1306-1313	craving	_	
8-23	1313-1314	.	_	

#Text=In contrast, dorsal anterior cingulate blood‐oxygen‐level‐dependent signal time course was higher than controls only during a period after cue exposure when craving levels were declining.
9-1	1315-1317	In	_	
9-2	1318-1326	contrast	_	
9-3	1326-1327	,	_	
9-4	1328-1334	dorsal	_	
9-5	1335-1343	anterior	_	
9-6	1344-1353	cingulate	_	
9-7	1354-1382	blood‐oxygen‐level‐dependent	_	
9-8	1383-1389	signal	_	
9-9	1390-1394	time	_	
9-10	1395-1401	course	_	
9-11	1402-1405	was	_	
9-12	1406-1412	higher	_	
9-13	1413-1417	than	_	
9-14	1418-1426	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-15	1427-1431	only	_	
9-16	1432-1438	during	_	
9-17	1439-1440	a	_	
9-18	1441-1447	period	_	
9-19	1448-1453	after	_	
9-20	1454-1457	cue	_	
9-21	1458-1466	exposure	_	
9-22	1467-1471	when	_	
9-23	1472-1479	craving	_	
9-24	1480-1486	levels	_	
9-25	1487-1491	were	_	
9-26	1492-1501	declining	_	
9-27	1501-1502	.	_	

#Text=Against expectations, neither the ventral striatum nor ventral PFC was significantly recruited by drug cue exposure.
10-1	1503-1510	Against	_	
10-2	1511-1523	expectations	_	
10-3	1523-1524	,	_	
10-4	1525-1532	neither	_	
10-5	1533-1536	the	_	
10-6	1537-1544	ventral	_	
10-7	1545-1553	striatum	_	
10-8	1554-1557	nor	_	
10-9	1558-1565	ventral	_	
10-10	1566-1569	PFC	_	
10-11	1570-1573	was	_	
10-12	1574-1587	significantly	_	
10-13	1588-1597	recruited	_	
10-14	1598-1600	by	_	
10-15	1601-1605	drug	_	
10-16	1606-1609	cue	_	
10-17	1610-1618	exposure	_	
10-18	1618-1619	.	_	

#Text=Findings suggest that the amygdala has a central role in craving, whereas the dorsal anterior cingulate may control craving in treatment‐seeking patients.
11-1	1620-1628	Findings	_	
11-2	1629-1636	suggest	_	
11-3	1637-1641	that	_	
11-4	1642-1645	the	_	
11-5	1646-1654	amygdala	_	
11-6	1655-1658	has	_	
11-7	1659-1660	a	_	
11-8	1661-1668	central	_	
11-9	1669-1673	role	_	
11-10	1674-1676	in	_	
11-11	1677-1684	craving	_	
11-12	1684-1685	,	_	
11-13	1686-1693	whereas	_	
11-14	1694-1697	the	_	
11-15	1698-1704	dorsal	_	
11-16	1705-1713	anterior	_	
11-17	1714-1723	cingulate	_	
11-18	1724-1727	may	_	
11-19	1728-1735	control	_	
11-20	1736-1743	craving	_	
11-21	1744-1746	in	_	
11-22	1747-1764	treatment‐seeking	_	
11-23	1765-1773	patients	_	
11-24	1773-1774	.	_	

#Text=Time course analysis yielded new insights into the neural substrates of craving that could objectively validate development of psychological and pharmacological approaches to sustained abstinence.
12-1	1775-1779	Time	_	
12-2	1780-1786	course	_	
12-3	1787-1795	analysis	_	
12-4	1796-1803	yielded	_	
12-5	1804-1807	new	_	
12-6	1808-1816	insights	_	
12-7	1817-1821	into	_	
12-8	1822-1825	the	_	
12-9	1826-1832	neural	_	
12-10	1833-1843	substrates	_	
12-11	1844-1846	of	_	
12-12	1847-1854	craving	_	
12-13	1855-1859	that	_	
12-14	1860-1865	could	_	
12-15	1866-1877	objectively	_	
12-16	1878-1886	validate	_	
12-17	1887-1898	development	_	
12-18	1899-1901	of	_	
12-19	1902-1915	psychological	_	
12-20	1916-1919	and	_	
12-21	1920-1935	pharmacological	_	
12-22	1936-1946	approaches	_	
12-23	1947-1949	to	_	
12-24	1950-1959	sustained	_	
12-25	1960-1970	abstinence	_	
12-26	1970-1971	.	_	

#Text=Introduction
#Text=Neural and psychological responses to stimuli or contexts previously associated with drug reward (i.e. drug cues) play a significant role in drug dependence (Lubman, Yucel, & Pantelis 2004; Epstein et al. 2009).
13-1	1972-1984	Introduction	_	
13-2	1985-1991	Neural	_	
13-3	1992-1995	and	_	
13-4	1996-2009	psychological	_	
13-5	2010-2019	responses	_	
13-6	2020-2022	to	_	
13-7	2023-2030	stimuli	_	
13-8	2031-2033	or	_	
13-9	2034-2042	contexts	_	
13-10	2043-2053	previously	_	
13-11	2054-2064	associated	_	
13-12	2065-2069	with	_	
13-13	2070-2074	drug	_	
13-14	2075-2081	reward	_	
13-15	2082-2083	(	_	
13-16	2083-2086	i.e	_	
13-17	2086-2087	.	_	
13-18	2088-2092	drug	_	
13-19	2093-2097	cues	_	
13-20	2097-2098	)	_	
13-21	2099-2103	play	_	
13-22	2104-2105	a	_	
13-23	2106-2117	significant	_	
13-24	2118-2122	role	_	
13-25	2123-2125	in	_	
13-26	2126-2130	drug	_	
13-27	2131-2141	dependence	_	
13-28	2142-2143	(	_	
13-29	2143-2149	Lubman	_	
13-30	2149-2150	,	_	
13-31	2151-2156	Yucel	_	
13-32	2156-2157	,	_	
13-33	2158-2159	&	_	
13-34	2160-2168	Pantelis	_	
13-35	2169-2173	2004	_	
13-36	2173-2174	;	_	
13-37	2175-2182	Epstein	_	
13-38	2183-2185	et	_	
13-39	2186-2188	al	_	
13-40	2188-2189	.	_	
13-41	2190-2194	2009	_	
13-42	2194-2195	)	_	
13-43	2195-2196	.	_	

#Text=Conditioning mechanisms increase the incentive value of these cues, creating powerful secondary reinforcers that can capture attention and elicit craving (Tiffany & Wray 2012), and contribute to further drug seeking and drug taking.
14-1	2197-2209	Conditioning	_	
14-2	2210-2220	mechanisms	_	
14-3	2221-2229	increase	_	
14-4	2230-2233	the	_	
14-5	2234-2243	incentive	_	
14-6	2244-2249	value	_	
14-7	2250-2252	of	_	
14-8	2253-2258	these	_	
14-9	2259-2263	cues	_	
14-10	2263-2264	,	_	
14-11	2265-2273	creating	_	
14-12	2274-2282	powerful	_	
14-13	2283-2292	secondary	_	
14-14	2293-2304	reinforcers	_	
14-15	2305-2309	that	_	
14-16	2310-2313	can	_	
14-17	2314-2321	capture	_	
14-18	2322-2331	attention	_	
14-19	2332-2335	and	_	
14-20	2336-2342	elicit	_	
14-21	2343-2350	craving	_	
14-22	2351-2352	(	_	
14-23	2352-2359	Tiffany	_	
14-24	2360-2361	&	_	
14-25	2362-2366	Wray	_	
14-26	2367-2371	2012	_	
14-27	2371-2372	)	_	
14-28	2372-2373	,	_	
14-29	2374-2377	and	_	
14-30	2378-2388	contribute	_	
14-31	2389-2391	to	_	
14-32	2392-2399	further	_	
14-33	2400-2404	drug	_	
14-34	2405-2412	seeking	_	
14-35	2413-2416	and	_	
14-36	2417-2421	drug	_	
14-37	2422-2428	taking	_	
14-38	2428-2429	.	_	

#Text=Consistent with this notion, several studies have reported that craving measured before or during treatment can predict subsequent relapse (Weiss et al. 2003; McHugh et al. 2014), whilst ‘real‐time’ craving and cue exposure have been shown to immediately precede relapse and drug use (Epstein et al. 2009; Moore et al. 2014; Fatseas et al. 2015).
15-1	2430-2440	Consistent	_	
15-2	2441-2445	with	_	
15-3	2446-2450	this	_	
15-4	2451-2457	notion	_	
15-5	2457-2458	,	_	
15-6	2459-2466	several	_	
15-7	2467-2474	studies	_	
15-8	2475-2479	have	_	
15-9	2480-2488	reported	_	
15-10	2489-2493	that	_	
15-11	2494-2501	craving	_	
15-12	2502-2510	measured	_	
15-13	2511-2517	before	_	
15-14	2518-2520	or	_	
15-15	2521-2527	during	_	
15-16	2528-2537	treatment	_	
15-17	2538-2541	can	_	
15-18	2542-2549	predict	_	
15-19	2550-2560	subsequent	_	
15-20	2561-2568	relapse	_	
15-21	2569-2570	(	_	
15-22	2570-2575	Weiss	_	
15-23	2576-2578	et	_	
15-24	2579-2581	al	_	
15-25	2581-2582	.	_	
15-26	2583-2587	2003	_	
15-27	2587-2588	;	_	
15-28	2589-2595	McHugh	_	
15-29	2596-2598	et	_	
15-30	2599-2601	al	_	
15-31	2601-2602	.	_	
15-32	2603-2607	2014	_	
15-33	2607-2608	)	_	
15-34	2608-2609	,	_	
15-35	2610-2616	whilst	_	
15-36	2617-2618	‘	_	
15-37	2618-2627	real‐time	_	
15-38	2627-2628	’	_	
15-39	2629-2636	craving	_	
15-40	2637-2640	and	_	
15-41	2641-2644	cue	_	
15-42	2645-2653	exposure	_	
15-43	2654-2658	have	_	
15-44	2659-2663	been	_	
15-45	2664-2669	shown	_	
15-46	2670-2672	to	_	
15-47	2673-2684	immediately	_	
15-48	2685-2692	precede	_	
15-49	2693-2700	relapse	_	
15-50	2701-2704	and	_	
15-51	2705-2709	drug	_	
15-52	2710-2713	use	_	
15-53	2714-2715	(	_	
15-54	2715-2722	Epstein	_	
15-55	2723-2725	et	_	
15-56	2726-2728	al	_	
15-57	2728-2729	.	_	
15-58	2730-2734	2009	_	
15-59	2734-2735	;	_	
15-60	2736-2741	Moore	_	
15-61	2742-2744	et	_	
15-62	2745-2747	al	_	
15-63	2747-2748	.	_	
15-64	2749-2753	2014	_	
15-65	2753-2754	;	_	
15-66	2755-2762	Fatseas	_	
15-67	2763-2765	et	_	
15-68	2766-2768	al	_	
15-69	2768-2769	.	_	
15-70	2770-2774	2015	_	
15-71	2774-2775	)	_	
15-72	2775-2776	.	_	

#Text=Functional magnetic resonance imaging (fMRI) studies have attempted to identify brain systems that mediate cue‐elicited craving (Zijlstra et al. 2009; Li et al. 2012; Jasinska et al. 2014).
16-1	2777-2787	Functional	_	
16-2	2788-2796	magnetic	_	
16-3	2797-2806	resonance	_	
16-4	2807-2814	imaging	_	
16-5	2815-2816	(	_	
16-6	2816-2820	fMRI	_	
16-7	2820-2821	)	_	
16-8	2822-2829	studies	_	
16-9	2830-2834	have	_	
16-10	2835-2844	attempted	_	
16-11	2845-2847	to	_	
16-12	2848-2856	identify	_	
16-13	2857-2862	brain	_	
16-14	2863-2870	systems	_	
16-15	2871-2875	that	_	
16-16	2876-2883	mediate	_	
16-17	2884-2896	cue‐elicited	_	
16-18	2897-2904	craving	_	
16-19	2905-2906	(	_	
16-20	2906-2914	Zijlstra	_	
16-21	2915-2917	et	_	
16-22	2918-2920	al	_	
16-23	2920-2921	.	_	
16-24	2922-2926	2009	_	
16-25	2926-2927	;	_	
16-26	2928-2930	Li	_	
16-27	2931-2933	et	_	
16-28	2934-2936	al	_	
16-29	2936-2937	.	_	
16-30	2938-2942	2012	_	
16-31	2942-2943	;	_	
16-32	2944-2952	Jasinska	_	
16-33	2953-2955	et	_	
16-34	2956-2958	al	_	
16-35	2958-2959	.	_	
16-36	2960-2964	2014	_	
16-37	2964-2965	)	_	
16-38	2965-2966	.	_	

#Text=Two recent meta‐analyses of these studies (Chase et al. 2011; Kuhn & Gallinat 2011) report reliable activation to drug cues within regions including the amygdala and ventral striatum, which are important for processing reward‐related stimuli and motivation (Haber & Knutson 2010), and medial prefrontal regions.
17-1	2967-2970	Two	_	
17-2	2971-2977	recent	_	
17-3	2978-2991	meta‐analyses	_	
17-4	2992-2994	of	_	
17-5	2995-3000	these	_	
17-6	3001-3008	studies	_	
17-7	3009-3010	(	_	
17-8	3010-3015	Chase	_	
17-9	3016-3018	et	_	
17-10	3019-3021	al	_	
17-11	3021-3022	.	_	
17-12	3023-3027	2011	_	
17-13	3027-3028	;	_	
17-14	3029-3033	Kuhn	_	
17-15	3034-3035	&	_	
17-16	3036-3044	Gallinat	_	
17-17	3045-3049	2011	_	
17-18	3049-3050	)	_	
17-19	3051-3057	report	_	
17-20	3058-3066	reliable	_	
17-21	3067-3077	activation	_	
17-22	3078-3080	to	_	
17-23	3081-3085	drug	_	
17-24	3086-3090	cues	_	
17-25	3091-3097	within	_	
17-26	3098-3105	regions	_	
17-27	3106-3115	including	_	
17-28	3116-3119	the	_	
17-29	3120-3128	amygdala	_	
17-30	3129-3132	and	_	
17-31	3133-3140	ventral	_	
17-32	3141-3149	striatum	_	
17-33	3149-3150	,	_	
17-34	3151-3156	which	_	
17-35	3157-3160	are	_	
17-36	3161-3170	important	_	
17-37	3171-3174	for	_	
17-38	3175-3185	processing	_	
17-39	3186-3200	reward‐related	_	
17-40	3201-3208	stimuli	_	
17-41	3209-3212	and	_	
17-42	3213-3223	motivation	_	
17-43	3224-3225	(	_	
17-44	3225-3230	Haber	_	
17-45	3231-3232	&	_	
17-46	3233-3240	Knutson	_	
17-47	3241-3245	2010	_	
17-48	3245-3246	)	_	
17-49	3246-3247	,	_	
17-50	3248-3251	and	_	
17-51	3252-3258	medial	_	
17-52	3259-3269	prefrontal	_	
17-53	3270-3277	regions	_	
17-54	3277-3278	.	_	

#Text=These include the ventral medial prefrontal cortex (VmPFC) (Chase et al. 2011), which is involved in the representation of reward value and reward‐related decision making (Elliott, Agnew, & Deakin 2008; Grabenhorst & Rolls 2011), and the anterior cingulate cortex (Kuhn & Gallinat 2011), which is important for reward and error‐related behavioural and cognitive control (Shenhav, Botvinick, & Cohen 2013).
18-1	3279-3284	These	_	
18-2	3285-3292	include	_	
18-3	3293-3296	the	_	
18-4	3297-3304	ventral	_	
18-5	3305-3311	medial	_	
18-6	3312-3322	prefrontal	_	
18-7	3323-3329	cortex	_	
18-8	3330-3331	(	_	
18-9	3331-3336	VmPFC	_	
18-10	3336-3337	)	_	
18-11	3338-3339	(	_	
18-12	3339-3344	Chase	_	
18-13	3345-3347	et	_	
18-14	3348-3350	al	_	
18-15	3350-3351	.	_	
18-16	3352-3356	2011	_	
18-17	3356-3357	)	_	
18-18	3357-3358	,	_	
18-19	3359-3364	which	_	
18-20	3365-3367	is	_	
18-21	3368-3376	involved	_	
18-22	3377-3379	in	_	
18-23	3380-3383	the	_	
18-24	3384-3398	representation	_	
18-25	3399-3401	of	_	
18-26	3402-3408	reward	_	
18-27	3409-3414	value	_	
18-28	3415-3418	and	_	
18-29	3419-3433	reward‐related	_	
18-30	3434-3442	decision	_	
18-31	3443-3449	making	_	
18-32	3450-3451	(	_	
18-33	3451-3458	Elliott	_	
18-34	3458-3459	,	_	
18-35	3460-3465	Agnew	_	
18-36	3465-3466	,	_	
18-37	3467-3468	&	_	
18-38	3469-3475	Deakin	_	
18-39	3476-3480	2008	_	
18-40	3480-3481	;	_	
18-41	3482-3493	Grabenhorst	_	
18-42	3494-3495	&	_	
18-43	3496-3501	Rolls	_	
18-44	3502-3506	2011	_	
18-45	3506-3507	)	_	
18-46	3507-3508	,	_	
18-47	3509-3512	and	_	
18-48	3513-3516	the	_	
18-49	3517-3525	anterior	_	
18-50	3526-3535	cingulate	_	
18-51	3536-3542	cortex	_	
18-52	3543-3544	(	_	
18-53	3544-3548	Kuhn	_	
18-54	3549-3550	&	_	
18-55	3551-3559	Gallinat	_	
18-56	3560-3564	2011	_	
18-57	3564-3565	)	_	
18-58	3565-3566	,	_	
18-59	3567-3572	which	_	
18-60	3573-3575	is	_	
18-61	3576-3585	important	_	
18-62	3586-3589	for	_	
18-63	3590-3596	reward	_	
18-64	3597-3600	and	_	
18-65	3601-3614	error‐related	_	
18-66	3615-3626	behavioural	_	
18-67	3627-3630	and	_	
18-68	3631-3640	cognitive	_	
18-69	3641-3648	control	_	
18-70	3649-3650	(	_	
18-71	3650-3657	Shenhav	_	
18-72	3657-3658	,	_	
18-73	3659-3668	Botvinick	_	
18-74	3668-3669	,	_	
18-75	3670-3671	&	_	
18-76	3672-3677	Cohen	_	
18-77	3678-3682	2013	_	
18-78	3682-3683	)	_	
18-79	3683-3684	.	_	

#Text=Although there are some consistencies in the regions that are activated by drug cues, there is little evidence that any reliably correlate with craving (Tiffany & Wray 2012).
19-1	3685-3693	Although	_	
19-2	3694-3699	there	_	
19-3	3700-3703	are	_	
19-4	3704-3708	some	_	
19-5	3709-3722	consistencies	_	
19-6	3723-3725	in	_	
19-7	3726-3729	the	_	
19-8	3730-3737	regions	_	
19-9	3738-3742	that	_	
19-10	3743-3746	are	_	
19-11	3747-3756	activated	_	
19-12	3757-3759	by	_	
19-13	3760-3764	drug	_	
19-14	3765-3769	cues	_	
19-15	3769-3770	,	_	
19-16	3771-3776	there	_	
19-17	3777-3779	is	_	
19-18	3780-3786	little	_	
19-19	3787-3795	evidence	_	
19-20	3796-3800	that	_	
19-21	3801-3804	any	_	
19-22	3805-3813	reliably	_	
19-23	3814-3823	correlate	_	
19-24	3824-3828	with	_	
19-25	3829-3836	craving	_	
19-26	3837-3838	(	_	
19-27	3838-3845	Tiffany	_	
19-28	3846-3847	&	_	
19-29	3848-3852	Wray	_	
19-30	3853-3857	2012	_	
19-31	3857-3858	)	_	
19-32	3858-3859	.	_	

#Text=This suggests the typical design of cue‐elicited craving studies, that measure brief presentations of drug‐related images interspersed with neutral control images, identify immediate brain responses to drug cues, rather than craving per se.
20-1	3860-3864	This	_	
20-2	3865-3873	suggests	_	
20-3	3874-3877	the	_	
20-4	3878-3885	typical	_	
20-5	3886-3892	design	_	
20-6	3893-3895	of	_	
20-7	3896-3908	cue‐elicited	_	
20-8	3909-3916	craving	_	
20-9	3917-3924	studies	_	
20-10	3924-3925	,	_	
20-11	3926-3930	that	_	
20-12	3931-3938	measure	_	
20-13	3939-3944	brief	_	
20-14	3945-3958	presentations	_	
20-15	3959-3961	of	_	
20-16	3962-3974	drug‐related	_	
20-17	3975-3981	images	_	
20-18	3982-3994	interspersed	_	
20-19	3995-3999	with	_	
20-20	4000-4007	neutral	_	
20-21	4008-4015	control	_	
20-22	4016-4022	images	_	
20-23	4022-4023	,	_	
20-24	4024-4032	identify	_	
20-25	4033-4042	immediate	_	
20-26	4043-4048	brain	_	
20-27	4049-4058	responses	_	
20-28	4059-4061	to	_	
20-29	4062-4066	drug	_	
20-30	4067-4071	cues	_	
20-31	4071-4072	,	_	
20-32	4073-4079	rather	_	
20-33	4080-4084	than	_	
20-34	4085-4092	craving	_	
20-35	4093-4096	per	_	
20-36	4097-4099	se	_	
20-37	4099-4100	.	_	

#Text=Video imagery of drug‐related activities provides contextually richer and more realistic cues that better model real‐world exposure and elicit strong craving responses (Childress et al. 1999; Tong, Bovbjerg, & Erblich 2007).
21-1	4101-4106	Video	_	
21-2	4107-4114	imagery	_	
21-3	4115-4117	of	_	
21-4	4118-4130	drug‐related	_	
21-5	4131-4141	activities	_	
21-6	4142-4150	provides	_	
21-7	4151-4163	contextually	_	
21-8	4164-4170	richer	_	
21-9	4171-4174	and	_	
21-10	4175-4179	more	_	
21-11	4180-4189	realistic	_	
21-12	4190-4194	cues	_	
21-13	4195-4199	that	_	
21-14	4200-4206	better	_	
21-15	4207-4212	model	_	
21-16	4213-4223	real‐world	_	
21-17	4224-4232	exposure	_	
21-18	4233-4236	and	_	
21-19	4237-4243	elicit	_	
21-20	4244-4250	strong	_	
21-21	4251-4258	craving	_	
21-22	4259-4268	responses	_	
21-23	4269-4270	(	_	
21-24	4270-4279	Childress	_	
21-25	4280-4282	et	_	
21-26	4283-4285	al	_	
21-27	4285-4286	.	_	
21-28	4287-4291	1999	_	
21-29	4291-4292	;	_	
21-30	4293-4297	Tong	_	
21-31	4297-4298	,	_	
21-32	4299-4307	Bovbjerg	_	
21-33	4307-4308	,	_	
21-34	4309-4310	&	_	
21-35	4311-4318	Erblich	_	
21-36	4319-4323	2007	_	
21-37	4323-4324	)	_	
21-38	4324-4325	.	_	

#Text=Videos have been extensively used to follow psychophysiological responses to craving although this has been limited to box‐car on‐off fMRI designs through the lack of techniques or tradition for following blood‐oxygen‐level‐dependent (BOLD) responses over minutes.
22-1	4326-4332	Videos	_	
22-2	4333-4337	have	_	
22-3	4338-4342	been	_	
22-4	4343-4354	extensively	_	
22-5	4355-4359	used	_	
22-6	4360-4362	to	_	
22-7	4363-4369	follow	_	
22-8	4370-4389	psychophysiological	_	
22-9	4390-4399	responses	_	
22-10	4400-4402	to	_	
22-11	4403-4410	craving	_	
22-12	4411-4419	although	_	
22-13	4420-4424	this	_	
22-14	4425-4428	has	_	
22-15	4429-4433	been	_	
22-16	4434-4441	limited	_	
22-17	4442-4444	to	_	
22-18	4445-4452	box‐car	_	
22-19	4453-4459	on‐off	_	
22-20	4460-4464	fMRI	_	
22-21	4465-4472	designs	_	
22-22	4473-4480	through	_	
22-23	4481-4484	the	_	
22-24	4485-4489	lack	_	
22-25	4490-4492	of	_	
22-26	4493-4503	techniques	_	
22-27	4504-4506	or	_	
22-28	4507-4516	tradition	_	
22-29	4517-4520	for	_	
22-30	4521-4530	following	_	
22-31	4531-4559	blood‐oxygen‐level‐dependent	_	
22-32	4560-4561	(	_	
22-33	4561-4565	BOLD	_	
22-34	4565-4566	)	_	
22-35	4567-4576	responses	_	
22-36	4577-4581	over	_	
22-37	4582-4589	minutes	_	
22-38	4589-4590	.	_	

#Text=We borrowed pharmaco‐MRI methods developed to follow and localize the action of drugs on the CNS, to follow the effect of sustained craving elicited by video cues, in hypothesized regions of interest.
23-1	4591-4593	We	_	
23-2	4594-4602	borrowed	_	
23-3	4603-4615	pharmaco‐MRI	_	
23-4	4616-4623	methods	_	
23-5	4624-4633	developed	_	
23-6	4634-4636	to	_	
23-7	4637-4643	follow	_	
23-8	4644-4647	and	_	
23-9	4648-4656	localize	_	
23-10	4657-4660	the	_	
23-11	4661-4667	action	_	
23-12	4668-4670	of	_	
23-13	4671-4676	drugs	_	
23-14	4677-4679	on	_	
23-15	4680-4683	the	_	
23-16	4684-4687	CNS	_	
23-17	4687-4688	,	_	
23-18	4689-4691	to	_	
23-19	4692-4698	follow	_	
23-20	4699-4702	the	_	
23-21	4703-4709	effect	_	
23-22	4710-4712	of	_	
23-23	4713-4722	sustained	_	
23-24	4723-4730	craving	_	
23-25	4731-4739	elicited	_	
23-26	4740-4742	by	_	
23-27	4743-4748	video	_	
23-28	4749-4753	cues	_	
23-29	4753-4754	,	_	
23-30	4755-4757	in	_	
23-31	4758-4770	hypothesized	_	
23-32	4771-4778	regions	_	
23-33	4779-4781	of	_	
23-34	4782-4790	interest	_	
23-35	4790-4791	.	_	

#Text=We reasoned that this approach could capitalize on the video mode of drug cue delivery, providing time course fMRI information for investigation of how psychological variables relate to brain response over time.
24-1	4792-4794	We	_	
24-2	4795-4803	reasoned	_	
24-3	4804-4808	that	_	
24-4	4809-4813	this	_	
24-5	4814-4822	approach	_	
24-6	4823-4828	could	_	
24-7	4829-4839	capitalize	_	
24-8	4840-4842	on	_	
24-9	4843-4846	the	_	
24-10	4847-4852	video	_	
24-11	4853-4857	mode	_	
24-12	4858-4860	of	_	
24-13	4861-4865	drug	_	
24-14	4866-4869	cue	_	
24-15	4870-4878	delivery	_	
24-16	4878-4879	,	_	
24-17	4880-4889	providing	_	
24-18	4890-4894	time	_	
24-19	4895-4901	course	_	
24-20	4902-4906	fMRI	_	
24-21	4907-4918	information	_	
24-22	4919-4922	for	_	
24-23	4923-4936	investigation	_	
24-24	4937-4939	of	_	
24-25	4940-4943	how	_	
24-26	4944-4957	psychological	_	
24-27	4958-4967	variables	_	
24-28	4968-4974	relate	_	
24-29	4975-4977	to	_	
24-30	4978-4983	brain	_	
24-31	4984-4992	response	_	
24-32	4993-4997	over	_	
24-33	4998-5002	time	_	
24-34	5002-5003	.	_	

#Text=We applied this approach in recently abstinent individuals with opioid dependence (OD), to better delineate brain responses related to the experience of craving over a period of cue exposure.
25-1	5004-5006	We	_	
25-2	5007-5014	applied	_	
25-3	5015-5019	this	_	
25-4	5020-5028	approach	_	
25-5	5029-5031	in	_	
25-6	5032-5040	recently	_	
25-7	5041-5050	abstinent	_	
25-8	5051-5062	individuals	_	
25-9	5063-5067	with	_	
25-10	5068-5074	opioid	_	
25-11	5075-5085	dependence	_	
25-12	5086-5087	(	_	
25-13	5087-5089	OD	_	
25-14	5089-5090	)	_	
25-15	5090-5091	,	_	
25-16	5092-5094	to	_	
25-17	5095-5101	better	_	
25-18	5102-5111	delineate	_	
25-19	5112-5117	brain	_	
25-20	5118-5127	responses	_	
25-21	5128-5135	related	_	
25-22	5136-5138	to	_	
25-23	5139-5142	the	_	
25-24	5143-5153	experience	_	
25-25	5154-5156	of	_	
25-26	5157-5164	craving	_	
25-27	5165-5169	over	_	
25-28	5170-5171	a	_	
25-29	5172-5178	period	_	
25-30	5179-5181	of	_	
25-31	5182-5185	cue	_	
25-32	5186-5194	exposure	_	
25-33	5194-5195	.	_	

#Text=We additionally investigated brain response for a period after cue exposure to gain insights into regions that may be involved in cognitive/behavioural control.
26-1	5196-5198	We	_	
26-2	5199-5211	additionally	_	
26-3	5212-5224	investigated	_	
26-4	5225-5230	brain	_	
26-5	5231-5239	response	_	
26-6	5240-5243	for	_	
26-7	5244-5245	a	_	
26-8	5246-5252	period	_	
26-9	5253-5258	after	_	
26-10	5259-5262	cue	_	
26-11	5263-5271	exposure	_	
26-12	5272-5274	to	_	
26-13	5275-5279	gain	_	
26-14	5280-5288	insights	_	
26-15	5289-5293	into	_	
26-16	5294-5301	regions	_	
26-17	5302-5306	that	_	
26-18	5307-5310	may	_	
26-19	5311-5313	be	_	
26-20	5314-5322	involved	_	
26-21	5323-5325	in	_	
26-22	5326-5335	cognitive	_	
26-23	5335-5336	/	_	
26-24	5336-5347	behavioural	_	
26-25	5348-5355	control	_	
26-26	5355-5356	.	_	

#Text=Although videos have previously been used in fMRI studies of substance dependence, to our knowledge, dynamic brain responses to these cues have not previously been explored.
27-1	5357-5365	Although	_	
27-2	5366-5372	videos	_	
27-3	5373-5377	have	_	
27-4	5378-5388	previously	_	
27-5	5389-5393	been	_	
27-6	5394-5398	used	_	
27-7	5399-5401	in	_	
27-8	5402-5406	fMRI	_	
27-9	5407-5414	studies	_	
27-10	5415-5417	of	_	
27-11	5418-5427	substance	_	
27-12	5428-5438	dependence	_	
27-13	5438-5439	,	_	
27-14	5440-5442	to	_	
27-15	5443-5446	our	_	
27-16	5447-5456	knowledge	_	
27-17	5456-5457	,	_	
27-18	5458-5465	dynamic	_	
27-19	5466-5471	brain	_	
27-20	5472-5481	responses	_	
27-21	5482-5484	to	_	
27-22	5485-5490	these	_	
27-23	5491-5495	cues	_	
27-24	5496-5500	have	_	
27-25	5501-5504	not	_	
27-26	5505-5515	previously	_	
27-27	5516-5520	been	_	
27-28	5521-5529	explored	_	
27-29	5529-5530	.	_	

#Text=In recovering dependent individuals, brain responses to drug cues may reflect not only craving‐related activity but also attempts to control craving (Goldstein & Volkow 2011).
28-1	5531-5533	In	_	
28-2	5534-5544	recovering	_	
28-3	5545-5554	dependent	_	
28-4	5555-5566	individuals	_	
28-5	5566-5567	,	_	
28-6	5568-5573	brain	_	
28-7	5574-5583	responses	_	
28-8	5584-5586	to	_	
28-9	5587-5591	drug	_	
28-10	5592-5596	cues	_	
28-11	5597-5600	may	_	
28-12	5601-5608	reflect	_	
28-13	5609-5612	not	_	
28-14	5613-5617	only	_	
28-15	5618-5633	craving‐related	_	
28-16	5634-5642	activity	_	
28-17	5643-5646	but	_	
28-18	5647-5651	also	_	
28-19	5652-5660	attempts	_	
28-20	5661-5663	to	_	
28-21	5664-5671	control	_	
28-22	5672-5679	craving	_	
28-23	5680-5681	(	_	
28-24	5681-5690	Goldstein	_	
28-25	5691-5692	&	_	
28-26	5693-5699	Volkow	_	
28-27	5700-5704	2011	_	
28-28	5704-5705	)	_	
28-29	5705-5706	.	_	

#Text=This may explain why some participants in previous cue exposure studies have not reported significant overall changes in craving scores (Zijlstra et al. 2009; Wang et al. 2011).
29-1	5707-5711	This	_	
29-2	5712-5715	may	_	
29-3	5716-5723	explain	_	
29-4	5724-5727	why	_	
29-5	5728-5732	some	_	
29-6	5733-5745	participants	_	
29-7	5746-5748	in	_	
29-8	5749-5757	previous	_	
29-9	5758-5761	cue	_	
29-10	5762-5770	exposure	_	
29-11	5771-5778	studies	_	
29-12	5779-5783	have	_	
29-13	5784-5787	not	_	
29-14	5788-5796	reported	_	
29-15	5797-5808	significant	_	
29-16	5809-5816	overall	_	
29-17	5817-5824	changes	_	
29-18	5825-5827	in	_	
29-19	5828-5835	craving	_	
29-20	5836-5842	scores	_	
29-21	5843-5844	(	_	
29-22	5844-5852	Zijlstra	_	
29-23	5853-5855	et	_	
29-24	5856-5858	al	_	
29-25	5858-5859	.	_	
29-26	5860-5864	2009	_	
29-27	5864-5865	;	_	
29-28	5866-5870	Wang	_	
29-29	5871-5873	et	_	
29-30	5874-5876	al	_	
29-31	5876-5877	.	_	
29-32	5878-5882	2011	_	
29-33	5882-5883	)	_	
29-34	5883-5884	.	_	

#Text=Time course information derived dynamically across video stimuli could help distinguish briefly induced craving and subsequent control at a neuronal level, thereby disambiguating distinct processes that may have been compounded in previous studies.
30-1	5885-5889	Time	_	
30-2	5890-5896	course	_	
30-3	5897-5908	information	_	
30-4	5909-5916	derived	_	
30-5	5917-5928	dynamically	_	
30-6	5929-5935	across	_	
30-7	5936-5941	video	_	
30-8	5942-5949	stimuli	_	
30-9	5950-5955	could	_	
30-10	5956-5960	help	_	
30-11	5961-5972	distinguish	_	
30-12	5973-5980	briefly	_	
30-13	5981-5988	induced	_	
30-14	5989-5996	craving	_	
30-15	5997-6000	and	_	
30-16	6001-6011	subsequent	_	
30-17	6012-6019	control	_	
30-18	6020-6022	at	_	
30-19	6023-6024	a	_	
30-20	6025-6033	neuronal	_	
30-21	6034-6039	level	_	
30-22	6039-6040	,	_	
30-23	6041-6048	thereby	_	
30-24	6049-6063	disambiguating	_	
30-25	6064-6072	distinct	_	
30-26	6073-6082	processes	_	
30-27	6083-6087	that	_	
30-28	6088-6091	may	_	
30-29	6092-6096	have	_	
30-30	6097-6101	been	_	
30-31	6102-6112	compounded	_	
30-32	6113-6115	in	_	
30-33	6116-6124	previous	_	
30-34	6125-6132	studies	_	
30-35	6132-6133	.	_	

#Text=We hypothesized that early development of craving would be associated with activation of amygdala, ventral striatum and ventral medial prefrontal regions involved in processing reward value and incentive motivation.
31-1	6134-6136	We	_	
31-2	6137-6149	hypothesized	_	
31-3	6150-6154	that	_	
31-4	6155-6160	early	_	
31-5	6161-6172	development	_	
31-6	6173-6175	of	_	
31-7	6176-6183	craving	_	
31-8	6184-6189	would	_	
31-9	6190-6192	be	_	
31-10	6193-6203	associated	_	
31-11	6204-6208	with	_	
31-12	6209-6219	activation	_	
31-13	6220-6222	of	_	
31-14	6223-6231	amygdala	_	
31-15	6231-6232	,	_	
31-16	6233-6240	ventral	_	
31-17	6241-6249	striatum	_	
31-18	6250-6253	and	_	
31-19	6254-6261	ventral	_	
31-20	6262-6268	medial	_	
31-21	6269-6279	prefrontal	_	
31-22	6280-6287	regions	_	
31-23	6288-6296	involved	_	
31-24	6297-6299	in	_	
31-25	6300-6310	processing	_	
31-26	6311-6317	reward	_	
31-27	6318-6323	value	_	
31-28	6324-6327	and	_	
31-29	6328-6337	incentive	_	
31-30	6338-6348	motivation	_	
31-31	6348-6349	.	_	

#Text=In our treatment‐seeking sample, with long‐term goals of abstinence, we further hypothesized that response in the dorsal anterior cingulate cortex would develop both during and after the video as subjective craving decreased, reflecting conscious control mechanisms.
32-1	6350-6352	In	_	
32-2	6353-6356	our	_	
32-3	6357-6374	treatment‐seeking	_	
32-4	6375-6381	sample	_	
32-5	6381-6382	,	_	
32-6	6383-6387	with	_	
32-7	6388-6397	long‐term	_	
32-8	6398-6403	goals	_	
32-9	6404-6406	of	_	
32-10	6407-6417	abstinence	_	
32-11	6417-6418	,	_	
32-12	6419-6421	we	_	
32-13	6422-6429	further	_	
32-14	6430-6442	hypothesized	_	
32-15	6443-6447	that	_	
32-16	6448-6456	response	_	
32-17	6457-6459	in	_	
32-18	6460-6463	the	_	
32-19	6464-6470	dorsal	_	
32-20	6471-6479	anterior	_	
32-21	6480-6489	cingulate	_	
32-22	6490-6496	cortex	_	
32-23	6497-6502	would	_	
32-24	6503-6510	develop	_	
32-25	6511-6515	both	_	
32-26	6516-6522	during	_	
32-27	6523-6526	and	_	
32-28	6527-6532	after	_	
32-29	6533-6536	the	_	
32-30	6537-6542	video	_	
32-31	6543-6545	as	_	
32-32	6546-6556	subjective	_	
32-33	6557-6564	craving	_	
32-34	6565-6574	decreased	_	
32-35	6574-6575	,	_	
32-36	6576-6586	reflecting	_	
32-37	6587-6596	conscious	_	
32-38	6597-6604	control	_	
32-39	6605-6615	mechanisms	_	
32-40	6615-6616	.	_	

#Text=Methods and Materials
#Text=Participants
#Text=Opioid‐dependent individuals (n = 18)
#Text=This study was approved by the NHS Research Ethics Committee.
33-1	6617-6624	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
33-2	6625-6628	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
33-3	6629-6638	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]	
33-4	6639-6651	Participants	_	
33-5	6652-6668	Opioid‐dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[10]	
33-6	6669-6680	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[10]	
33-7	6681-6682	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-8	6682-6683	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-9	6683-6684	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-10	6684-6685	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-11	6685-6686	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-12	6686-6688	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-13	6688-6689	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-14	6690-6694	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-15	6695-6700	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-16	6701-6704	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-17	6705-6713	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-18	6714-6716	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-19	6717-6720	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-20	6721-6724	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-21	6725-6733	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-22	6734-6740	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-23	6741-6750	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
33-24	6750-6751	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Participants with OD were recruited from a residential detoxification unit within Greater Manchester (see Table 1 for demographic information).
34-1	6752-6764	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-2	6765-6769	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-3	6770-6772	OD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[12]	
34-4	6773-6777	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-5	6778-6787	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-6	6788-6792	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-7	6793-6794	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-8	6795-6806	residential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-9	6807-6821	detoxification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-10	6822-6826	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-11	6827-6833	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-12	6834-6841	Greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-13	6842-6852	Manchester	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-14	6853-6854	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-15	6854-6857	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-16	6858-6863	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-17	6863-6864	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-18	6864-6865	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-19	6866-6869	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-20	6870-6881	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-21	6882-6893	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-22	6893-6894	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
34-23	6894-6895	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Treatment involved a 4‐week residential stay with a 10‐day methadone stabilization and reduction, followed by 10 days of lofexidine treatment, an alpha‐2 adrenergic receptor agonist used to treat opioid withdrawal symptoms.
35-1	6896-6905	Treatment	_	
35-2	6906-6914	involved	_	
35-3	6915-6916	a	_	
35-4	6917-6918	4	_	
35-5	6918-6919	‐	_	
35-6	6919-6923	week	_	
35-7	6924-6935	residential	_	
35-8	6936-6940	stay	_	
35-9	6941-6945	with	_	
35-10	6946-6947	a	_	
35-11	6948-6950	10	_	
35-12	6950-6951	‐	_	
35-13	6951-6954	day	_	
35-14	6955-6964	methadone	_	
35-15	6965-6978	stabilization	_	
35-16	6979-6982	and	_	
35-17	6983-6992	reduction	_	
35-18	6992-6993	,	_	
35-19	6994-7002	followed	_	
35-20	7003-7005	by	_	
35-21	7006-7008	10	_	
35-22	7008-7009	 	_	
35-23	7009-7013	days	_	
35-24	7014-7016	of	_	
35-25	7017-7027	lofexidine	_	
35-26	7028-7037	treatment	_	
35-27	7037-7038	,	_	
35-28	7039-7041	an	_	
35-29	7042-7047	alpha	_	
35-30	7047-7048	‐	_	
35-31	7048-7049	2	_	
35-32	7050-7060	adrenergic	_	
35-33	7061-7069	receptor	_	
35-34	7070-7077	agonist	_	
35-35	7078-7082	used	_	
35-36	7083-7085	to	_	
35-37	7086-7091	treat	_	
35-38	7092-7098	opioid	_	
35-39	7099-7109	withdrawal	_	
35-40	7110-7118	symptoms	_	
35-41	7118-7119	.	_	

#Text=Participants took part in the study during the last week of their residential stay when they were opioid free (confirmed by urine drug screen).
36-1	7120-7132	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-2	7133-7137	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-3	7138-7142	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-4	7143-7145	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-5	7146-7149	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-6	7150-7155	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-7	7156-7162	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-8	7163-7166	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-9	7167-7171	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-10	7172-7176	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-11	7177-7179	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-12	7180-7185	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-13	7186-7197	residential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-14	7198-7202	stay	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-15	7203-7207	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-16	7208-7212	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-17	7213-7217	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-18	7218-7224	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-19	7225-7229	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-20	7230-7231	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-21	7231-7240	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-22	7241-7243	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-23	7244-7249	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-24	7250-7254	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-25	7255-7261	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-26	7261-7262	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
36-27	7262-7263	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Lofexidine was extended at low doses for participants still experiencing withdrawal symptoms during this final week, and some ODs were receiving other psychoactive medications as indicated by Supporting Information Table  S1 .
37-1	7264-7274	Lofexidine	_	
37-2	7275-7278	was	_	
37-3	7279-7287	extended	_	
37-4	7288-7290	at	_	
37-5	7291-7294	low	_	
37-6	7295-7300	doses	_	
37-7	7301-7304	for	_	
37-8	7305-7317	participants	_	
37-9	7318-7323	still	_	
37-10	7324-7336	experiencing	_	
37-11	7337-7347	withdrawal	_	
37-12	7348-7356	symptoms	_	
37-13	7357-7363	during	_	
37-14	7364-7368	this	_	
37-15	7369-7374	final	_	
37-16	7375-7379	week	_	
37-17	7379-7380	,	_	
37-18	7381-7384	and	_	
37-19	7385-7389	some	_	
37-20	7390-7393	ODs	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
37-21	7394-7398	were	_	
37-22	7399-7408	receiving	_	
37-23	7409-7414	other	_	
37-24	7415-7427	psychoactive	_	
37-25	7428-7439	medications	_	
37-26	7440-7442	as	_	
37-27	7443-7452	indicated	_	
37-28	7453-7455	by	_	
37-29	7456-7466	Supporting	_	
37-30	7467-7478	Information	_	
37-31	7479-7484	Table	_	
37-32	7484-7485	 	_	
37-33	7486-7488	S1	_	
37-34	7489-7490	.	_	

#Text=The OD group was recruited according to the following inclusion criteria: male, aged 18–55; current DSM IV heroin dependence (the majority of patients also met criteria for current or past dependence on other substances; Table 1); no history of serious psychiatric, neurological or physical illness; no contraindications for MRI; and IQ of ≥85 [determined using the Wechsler Test of Adult Reading (Holdnack 2001)].
38-1	7491-7494	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-2	7495-7497	OD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
38-3	7498-7503	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[15]	
38-4	7504-7507	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-5	7508-7517	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-6	7518-7527	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-7	7528-7530	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-8	7531-7534	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-9	7535-7544	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-10	7545-7554	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-11	7555-7563	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-12	7563-7564	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-13	7565-7569	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-14	7569-7570	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-15	7571-7575	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-16	7576-7578	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-17	7578-7579	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-18	7579-7581	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-19	7581-7582	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-20	7583-7590	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-21	7591-7594	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[16]	
38-22	7595-7597	IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[16]	
38-23	7598-7604	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[16]	
38-24	7605-7615	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[16]	
38-25	7616-7617	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-26	7617-7620	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-27	7621-7629	majority	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-28	7630-7632	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-29	7633-7641	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-30	7642-7646	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-31	7647-7650	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-32	7651-7659	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-33	7660-7663	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-34	7664-7671	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-35	7672-7674	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-36	7675-7679	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-37	7680-7690	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-38	7691-7693	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-39	7694-7699	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-40	7700-7710	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-41	7710-7711	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-42	7712-7717	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-43	7717-7718	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-44	7718-7719	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-45	7719-7720	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-46	7720-7721	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-47	7722-7724	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-48	7725-7732	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-49	7733-7735	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-50	7736-7743	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-51	7744-7755	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-52	7755-7756	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-53	7757-7769	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-54	7770-7772	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-55	7773-7781	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-56	7782-7789	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-57	7789-7790	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-58	7791-7793	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-59	7794-7811	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-60	7812-7815	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-61	7816-7819	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]	
38-62	7819-7820	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-63	7821-7824	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-64	7825-7827	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-65	7828-7830	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-66	7831-7832	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-67	7832-7834	85	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-68	7835-7836	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-69	7836-7846	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-70	7847-7852	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-71	7853-7856	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-72	7857-7865	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-73	7866-7870	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-74	7871-7873	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-75	7874-7879	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-76	7880-7887	Reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-77	7888-7889	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-78	7889-7897	Holdnack	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-79	7898-7902	2001	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-80	7902-7903	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-81	7903-7904	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
38-82	7904-7905	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=Participants were identified and approached by members of the clinical team on the basis of detailed physical and mental health assessments on admission to the unit.
39-1	7906-7918	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-2	7919-7923	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-3	7924-7934	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-4	7935-7938	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-5	7939-7949	approached	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-6	7950-7952	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-7	7953-7960	members	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-8	7961-7963	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-9	7964-7967	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-10	7968-7976	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-11	7977-7981	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-12	7982-7984	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-13	7985-7988	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-14	7989-7994	basis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-15	7995-7997	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-16	7998-8006	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-17	8007-8015	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-18	8016-8019	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-19	8020-8026	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-20	8027-8033	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-21	8034-8045	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-22	8046-8048	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-23	8049-8058	admission	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-24	8059-8061	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-25	8062-8065	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-26	8066-8070	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-27	8070-8071	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=All participants meeting the inclusion criteria were approached to take part in the study.
40-1	8072-8075	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-2	8076-8088	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-3	8089-8096	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-4	8097-8100	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-5	8101-8110	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-6	8111-8119	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-7	8120-8124	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-8	8125-8135	approached	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-9	8136-8138	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-10	8139-8143	take	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-11	8144-8148	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-12	8149-8151	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-13	8152-8155	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-14	8156-8161	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
40-15	8161-8162	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=A total of 39 patients were enrolled in the craving study; however, 19 were discharged from the unit before any testing could take place (mainly self‐discharge or early discharge due to use of prohibited substances).
41-1	8163-8164	A	_	
41-2	8165-8170	total	_	
41-3	8171-8173	of	_	
41-4	8174-8176	39	_	
41-5	8177-8185	patients	_	
41-6	8186-8190	were	_	
41-7	8191-8199	enrolled	_	
41-8	8200-8202	in	_	
41-9	8203-8206	the	_	
41-10	8207-8214	craving	_	
41-11	8215-8220	study	_	
41-12	8220-8221	;	_	
41-13	8222-8229	however	_	
41-14	8229-8230	,	_	
41-15	8231-8233	19	_	
41-16	8234-8238	were	_	
41-17	8239-8249	discharged	_	
41-18	8250-8254	from	_	
41-19	8255-8258	the	_	
41-20	8259-8263	unit	_	
41-21	8264-8270	before	_	
41-22	8271-8274	any	_	
41-23	8275-8282	testing	_	
41-24	8283-8288	could	_	
41-25	8289-8293	take	_	
41-26	8294-8299	place	_	
41-27	8300-8301	(	_	
41-28	8301-8307	mainly	_	
41-29	8308-8322	self‐discharge	_	
41-30	8323-8325	or	_	
41-31	8326-8331	early	_	
41-32	8332-8341	discharge	_	
41-33	8342-8345	due	_	
41-34	8346-8348	to	_	
41-35	8349-8352	use	_	
41-36	8353-8355	of	_	
41-37	8356-8366	prohibited	_	
41-38	8367-8377	substances	_	
41-39	8377-8378	)	_	
41-40	8378-8379	.	_	

#Text=Twenty patients were scanned as part of the study, although two were excluded from analysis because of excessive movement (see Preprocessing section for further details), leaving n = 18 who were included in analysis.
42-1	8380-8386	Twenty	_	
42-2	8387-8395	patients	_	
42-3	8396-8400	were	_	
42-4	8401-8408	scanned	_	
42-5	8409-8411	as	_	
42-6	8412-8416	part	_	
42-7	8417-8419	of	_	
42-8	8420-8423	the	_	
42-9	8424-8429	study	_	
42-10	8429-8430	,	_	
42-11	8431-8439	although	_	
42-12	8440-8443	two	_	
42-13	8444-8448	were	_	
42-14	8449-8457	excluded	_	
42-15	8458-8462	from	_	
42-16	8463-8471	analysis	_	
42-17	8472-8479	because	_	
42-18	8480-8482	of	_	
42-19	8483-8492	excessive	_	
42-20	8493-8501	movement	_	
42-21	8502-8503	(	_	
42-22	8503-8506	see	_	
42-23	8507-8520	Preprocessing	_	
42-24	8521-8528	section	_	
42-25	8529-8532	for	_	
42-26	8533-8540	further	_	
42-27	8541-8548	details	_	
42-28	8548-8549	)	_	
42-29	8549-8550	,	_	
42-30	8551-8558	leaving	_	
42-31	8559-8560	n	_	
42-32	8560-8561	 	_	
42-33	8561-8562	=	_	
42-34	8562-8563	 	_	
42-35	8563-8565	18	_	
42-36	8566-8569	who	_	
42-37	8570-8574	were	_	
42-38	8575-8583	included	_	
42-39	8584-8586	in	_	
42-40	8587-8595	analysis	_	
42-41	8595-8596	.	_	

#Text=Handedness was assessed with the Edinburgh Handedness Inventory (Oldfield 1971).
43-1	8597-8607	Handedness	_	
43-2	8608-8611	was	_	
43-3	8612-8620	assessed	_	
43-4	8621-8625	with	_	
43-5	8626-8629	the	_	
43-6	8630-8639	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[20]	
43-7	8640-8650	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[20]	
43-8	8651-8660	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[20]	
43-9	8661-8662	(	_	
43-10	8662-8670	Oldfield	_	
43-11	8671-8675	1971	_	
43-12	8675-8676	)	_	
43-13	8676-8677	.	_	

#Text=Demographic and clinical information of OD (n = 18) and HC (n = 20) groups included in the analysis.
44-1	8678-8689	Demographic	_	
44-2	8690-8693	and	_	
44-3	8694-8702	clinical	_	
44-4	8703-8714	information	_	
44-5	8715-8717	of	_	
44-6	8718-8720	OD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
44-7	8721-8722	(	_	
44-8	8722-8723	n	_	
44-9	8723-8724	 	_	
44-10	8724-8725	=	_	
44-11	8725-8726	 	_	
44-12	8726-8728	18	_	
44-13	8728-8729	)	_	
44-14	8730-8733	and	_	
44-15	8734-8736	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
44-16	8737-8738	(	_	
44-17	8738-8739	n	_	
44-18	8739-8740	 	_	
44-19	8740-8741	=	_	
44-20	8741-8742	 	_	
44-21	8742-8744	20	_	
44-22	8744-8745	)	_	
44-23	8746-8752	groups	_	
44-24	8753-8761	included	_	
44-25	8762-8764	in	_	
44-26	8765-8768	the	_	
44-27	8769-8777	analysis	_	
44-28	8777-8778	.	_	

#Text=OD group\tHC group\tp‐value\t \tAge\t34.8 (6.3)\t31.6 (7.2)\t0.15\t \tIQ\t103.1.9 (7.7)\t114.1 (4.7)\t<0.05\t \tYears of education\t11.5 (2.2)\t16.5 (3.3)\t<0.05\t \tNo. of right handers\t16 (89 percent)\t18 (90 percent)\t0.91\t \tNo. of smokers (nicotine)\t13 (72 percent)\t9 (45 percent)\t0.09\t \tClinical Variables for OD group\t\t\t\t \tYears of opioid dependence\t12.8 (7.7)\t—\t\t \tAverage daily opioid use (g)\t0.7 (0.6)\t—\t\t \tAge of first use (years)\t20.3 (4.3)\t\t\t \tNo. who primarily smoke/inject/ or use both methods for heroin administration\t5 (28 percent)/5 (28 percent)/8 (44 percent)\t—\t\t \tNo. of OD group with current/past history of:\t\t—\t\t \tAlcohol dependence\t7 (39 percent)\t—\t\t \tCocaine dependence\t7 (39 percent)\t\t\t \tAmphetamine dependence\t1 (6 percent)\t—\t\t \tBenzodiazepine dependence\t3 (17 percent)\t—\t\t \tHeroin dependence only (except nicotine)\t6 (33 percent)\t—\t\t \t
#Text=Age, IQ, years of education, years of dependence, average daily amount used and age of first use expressed as mean and standard deviation (in brackets).
45-1	8780-8782	OD	_	
45-2	8783-8788	group	_	
45-3	8789-8791	HC	_	
45-4	8792-8797	group	_	
45-5	8798-8805	p‐value	_	
45-6	8808-8811	Age	_	
45-7	8812-8816	34.8	_	
45-8	8817-8818	(	_	
45-9	8818-8821	6.3	_	
45-10	8821-8822	)	_	
45-11	8823-8827	31.6	_	
45-12	8828-8829	(	_	
45-13	8829-8832	7.2	_	
45-14	8832-8833	)	_	
45-15	8834-8838	0.15	_	
45-16	8841-8843	IQ	_	
45-17	8844-8851	103.1.9	_	
45-18	8852-8853	(	_	
45-19	8853-8856	7.7	_	
45-20	8856-8857	)	_	
45-21	8858-8863	114.1	_	
45-22	8864-8865	(	_	
45-23	8865-8868	4.7	_	
45-24	8868-8869	)	_	
45-25	8870-8871	<	_	
45-26	8871-8875	0.05	_	
45-27	8878-8883	Years	_	
45-28	8884-8886	of	_	
45-29	8887-8896	education	_	
45-30	8897-8901	11.5	_	
45-31	8902-8903	(	_	
45-32	8903-8906	2.2	_	
45-33	8906-8907	)	_	
45-34	8908-8912	16.5	_	
45-35	8913-8914	(	_	
45-36	8914-8917	3.3	_	
45-37	8917-8918	)	_	
45-38	8919-8920	<	_	
45-39	8920-8924	0.05	_	
45-40	8927-8929	No	_	
45-41	8929-8930	.	_	
45-42	8931-8933	of	_	
45-43	8934-8939	right	_	
45-44	8940-8947	handers	_	
45-45	8948-8950	16	_	
45-46	8951-8952	(	_	
45-47	8952-8954	89	_	
45-48	8955-8962	percent	_	
45-49	8962-8963	)	_	
45-50	8964-8966	18	_	
45-51	8967-8968	(	_	
45-52	8968-8970	90	_	
45-53	8971-8978	percent	_	
45-54	8978-8979	)	_	
45-55	8980-8984	0.91	_	
45-56	8987-8989	No	_	
45-57	8989-8990	.	_	
45-58	8991-8993	of	_	
45-59	8994-9001	smokers	_	
45-60	9002-9003	(	_	
45-61	9003-9011	nicotine	_	
45-62	9011-9012	)	_	
45-63	9013-9015	13	_	
45-64	9016-9017	(	_	
45-65	9017-9019	72	_	
45-66	9020-9027	percent	_	
45-67	9027-9028	)	_	
45-68	9029-9030	9	_	
45-69	9031-9032	(	_	
45-70	9032-9034	45	_	
45-71	9035-9042	percent	_	
45-72	9042-9043	)	_	
45-73	9044-9048	0.09	_	
45-74	9051-9059	Clinical	_	
45-75	9060-9069	Variables	_	
45-76	9070-9073	for	_	
45-77	9074-9076	OD	_	
45-78	9077-9082	group	_	
45-79	9088-9093	Years	_	
45-80	9094-9096	of	_	
45-81	9097-9103	opioid	_	
45-82	9104-9114	dependence	_	
45-83	9115-9119	12.8	_	
45-84	9120-9121	(	_	
45-85	9121-9124	7.7	_	
45-86	9124-9125	)	_	
45-87	9126-9127	—	_	
45-88	9131-9138	Average	_	
45-89	9139-9144	daily	_	
45-90	9145-9151	opioid	_	
45-91	9152-9155	use	_	
45-92	9156-9157	(	_	
45-93	9157-9158	g	_	
45-94	9158-9159	)	_	
45-95	9160-9163	0.7	_	
45-96	9164-9165	(	_	
45-97	9165-9168	0.6	_	
45-98	9168-9169	)	_	
45-99	9170-9171	—	_	
45-100	9175-9178	Age	_	
45-101	9179-9181	of	_	
45-102	9182-9187	first	_	
45-103	9188-9191	use	_	
45-104	9192-9193	(	_	
45-105	9193-9198	years	_	
45-106	9198-9199	)	_	
45-107	9200-9204	20.3	_	
45-108	9205-9206	(	_	
45-109	9206-9209	4.3	_	
45-110	9209-9210	)	_	
45-111	9215-9217	No	_	
45-112	9217-9218	.	_	
45-113	9219-9222	who	_	
45-114	9223-9232	primarily	_	
45-115	9233-9238	smoke	_	
45-116	9238-9239	/	_	
45-117	9239-9245	inject	_	
45-118	9245-9246	/	_	
45-119	9247-9249	or	_	
45-120	9250-9253	use	_	
45-121	9254-9258	both	_	
45-122	9259-9266	methods	_	
45-123	9267-9270	for	_	
45-124	9271-9277	heroin	_	
45-125	9278-9292	administration	_	
45-126	9293-9294	5	_	
45-127	9295-9296	(	_	
45-128	9296-9298	28	_	
45-129	9299-9306	percent	_	
45-130	9306-9307	)	_	
45-131	9307-9308	/	_	
45-132	9308-9309	5	_	
45-133	9310-9311	(	_	
45-134	9311-9313	28	_	
45-135	9314-9321	percent	_	
45-136	9321-9322	)	_	
45-137	9322-9323	/	_	
45-138	9323-9324	8	_	
45-139	9325-9326	(	_	
45-140	9326-9328	44	_	
45-141	9329-9336	percent	_	
45-142	9336-9337	)	_	
45-143	9338-9339	—	_	
45-144	9343-9345	No	_	
45-145	9345-9346	.	_	
45-146	9347-9349	of	_	
45-147	9350-9352	OD	_	
45-148	9353-9358	group	_	
45-149	9359-9363	with	_	
45-150	9364-9371	current	_	
45-151	9371-9372	/	_	
45-152	9372-9376	past	_	
45-153	9377-9384	history	_	
45-154	9385-9387	of	_	
45-155	9387-9388	:	_	
45-156	9390-9391	—	_	
45-157	9395-9402	Alcohol	_	
45-158	9403-9413	dependence	_	
45-159	9414-9415	7	_	
45-160	9416-9417	(	_	
45-161	9417-9419	39	_	
45-162	9420-9427	percent	_	
45-163	9427-9428	)	_	
45-164	9429-9430	—	_	
45-165	9434-9441	Cocaine	_	
45-166	9442-9452	dependence	_	
45-167	9453-9454	7	_	
45-168	9455-9456	(	_	
45-169	9456-9458	39	_	
45-170	9459-9466	percent	_	
45-171	9466-9467	)	_	
45-172	9472-9483	Amphetamine	_	
45-173	9484-9494	dependence	_	
45-174	9495-9496	1	_	
45-175	9497-9498	(	_	
45-176	9498-9499	6	_	
45-177	9500-9507	percent	_	
45-178	9507-9508	)	_	
45-179	9509-9510	—	_	
45-180	9514-9528	Benzodiazepine	_	
45-181	9529-9539	dependence	_	
45-182	9540-9541	3	_	
45-183	9542-9543	(	_	
45-184	9543-9545	17	_	
45-185	9546-9553	percent	_	
45-186	9553-9554	)	_	
45-187	9555-9556	—	_	
45-188	9560-9566	Heroin	_	
45-189	9567-9577	dependence	_	
45-190	9578-9582	only	_	
45-191	9583-9584	(	_	
45-192	9584-9590	except	_	
45-193	9591-9599	nicotine	_	
45-194	9599-9600	)	_	
45-195	9601-9602	6	_	
45-196	9603-9604	(	_	
45-197	9604-9606	33	_	
45-198	9607-9614	percent	_	
45-199	9614-9615	)	_	
45-200	9616-9617	—	_	
45-201	9622-9625	Age	_	
45-202	9625-9626	,	_	
45-203	9627-9629	IQ	_	
45-204	9629-9630	,	_	
45-205	9631-9636	years	_	
45-206	9637-9639	of	_	
45-207	9640-9649	education	_	
45-208	9649-9650	,	_	
45-209	9651-9656	years	_	
45-210	9657-9659	of	_	
45-211	9660-9670	dependence	_	
45-212	9670-9671	,	_	
45-213	9672-9679	average	_	
45-214	9680-9685	daily	_	
45-215	9686-9692	amount	_	
45-216	9693-9697	used	_	
45-217	9698-9701	and	_	
45-218	9702-9705	age	_	
45-219	9706-9708	of	_	
45-220	9709-9714	first	_	
45-221	9715-9718	use	_	
45-222	9719-9728	expressed	_	
45-223	9729-9731	as	_	
45-224	9732-9736	mean	_	
45-225	9737-9740	and	_	
45-226	9741-9749	standard	_	
45-227	9750-9759	deviation	_	
45-228	9760-9761	(	_	
45-229	9761-9763	in	_	
45-230	9764-9772	brackets	_	
45-231	9772-9773	)	_	
45-232	9773-9774	.	_	

#Text=All other variables expressed as frequency and proportion of group (in brackets).
46-1	9775-9778	All	_	
46-2	9779-9784	other	_	
46-3	9785-9794	variables	_	
46-4	9795-9804	expressed	_	
46-5	9805-9807	as	_	
46-6	9808-9817	frequency	_	
46-7	9818-9821	and	_	
46-8	9822-9832	proportion	_	
46-9	9833-9835	of	_	
46-10	9836-9841	group	_	
46-11	9842-9843	(	_	
46-12	9843-9845	in	_	
46-13	9846-9854	brackets	_	
46-14	9854-9855	)	_	
46-15	9855-9856	.	_	

#Text=P‐values taken from independent t‐tests for continuous data and chi‐squared tests for frequency data.
47-1	9857-9865	P‐values	_	
47-2	9866-9871	taken	_	
47-3	9872-9876	from	_	
47-4	9877-9888	independent	_	
47-5	9889-9896	t‐tests	_	
47-6	9897-9900	for	_	
47-7	9901-9911	continuous	_	
47-8	9912-9916	data	_	
47-9	9917-9920	and	_	
47-10	9921-9932	chi‐squared	_	
47-11	9933-9938	tests	_	
47-12	9939-9942	for	_	
47-13	9943-9952	frequency	_	
47-14	9953-9957	data	_	
47-15	9957-9958	.	_	

#Text=Healthy controls (n = 20)
#Text=Healthy controls (HCs) were recruited who were familiar with graphic scenes of drug use because of occupational experience (e.g. drug treatment workers and other health professionals).
48-1	9959-9966	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-2	9967-9975	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-3	9976-9977	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-4	9977-9978	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-5	9978-9979	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-6	9979-9980	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-7	9980-9981	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-8	9981-9983	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-9	9983-9984	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-10	9985-9992	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]	
48-11	9993-10001	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]	
48-12	10002-10003	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]	
48-13	10003-10006	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]	
48-14	10006-10007	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[22]	
48-15	10008-10012	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-16	10013-10022	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-17	10023-10026	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-18	10027-10031	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-19	10032-10040	familiar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-20	10041-10045	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-21	10046-10053	graphic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-22	10054-10060	scenes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-23	10061-10063	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-24	10064-10068	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-25	10069-10072	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-26	10073-10080	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-27	10081-10083	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-28	10084-10096	occupational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-29	10097-10107	experience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-30	10108-10109	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-31	10109-10112	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-32	10112-10113	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-33	10114-10118	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-34	10119-10128	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-35	10129-10136	workers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-36	10137-10140	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-37	10141-10146	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-38	10147-10153	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-39	10154-10167	professionals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-40	10167-10168	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
48-41	10168-10169	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The HC group met the same inclusion criteria outlined previously and additionally had no current or past history of drug dependence or misuse (except nicotine) and had never used heroin in their lifetime.
49-1	10170-10173	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-2	10174-10176	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
49-3	10177-10182	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[24]	
49-4	10183-10186	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-5	10187-10190	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-6	10191-10195	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-7	10196-10205	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-8	10206-10214	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-9	10215-10223	outlined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-10	10224-10234	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-11	10235-10238	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-12	10239-10251	additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-13	10252-10255	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-14	10256-10258	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-15	10259-10266	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-16	10267-10269	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-17	10270-10274	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-18	10275-10282	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-19	10283-10285	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-20	10286-10290	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-21	10291-10301	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-22	10302-10304	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-23	10305-10311	misuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-24	10312-10313	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-25	10313-10319	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-26	10320-10328	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-27	10328-10329	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-28	10330-10333	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-29	10334-10337	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-30	10338-10343	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-31	10344-10348	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-32	10349-10355	heroin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-33	10356-10358	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-34	10359-10364	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-35	10365-10373	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
49-36	10373-10374	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=No healthy volunteers were receiving psychoactive medications.
50-1	10375-10377	No	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
50-2	10378-10385	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
50-3	10386-10396	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
50-4	10397-10401	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
50-5	10402-10411	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
50-6	10412-10424	psychoactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
50-7	10425-10436	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
50-8	10436-10437	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=Participants were screened with the Mini International Neuropsychiatric Interview (Sheehan et al. 1998), Wechsler Test of Adult Reading and Edinburgh Handedness Inventory.
51-1	10438-10450	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-2	10451-10455	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-3	10456-10464	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-4	10465-10469	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-5	10470-10473	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-6	10474-10478	Mini	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
51-7	10479-10492	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
51-8	10493-10509	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
51-9	10510-10519	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
51-10	10520-10521	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-11	10521-10528	Sheehan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-12	10529-10531	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-13	10532-10534	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-14	10534-10535	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-15	10536-10540	1998	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-16	10540-10541	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-17	10541-10542	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-18	10543-10551	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
51-19	10552-10556	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
51-20	10557-10559	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
51-21	10560-10565	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
51-22	10566-10573	Reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[29]	
51-23	10574-10577	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	
51-24	10578-10587	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[30]	
51-25	10588-10598	Handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[30]	
51-26	10599-10608	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[30]	
51-27	10608-10609	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]	

#Text=All participants provided written consent and were paid for their participation with vouchers.
52-1	10610-10613	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-2	10614-10626	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-3	10627-10635	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-4	10636-10643	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-5	10644-10651	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-6	10652-10655	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-7	10656-10660	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-8	10661-10665	paid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-9	10666-10669	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-10	10670-10675	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-11	10676-10689	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-12	10690-10694	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-13	10695-10703	vouchers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	
52-14	10703-10704	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[31]	

#Text=Procedures
#Text=Participants attended two separate, counterbalanced sessions.
53-1	10705-10715	Procedures	_	
53-2	10716-10728	Participants	_	
53-3	10729-10737	attended	_	
53-4	10738-10741	two	_	
53-5	10742-10750	separate	_	
53-6	10750-10751	,	_	
53-7	10752-10767	counterbalanced	_	
53-8	10768-10776	sessions	_	
53-9	10776-10777	.	_	

#Text=Patients were scanned in the last week of their residential stay when they were opioid free.
54-1	10778-10786	Patients	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[32]	
54-2	10787-10791	were	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[32]	
54-3	10792-10799	scanned	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[32]	
54-4	10800-10802	in	_	
54-5	10803-10806	the	_	
54-6	10807-10811	last	_	
54-7	10812-10816	week	_	
54-8	10817-10819	of	_	
54-9	10820-10825	their	_	
54-10	10826-10837	residential	_	
54-11	10838-10842	stay	_	
54-12	10843-10847	when	_	
54-13	10848-10852	they	_	
54-14	10853-10857	were	_	
54-15	10858-10864	opioid	_	
54-16	10865-10869	free	_	
54-17	10869-10870	.	_	

#Text=On each occasion, participants underwent fMRI, once whilst viewing a 10‐minute heroin video (drug cue session) and once whilst viewing a 10‐minute video containing scenes matched for visual complexity but lacking emotionally arousing content (neutral session).
55-1	10871-10873	On	_	
55-2	10874-10878	each	_	
55-3	10879-10887	occasion	_	
55-4	10887-10888	,	_	
55-5	10889-10901	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-6	10902-10911	underwent	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-7	10912-10916	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]	
55-8	10916-10917	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-9	10918-10922	once	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-10	10923-10929	whilst	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-11	10930-10937	viewing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-12	10938-10939	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-13	10940-10942	10	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-14	10942-10943	‐	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-15	10943-10949	minute	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-16	10950-10956	heroin	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-17	10957-10962	video	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-18	10963-10964	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-19	10964-10968	drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-20	10969-10972	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-21	10973-10980	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-22	10980-10981	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-23	10982-10985	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-24	10986-10990	once	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-25	10991-10997	whilst	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-26	10998-11005	viewing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-27	11006-11007	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-28	11008-11010	10	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-29	11010-11011	‐	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-30	11011-11017	minute	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-31	11018-11023	video	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-32	11024-11034	containing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-33	11035-11041	scenes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-34	11042-11049	matched	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-35	11050-11053	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-36	11054-11060	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-37	11061-11071	complexity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-38	11072-11075	but	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-39	11076-11083	lacking	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-40	11084-11095	emotionally	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-41	11096-11104	arousing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-42	11105-11112	content	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-43	11113-11114	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-44	11114-11121	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-45	11122-11129	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-46	11129-11130	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	
55-47	11130-11131	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]	

#Text=Videos were preceded and followed by 5 minutes of fixation (Fig. 1).
56-1	11132-11138	Videos	_	
56-2	11139-11143	were	_	
56-3	11144-11152	preceded	_	
56-4	11153-11156	and	_	
56-5	11157-11165	followed	_	
56-6	11166-11168	by	_	
56-7	11169-11170	5	_	
56-8	11170-11171	 	_	
56-9	11171-11178	minutes	_	
56-10	11179-11181	of	_	
56-11	11182-11190	fixation	_	
56-12	11191-11192	(	_	
56-13	11192-11195	Fig	_	
56-14	11195-11196	.	_	
56-15	11196-11197	 	_	
56-16	11197-11198	1	_	
56-17	11198-11199	)	_	
56-18	11199-11200	.	_	

#Text=Images were presented using e‐prime (Psychology Software Tools, Inc, Sharpsburg, USA) (version 2.0).
57-1	11201-11207	Images	_	
57-2	11208-11212	were	_	
57-3	11213-11222	presented	_	
57-4	11223-11228	using	_	
57-5	11229-11236	e‐prime	_	
57-6	11237-11238	(	_	
57-7	11238-11248	Psychology	_	
57-8	11249-11257	Software	_	
57-9	11258-11263	Tools	_	
57-10	11263-11264	,	_	
57-11	11265-11268	Inc	_	
57-12	11268-11269	,	_	
57-13	11270-11280	Sharpsburg	_	
57-14	11280-11281	,	_	
57-15	11282-11285	USA	_	
57-16	11285-11286	)	_	
57-17	11287-11288	(	_	
57-18	11288-11295	version	_	
57-19	11296-11299	2.0	_	
57-20	11299-11300	)	_	
57-21	11300-11301	.	_	

#Text=Diagram illustrating 1‐minute time‐bins for the drug cue and neutral sessions.
58-1	11302-11309	Diagram	_	
58-2	11310-11322	illustrating	_	
58-3	11323-11324	1	_	
58-4	11324-11325	‐	_	
58-5	11325-11331	minute	_	
58-6	11332-11341	time‐bins	_	
58-7	11342-11345	for	_	
58-8	11346-11349	the	_	
58-9	11350-11354	drug	_	
58-10	11355-11358	cue	_	
58-11	11359-11362	and	_	
58-12	11363-11370	neutral	_	
58-13	11371-11379	sessions	_	
58-14	11379-11380	.	_	

#Text=The 480 scans were divided into 1 minute time‐bins.
59-1	11381-11384	The	_	
59-2	11385-11388	480	_	
59-3	11389-11394	scans	_	
59-4	11395-11399	were	_	
59-5	11400-11407	divided	_	
59-6	11408-11412	into	_	
59-7	11413-11414	1	_	
59-8	11414-11415	 	_	
59-9	11415-11421	minute	_	
59-10	11422-11431	time‐bins	_	
59-11	11431-11432	.	_	

#Text=T0 was the 5th minute of the pre‐video baseline, T1–T10 were the time‐bins acquired during the video and T11‐T15 were the post‐video time‐bins.
60-1	11433-11435	T0	_	
60-2	11436-11439	was	_	
60-3	11440-11443	the	_	
60-4	11444-11447	5th	_	
60-5	11448-11454	minute	_	
60-6	11455-11457	of	_	
60-7	11458-11461	the	_	
60-8	11462-11471	pre‐video	_	
60-9	11472-11480	baseline	_	
60-10	11480-11481	,	_	
60-11	11482-11484	T1	_	
60-12	11484-11485	–	_	
60-13	11485-11488	T10	_	
60-14	11489-11493	were	_	
60-15	11494-11497	the	_	
60-16	11498-11507	time‐bins	_	
60-17	11508-11516	acquired	_	
60-18	11517-11523	during	_	
60-19	11524-11527	the	_	
60-20	11528-11533	video	_	
60-21	11534-11537	and	_	
60-22	11538-11541	T11	_	
60-23	11541-11542	‐	_	
60-24	11542-11545	T15	_	
60-25	11546-11550	were	_	
60-26	11551-11554	the	_	
60-27	11555-11565	post‐video	_	
60-28	11566-11575	time‐bins	_	
60-29	11575-11576	.	_	

#Text=The arrows indicate the time points of the presentation of the Likert‐like subjective rating scales
#Text=Measures
#Text=Participants were presented with Likert‐like subjective rating scales throughout the scanning session.
61-1	11577-11580	The	_	
61-2	11581-11587	arrows	_	
61-3	11588-11596	indicate	_	
61-4	11597-11600	the	_	
61-5	11601-11605	time	_	
61-6	11606-11612	points	_	
61-7	11613-11615	of	_	
61-8	11616-11619	the	_	
61-9	11620-11632	presentation	_	
61-10	11633-11635	of	_	
61-11	11636-11639	the	_	
61-12	11640-11651	Likert‐like	_	
61-13	11652-11662	subjective	_	
61-14	11663-11669	rating	_	
61-15	11670-11676	scales	_	
61-16	11677-11685	Measures	_	
61-17	11686-11698	Participants	_	
61-18	11699-11703	were	_	
61-19	11704-11713	presented	_	
61-20	11714-11718	with	_	
61-21	11719-11730	Likert‐like	_	
61-22	11731-11741	subjective	_	
61-23	11742-11748	rating	_	
61-24	11749-11755	scales	_	
61-25	11756-11766	throughout	_	
61-26	11767-11770	the	_	
61-27	11771-11779	scanning	_	
61-28	11780-11787	session	_	
61-29	11787-11788	.	_	

#Text=Participants were prompted to respond by a screen displaying the following text ‘do you feel you are …’, which was presented for 3 seconds before slides stating ‘Craving?’
62-1	11789-11801	Participants	_	
62-2	11802-11806	were	_	
62-3	11807-11815	prompted	_	
62-4	11816-11818	to	_	
62-5	11819-11826	respond	_	
62-6	11827-11829	by	_	
62-7	11830-11831	a	_	
62-8	11832-11838	screen	_	
62-9	11839-11849	displaying	_	
62-10	11850-11853	the	_	
62-11	11854-11863	following	_	
62-12	11864-11868	text	_	
62-13	11869-11870	‘	_	
62-14	11870-11872	do	_	
62-15	11873-11876	you	_	
62-16	11877-11881	feel	_	
62-17	11882-11885	you	_	
62-18	11886-11889	are	_	
62-19	11890-11891	…	_	
62-20	11891-11892	’	_	
62-21	11892-11893	,	_	
62-22	11894-11899	which	_	
62-23	11900-11903	was	_	
62-24	11904-11913	presented	_	
62-25	11914-11917	for	_	
62-26	11918-11919	3	_	
62-27	11919-11920	 	_	
62-28	11920-11927	seconds	_	
62-29	11928-11934	before	_	
62-30	11935-11941	slides	_	
62-31	11942-11949	stating	_	
62-32	11950-11951	‘	_	
62-33	11951-11958	Craving	_	
62-34	11958-11959	?	_	
62-35	11959-11960	’	_	

#Text=, ‘Withdrawing?’
63-1	11960-11961	,	_	
63-2	11962-11963	‘	_	
63-3	11963-11974	Withdrawing	_	
63-4	11974-11975	?	_	
63-5	11975-11976	’	_	

#Text=, ‘Anxious?’
64-1	11976-11977	,	_	
64-2	11978-11979	‘	_	
64-3	11979-11986	Anxious	_	
64-4	11986-11987	?	_	
64-5	11987-11988	’	_	

#Text=or ‘High?’
65-1	11989-11991	or	_	
65-2	11992-11993	‘	_	
65-3	11993-11997	High	_	
65-4	11997-11998	?	_	
65-5	11998-11999	’	_	

#Text=, were presented for 4 seconds along with the following scale: 1 (not all), 2 (slightly), 3 (moderately) and 4 (extremely).
66-1	11999-12000	,	_	
66-2	12001-12005	were	_	
66-3	12006-12015	presented	_	
66-4	12016-12019	for	_	
66-5	12020-12021	4	_	
66-6	12021-12022	 	_	
66-7	12022-12029	seconds	_	
66-8	12030-12035	along	_	
66-9	12036-12040	with	_	
66-10	12041-12044	the	_	
66-11	12045-12054	following	_	
66-12	12055-12060	scale	_	
66-13	12060-12061	:	_	
66-14	12062-12063	1	_	
66-15	12064-12065	(	_	
66-16	12065-12068	not	_	
66-17	12069-12072	all	_	
66-18	12072-12073	)	_	
66-19	12073-12074	,	_	
66-20	12075-12076	2	_	
66-21	12077-12078	(	_	
66-22	12078-12086	slightly	_	
66-23	12086-12087	)	_	
66-24	12087-12088	,	_	
66-25	12089-12090	3	_	
66-26	12091-12092	(	_	
66-27	12092-12102	moderately	_	
66-28	12102-12103	)	_	
66-29	12104-12107	and	_	
66-30	12108-12109	4	_	
66-31	12110-12111	(	_	
66-32	12111-12120	extremely	_	
66-33	12120-12121	)	_	
66-34	12121-12122	.	_	

#Text=Participants responded via a button box.
67-1	12123-12135	Participants	_	
67-2	12136-12145	responded	_	
67-3	12146-12149	via	_	
67-4	12150-12151	a	_	
67-5	12152-12158	button	_	
67-6	12159-12162	box	_	
67-7	12162-12163	.	_	

#Text=The scales were presented at 3‐minute intervals in each session (Fig. 1)
#Text=Behavioural data
#Text=Mixed ANOVAs were carried out for each of the four subjective rating scales with time of rating (six levels including a pre‐video baseline rating, three during the video and two post‐video ratings) and session (drug cue, neutral) as within‐subject factors and group (HC, OD) as the between‐subject factor.
68-1	12164-12167	The	_	
68-2	12168-12174	scales	_	
68-3	12175-12179	were	_	
68-4	12180-12189	presented	_	
68-5	12190-12192	at	_	
68-6	12193-12194	3	_	
68-7	12194-12195	‐	_	
68-8	12195-12201	minute	_	
68-9	12202-12211	intervals	_	
68-10	12212-12214	in	_	
68-11	12215-12219	each	_	
68-12	12220-12227	session	_	
68-13	12228-12229	(	_	
68-14	12229-12232	Fig	_	
68-15	12232-12233	.	_	
68-16	12233-12234	 	_	
68-17	12234-12235	1	_	
68-18	12235-12236	)	_	
68-19	12237-12248	Behavioural	_	
68-20	12249-12253	data	_	
68-21	12254-12259	Mixed	_	
68-22	12260-12266	ANOVAs	_	
68-23	12267-12271	were	_	
68-24	12272-12279	carried	_	
68-25	12280-12283	out	_	
68-26	12284-12287	for	_	
68-27	12288-12292	each	_	
68-28	12293-12295	of	_	
68-29	12296-12299	the	_	
68-30	12300-12304	four	_	
68-31	12305-12315	subjective	_	
68-32	12316-12322	rating	_	
68-33	12323-12329	scales	_	
68-34	12330-12334	with	_	
68-35	12335-12339	time	_	
68-36	12340-12342	of	_	
68-37	12343-12349	rating	_	
68-38	12350-12351	(	_	
68-39	12351-12354	six	_	
68-40	12355-12361	levels	_	
68-41	12362-12371	including	_	
68-42	12372-12373	a	_	
68-43	12374-12383	pre‐video	_	
68-44	12384-12392	baseline	_	
68-45	12393-12399	rating	_	
68-46	12399-12400	,	_	
68-47	12401-12406	three	_	
68-48	12407-12413	during	_	
68-49	12414-12417	the	_	
68-50	12418-12423	video	_	
68-51	12424-12427	and	_	
68-52	12428-12431	two	_	
68-53	12432-12442	post‐video	_	
68-54	12443-12450	ratings	_	
68-55	12450-12451	)	_	
68-56	12452-12455	and	_	
68-57	12456-12463	session	_	
68-58	12464-12465	(	_	
68-59	12465-12469	drug	_	
68-60	12470-12473	cue	_	
68-61	12473-12474	,	_	
68-62	12475-12482	neutral	_	
68-63	12482-12483	)	_	
68-64	12484-12486	as	_	
68-65	12487-12501	within‐subject	_	
68-66	12502-12509	factors	_	
68-67	12510-12513	and	_	
68-68	12514-12519	group	_	
68-69	12520-12521	(	_	
68-70	12521-12523	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
68-71	12523-12524	,	_	
68-72	12525-12527	OD	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse	
68-73	12527-12528	)	_	
68-74	12529-12531	as	_	
68-75	12532-12535	the	_	
68-76	12536-12551	between‐subject	_	
68-77	12552-12558	factor	_	
68-78	12558-12559	.	_	

#Text=Session order was included as a covariate.
69-1	12560-12567	Session	_	
69-2	12568-12573	order	_	
69-3	12574-12577	was	_	
69-4	12578-12586	included	_	
69-5	12587-12589	as	_	
69-6	12590-12591	a	_	
69-7	12592-12601	covariate	_	
69-8	12601-12602	.	_	

#Text=The pre‐video rating taken during the last minute of the baseline period (T0) was used as the pre‐video baseline rating.
70-1	12603-12606	The	_	
70-2	12607-12616	pre‐video	_	
70-3	12617-12623	rating	_	
70-4	12624-12629	taken	_	
70-5	12630-12636	during	_	
70-6	12637-12640	the	_	
70-7	12641-12645	last	_	
70-8	12646-12652	minute	_	
70-9	12653-12655	of	_	
70-10	12656-12659	the	_	
70-11	12660-12668	baseline	_	
70-12	12669-12675	period	_	
70-13	12676-12677	(	_	
70-14	12677-12679	T0	_	
70-15	12679-12680	)	_	
70-16	12681-12684	was	_	
70-17	12685-12689	used	_	
70-18	12690-12692	as	_	
70-19	12693-12696	the	_	
70-20	12697-12706	pre‐video	_	
70-21	12707-12715	baseline	_	
70-22	12716-12722	rating	_	
70-23	12722-12723	.	_	

#Text=A Greenhouse‐Geisser correction was applied when Mauchley's assumption of sphericity was violated.
71-1	12724-12725	A	_	
71-2	12726-12744	Greenhouse‐Geisser	_	
71-3	12745-12755	correction	_	
71-4	12756-12759	was	_	
71-5	12760-12767	applied	_	
71-6	12768-12772	when	_	
71-7	12773-12783	Mauchley's	_	
71-8	12784-12794	assumption	_	
71-9	12795-12797	of	_	
71-10	12798-12808	sphericity	_	
71-11	12809-12812	was	_	
71-12	12813-12821	violated	_	
71-13	12821-12822	.	_	

#Text=Ratings from one HC were not included as the participant could not see the rating scales.
72-1	12823-12830	Ratings	_	
72-2	12831-12835	from	_	
72-3	12836-12839	one	_	
72-4	12840-12842	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
72-5	12843-12847	were	_	
72-6	12848-12851	not	_	
72-7	12852-12860	included	_	
72-8	12861-12863	as	_	
72-9	12864-12867	the	_	
72-10	12868-12879	participant	_	
72-11	12880-12885	could	_	
72-12	12886-12889	not	_	
72-13	12890-12893	see	_	
72-14	12894-12897	the	_	
72-15	12898-12904	rating	_	
72-16	12905-12911	scales	_	
72-17	12911-12912	.	_	

#Text=Scanning and analysis
#Text=Whole brain T2* weighted images were acquired on a 3 Tesla Philips Achieva scanner with single shot, multi‐slice echo planar (EPI) pulse sequence.
73-1	12913-12921	Scanning	_	
73-2	12922-12925	and	_	
73-3	12926-12934	analysis	_	
73-4	12935-12940	Whole	_	
73-5	12941-12946	brain	_	
73-6	12947-12949	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[35]	
73-7	12949-12950	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[35]	
73-8	12951-12959	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[35]	
73-9	12960-12966	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[35]	
73-10	12967-12971	were	_	
73-11	12972-12980	acquired	_	
73-12	12981-12983	on	_	
73-13	12984-12985	a	_	
73-14	12986-12987	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[36]	
73-15	12988-12993	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[36]	
73-16	12994-13001	Philips	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[36]	
73-17	13002-13009	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[36]	
73-18	13010-13017	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[36]	
73-19	13018-13022	with	_	
73-20	13023-13029	single	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-21	13030-13034	shot	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-22	13034-13035	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-23	13036-13047	multi‐slice	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-24	13048-13052	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-25	13053-13059	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-26	13060-13061	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-27	13061-13064	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-28	13064-13065	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-29	13066-13071	pulse	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-30	13072-13080	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[37]	
73-31	13080-13081	.	_	

#Text=Each volume comprised 34 contiguous axial slices (TR = 2.5 s, TE = 35 ms, 96 × 96 matrix, in‐plane voxel size 3.0 mm × 3.0 mm, slice thickness 3.5 mm).
74-1	13082-13086	Each	_	
74-2	13087-13093	volume	_	
74-3	13094-13103	comprised	_	
74-4	13104-13106	34	_	
74-5	13107-13117	contiguous	_	
74-6	13118-13123	axial	_	
74-7	13124-13130	slices	_	
74-8	13131-13132	(	_	
74-9	13132-13134	TR	_	
74-10	13134-13135	 	_	
74-11	13135-13136	=	_	
74-12	13136-13137	 	_	
74-13	13137-13140	2.5	_	
74-14	13140-13141	 	_	
74-15	13141-13142	s	_	
74-16	13142-13143	,	_	
74-17	13144-13146	TE	_	
74-18	13146-13147	 	_	
74-19	13147-13148	=	_	
74-20	13148-13149	 	_	
74-21	13149-13151	35	_	
74-22	13151-13152	 	_	
74-23	13152-13154	ms	_	
74-24	13154-13155	,	_	
74-25	13156-13158	96	_	
74-26	13158-13159	 	_	
74-27	13159-13160	×	_	
74-28	13160-13161	 	_	
74-29	13161-13163	96	_	
74-30	13164-13170	matrix	_	
74-31	13170-13171	,	_	
74-32	13172-13180	in‐plane	_	
74-33	13181-13186	voxel	_	
74-34	13187-13191	size	_	
74-35	13192-13195	3.0	_	
74-36	13195-13196	 	_	
74-37	13196-13198	mm	_	
74-38	13198-13199	 	_	
74-39	13199-13200	×	_	
74-40	13200-13201	 	_	
74-41	13201-13204	3.0	_	
74-42	13204-13205	 	_	
74-43	13205-13207	mm	_	
74-44	13207-13208	,	_	
74-45	13209-13214	slice	_	
74-46	13215-13224	thickness	_	
74-47	13225-13228	3.5	_	
74-48	13228-13229	 	_	
74-49	13229-13231	mm	_	
74-50	13231-13232	)	_	
74-51	13232-13233	.	_	

#Text=A high‐resolution T1‐weighted structural image was also acquired for each participant for coregistration during preprocessing and to exclude any structural abnormality.
75-1	13234-13235	A	_	
75-2	13236-13251	high‐resolution	_	
75-3	13252-13254	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
75-4	13254-13255	‐	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
75-5	13255-13263	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
75-6	13264-13274	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
75-7	13275-13280	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[38]	
75-8	13281-13284	was	_	
75-9	13285-13289	also	_	
75-10	13290-13298	acquired	_	
75-11	13299-13302	for	_	
75-12	13303-13307	each	_	
75-13	13308-13319	participant	_	
75-14	13320-13323	for	_	
75-15	13324-13338	coregistration	_	
75-16	13339-13345	during	_	
75-17	13346-13359	preprocessing	_	
75-18	13360-13363	and	_	
75-19	13364-13366	to	_	
75-20	13367-13374	exclude	_	
75-21	13375-13378	any	_	
75-22	13379-13389	structural	_	
75-23	13390-13401	abnormality	_	
75-24	13401-13402	.	_	

#Text=Preprocessing
#Text=Functional data were analysed using statistical parametric mapping (SPM8; The Wellcome Department of Cognitive Neurology, London, UK) running in MATLAB (Matlab, R2012a; Mathworks, Natick, Massachusetts, U.S.A.).
76-1	13403-13416	Preprocessing	_	
76-2	13417-13427	Functional	_	
76-3	13428-13432	data	_	
76-4	13433-13437	were	_	
76-5	13438-13446	analysed	_	
76-6	13447-13452	using	_	
76-7	13453-13464	statistical	_	
76-8	13465-13475	parametric	_	
76-9	13476-13483	mapping	_	
76-10	13484-13485	(	_	
76-11	13485-13489	SPM8	_	
76-12	13489-13490	;	_	
76-13	13491-13494	The	_	
76-14	13495-13503	Wellcome	_	
76-15	13504-13514	Department	_	
76-16	13515-13517	of	_	
76-17	13518-13527	Cognitive	_	
76-18	13528-13537	Neurology	_	
76-19	13537-13538	,	_	
76-20	13539-13545	London	_	
76-21	13545-13546	,	_	
76-22	13547-13549	UK	_	
76-23	13549-13550	)	_	
76-24	13551-13558	running	_	
76-25	13559-13561	in	_	
76-26	13562-13568	MATLAB	_	
76-27	13569-13570	(	_	
76-28	13570-13576	Matlab	_	
76-29	13576-13577	,	_	
76-30	13578-13584	R2012a	_	
76-31	13584-13585	;	_	
76-32	13586-13595	Mathworks	_	
76-33	13595-13596	,	_	
76-34	13597-13603	Natick	_	
76-35	13603-13604	,	_	
76-36	13605-13618	Massachusetts	_	
76-37	13618-13619	,	_	
76-38	13620-13625	U.S.A	_	
76-39	13625-13626	.	_	
76-40	13626-13627	)	_	
76-41	13627-13628	.	_	

#Text=Functional images were realigned and coregistered with the T1 structural image before normalization of the functional images into standard space was carried out using the unified segmentation approach (Ashburner & Friston 2005).
77-1	13629-13639	Functional	_	
77-2	13640-13646	images	_	
77-3	13647-13651	were	_	
77-4	13652-13661	realigned	_	
77-5	13662-13665	and	_	
77-6	13666-13678	coregistered	_	
77-7	13679-13683	with	_	
77-8	13684-13687	the	_	
77-9	13688-13690	T1	_	
77-10	13691-13701	structural	_	
77-11	13702-13707	image	_	
77-12	13708-13714	before	_	
77-13	13715-13728	normalization	_	
77-14	13729-13731	of	_	
77-15	13732-13735	the	_	
77-16	13736-13746	functional	_	
77-17	13747-13753	images	_	
77-18	13754-13758	into	_	
77-19	13759-13767	standard	_	
77-20	13768-13773	space	_	
77-21	13774-13777	was	_	
77-22	13778-13785	carried	_	
77-23	13786-13789	out	_	
77-24	13790-13795	using	_	
77-25	13796-13799	the	_	
77-26	13800-13807	unified	_	
77-27	13808-13820	segmentation	_	
77-28	13821-13829	approach	_	
77-29	13830-13831	(	_	
77-30	13831-13840	Ashburner	_	
77-31	13841-13842	&	_	
77-32	13843-13850	Friston	_	
77-33	13851-13855	2005	_	
77-34	13855-13856	)	_	
77-35	13856-13857	.	_	

#Text=Normalized images were smoothed using an 8‐mm Gaussian kernel.
78-1	13858-13868	Normalized	_	
78-2	13869-13875	images	_	
78-3	13876-13880	were	_	
78-4	13881-13889	smoothed	_	
78-5	13890-13895	using	_	
78-6	13896-13898	an	_	
78-7	13899-13900	8	_	
78-8	13900-13901	‐	_	
78-9	13901-13903	mm	_	
78-10	13904-13912	Gaussian	_	
78-11	13913-13919	kernel	_	
78-12	13919-13920	.	_	

#Text=The smoothed functional images of the participants who moved more than 1 voxel were repaired by an interpolation method using the artefact repair toolbox (http://cibsr.stanford.edu/tools/ArtRepair/ArtRepair.htm).
79-1	13921-13924	The	_	
79-2	13925-13933	smoothed	_	
79-3	13934-13944	functional	_	
79-4	13945-13951	images	_	
79-5	13952-13954	of	_	
79-6	13955-13958	the	_	
79-7	13959-13971	participants	_	
79-8	13972-13975	who	_	
79-9	13976-13981	moved	_	
79-10	13982-13986	more	_	
79-11	13987-13991	than	_	
79-12	13992-13993	1	_	
79-13	13993-13994	 	_	
79-14	13994-13999	voxel	_	
79-15	14000-14004	were	_	
79-16	14005-14013	repaired	_	
79-17	14014-14016	by	_	
79-18	14017-14019	an	_	
79-19	14020-14033	interpolation	_	
79-20	14034-14040	method	_	
79-21	14041-14046	using	_	
79-22	14047-14050	the	_	
79-23	14051-14059	artefact	_	
79-24	14060-14066	repair	_	
79-25	14067-14074	toolbox	_	
79-26	14075-14076	(	_	
79-27	14076-14080	http	_	
79-28	14080-14081	:	_	
79-29	14081-14082	/	_	
79-30	14082-14083	/	_	
79-31	14083-14101	cibsr.stanford.edu	_	
79-32	14101-14102	/	_	
79-33	14102-14107	tools	_	
79-34	14107-14108	/	_	
79-35	14108-14117	ArtRepair	_	
79-36	14117-14118	/	_	
79-37	14118-14131	ArtRepair.htm	_	
79-38	14131-14132	)	_	
79-39	14132-14133	.	_	

#Text=Two ODs with excessive movement were excluded (>10 percent volumes needing repairing).
80-1	14134-14137	Two	_	
80-2	14138-14141	ODs	_	
80-3	14142-14146	with	_	
80-4	14147-14156	excessive	_	
80-5	14157-14165	movement	_	
80-6	14166-14170	were	_	
80-7	14171-14179	excluded	_	
80-8	14180-14181	(	_	
80-9	14181-14182	>	_	
80-10	14182-14184	10	_	
80-11	14185-14192	percent	_	
80-12	14193-14200	volumes	_	
80-13	14201-14208	needing	_	
80-14	14209-14218	repairing	_	
80-15	14218-14219	)	_	
80-16	14219-14220	.	_	

#Text=Eighteen ODs and 20 HCs were entered into subsequent analyses.
81-1	14221-14229	Eighteen	_	
81-2	14230-14233	ODs	_	
81-3	14234-14237	and	_	
81-4	14238-14240	20	_	
81-5	14241-14244	HCs	_	
81-6	14245-14249	were	_	
81-7	14250-14257	entered	_	
81-8	14258-14262	into	_	
81-9	14263-14273	subsequent	_	
81-10	14274-14282	analyses	_	
81-11	14282-14283	.	_	

#Text=First‐level analysis
#Text=For both the drug cue and the neutral session, data were acquired continuously for 20 minutes (5 minutes before the start of each video to allow participants to acclimatize to the scanner environment, 10 minutes during presentation of the video and an additional 5 minutes after the end of the video) (Fig. 1).
82-1	14284-14295	First‐level	_	
82-2	14296-14304	analysis	_	
82-3	14305-14308	For	_	
82-4	14309-14313	both	_	
82-5	14314-14317	the	_	
82-6	14318-14322	drug	_	
82-7	14323-14326	cue	_	
82-8	14327-14330	and	_	
82-9	14331-14334	the	_	
82-10	14335-14342	neutral	_	
82-11	14343-14350	session	_	
82-12	14350-14351	,	_	
82-13	14352-14356	data	_	
82-14	14357-14361	were	_	
82-15	14362-14370	acquired	_	
82-16	14371-14383	continuously	_	
82-17	14384-14387	for	_	
82-18	14388-14390	20	_	
82-19	14390-14391	 	_	
82-20	14391-14398	minutes	_	
82-21	14399-14400	(	_	
82-22	14400-14401	5	_	
82-23	14401-14402	 	_	
82-24	14402-14409	minutes	_	
82-25	14410-14416	before	_	
82-26	14417-14420	the	_	
82-27	14421-14426	start	_	
82-28	14427-14429	of	_	
82-29	14430-14434	each	_	
82-30	14435-14440	video	_	
82-31	14441-14443	to	_	
82-32	14444-14449	allow	_	
82-33	14450-14462	participants	_	
82-34	14463-14465	to	_	
82-35	14466-14477	acclimatize	_	
82-36	14478-14480	to	_	
82-37	14481-14484	the	_	
82-38	14485-14492	scanner	_	
82-39	14493-14504	environment	_	
82-40	14504-14505	,	_	
82-41	14506-14508	10	_	
82-42	14508-14509	 	_	
82-43	14509-14516	minutes	_	
82-44	14517-14523	during	_	
82-45	14524-14536	presentation	_	
82-46	14537-14539	of	_	
82-47	14540-14543	the	_	
82-48	14544-14549	video	_	
82-49	14550-14553	and	_	
82-50	14554-14556	an	_	
82-51	14557-14567	additional	_	
82-52	14568-14569	5	_	
82-53	14569-14570	 	_	
82-54	14570-14577	minutes	_	
82-55	14578-14583	after	_	
82-56	14584-14587	the	_	
82-57	14588-14591	end	_	
82-58	14592-14594	of	_	
82-59	14595-14598	the	_	
82-60	14599-14604	video	_	
82-61	14604-14605	)	_	
82-62	14606-14607	(	_	
82-63	14607-14610	Fig	_	
82-64	14610-14611	.	_	
82-65	14611-14612	 	_	
82-66	14612-14613	1	_	
82-67	14613-14614	)	_	
82-68	14614-14615	.	_	

#Text=The resultant 480 acquired scans were divided into 1‐minute time‐bins (20 time‐bins in total).
83-1	14616-14619	The	_	
83-2	14620-14629	resultant	_	
83-3	14630-14633	480	_	
83-4	14634-14642	acquired	_	
83-5	14643-14648	scans	_	
83-6	14649-14653	were	_	
83-7	14654-14661	divided	_	
83-8	14662-14666	into	_	
83-9	14667-14668	1	_	
83-10	14668-14669	‐	_	
83-11	14669-14675	minute	_	
83-12	14676-14685	time‐bins	_	
83-13	14686-14687	(	_	
83-14	14687-14689	20	_	
83-15	14690-14699	time‐bins	_	
83-16	14700-14702	in	_	
83-17	14703-14708	total	_	
83-18	14708-14709	)	_	
83-19	14709-14710	.	_	

#Text=The 5th minute of the pre‐video baseline was treated as the baseline time‐bin T0, with each subsequent time‐bin (T1–15) compared with T0 using regression analysis within a general linear model framework.
84-1	14711-14714	The	_	
84-2	14715-14718	5th	_	
84-3	14719-14725	minute	_	
84-4	14726-14728	of	_	
84-5	14729-14732	the	_	
84-6	14733-14742	pre‐video	_	
84-7	14743-14751	baseline	_	
84-8	14752-14755	was	_	
84-9	14756-14763	treated	_	
84-10	14764-14766	as	_	
84-11	14767-14770	the	_	
84-12	14771-14779	baseline	_	
84-13	14780-14788	time‐bin	_	
84-14	14789-14791	T0	_	
84-15	14791-14792	,	_	
84-16	14793-14797	with	_	
84-17	14798-14802	each	_	
84-18	14803-14813	subsequent	_	
84-19	14814-14822	time‐bin	_	
84-20	14823-14824	(	_	
84-21	14824-14826	T1	_	
84-22	14826-14827	–	_	
84-23	14827-14829	15	_	
84-24	14829-14830	)	_	
84-25	14831-14839	compared	_	
84-26	14840-14844	with	_	
84-27	14845-14847	T0	_	
84-28	14848-14853	using	_	
84-29	14854-14864	regression	_	
84-30	14865-14873	analysis	_	
84-31	14874-14880	within	_	
84-32	14881-14882	a	_	
84-33	14883-14890	general	_	
84-34	14891-14897	linear	_	
84-35	14898-14903	model	_	
84-36	14904-14913	framework	_	
84-37	14913-14914	.	_	

#Text=The exact shape of the signal of interest was unknown; therefore, no high‐pass filter was used.
85-1	14915-14918	The	_	
85-2	14919-14924	exact	_	
85-3	14925-14930	shape	_	
85-4	14931-14933	of	_	
85-5	14934-14937	the	_	
85-6	14938-14944	signal	_	
85-7	14945-14947	of	_	
85-8	14948-14956	interest	_	
85-9	14957-14960	was	_	
85-10	14961-14968	unknown	_	
85-11	14968-14969	;	_	
85-12	14970-14979	therefore	_	
85-13	14979-14980	,	_	
85-14	14981-14983	no	_	
85-15	14984-14993	high‐pass	_	
85-16	14994-15000	filter	_	
85-17	15001-15004	was	_	
85-18	15005-15009	used	_	
85-19	15009-15010	.	_	

#Text=The neutral session averages were subtracted from the time equivalent drug cue session averages, resulting in ‘drug cue session–neutral session’ contrast images.
86-1	15011-15014	The	_	
86-2	15015-15022	neutral	_	
86-3	15023-15030	session	_	
86-4	15031-15039	averages	_	
86-5	15040-15044	were	_	
86-6	15045-15055	subtracted	_	
86-7	15056-15060	from	_	
86-8	15061-15064	the	_	
86-9	15065-15069	time	_	
86-10	15070-15080	equivalent	_	
86-11	15081-15085	drug	_	
86-12	15086-15089	cue	_	
86-13	15090-15097	session	_	
86-14	15098-15106	averages	_	
86-15	15106-15107	,	_	
86-16	15108-15117	resulting	_	
86-17	15118-15120	in	_	
86-18	15121-15122	‘	_	
86-19	15122-15126	drug	_	
86-20	15127-15130	cue	_	
86-21	15131-15146	session–neutral	_	
86-22	15147-15154	session	_	
86-23	15154-15155	’	_	
86-24	15156-15164	contrast	_	
86-25	15165-15171	images	_	
86-26	15171-15172	.	_	

#Text=Region‐of‐interest analysis
#Text=A region‐of‐interest (ROI) approach was used to extract time course signals from key brain regions involved in drug cue reactivity based on recent meta‐analyses (Chase et al. 2011; Kuhn & Gallinat 2011).
87-1	15173-15191	Region‐of‐interest	_	
87-2	15192-15200	analysis	_	
87-3	15201-15202	A	_	
87-4	15203-15221	region‐of‐interest	_	
87-5	15222-15223	(	_	
87-6	15223-15226	ROI	_	
87-7	15226-15227	)	_	
87-8	15228-15236	approach	_	
87-9	15237-15240	was	_	
87-10	15241-15245	used	_	
87-11	15246-15248	to	_	
87-12	15249-15256	extract	_	
87-13	15257-15261	time	_	
87-14	15262-15268	course	_	
87-15	15269-15276	signals	_	
87-16	15277-15281	from	_	
87-17	15282-15285	key	_	
87-18	15286-15291	brain	_	
87-19	15292-15299	regions	_	
87-20	15300-15308	involved	_	
87-21	15309-15311	in	_	
87-22	15312-15316	drug	_	
87-23	15317-15320	cue	_	
87-24	15321-15331	reactivity	_	
87-25	15332-15337	based	_	
87-26	15338-15340	on	_	
87-27	15341-15347	recent	_	
87-28	15348-15361	meta‐analyses	_	
87-29	15362-15363	(	_	
87-30	15363-15368	Chase	_	
87-31	15369-15371	et	_	
87-32	15372-15374	al	_	
87-33	15374-15375	.	_	
87-34	15376-15380	2011	_	
87-35	15380-15381	;	_	
87-36	15382-15386	Kuhn	_	
87-37	15387-15388	&	_	
87-38	15389-15397	Gallinat	_	
87-39	15398-15402	2011	_	
87-40	15402-15403	)	_	
87-41	15403-15404	.	_	

#Text=These composed of spheres of 7‐mm radius centred around the bilateral ventral striatum, amygdala and VmPFC, coordinates from Chase et al. (2011), and anterior cingulate cortex, coordinates from Kuhn & Gallinat (2011), as displayed in Fig. 3.
88-1	15405-15410	These	_	
88-2	15411-15419	composed	_	
88-3	15420-15422	of	_	
88-4	15423-15430	spheres	_	
88-5	15431-15433	of	_	
88-6	15434-15435	7	_	
88-7	15435-15436	‐	_	
88-8	15436-15438	mm	_	
88-9	15439-15445	radius	_	
88-10	15446-15453	centred	_	
88-11	15454-15460	around	_	
88-12	15461-15464	the	_	
88-13	15465-15474	bilateral	_	
88-14	15475-15482	ventral	_	
88-15	15483-15491	striatum	_	
88-16	15491-15492	,	_	
88-17	15493-15501	amygdala	_	
88-18	15502-15505	and	_	
88-19	15506-15511	VmPFC	_	
88-20	15511-15512	,	_	
88-21	15513-15524	coordinates	_	
88-22	15525-15529	from	_	
88-23	15530-15535	Chase	_	
88-24	15536-15538	et	_	
88-25	15539-15541	al	_	
88-26	15541-15542	.	_	
88-27	15543-15544	(	_	
88-28	15544-15548	2011	_	
88-29	15548-15549	)	_	
88-30	15549-15550	,	_	
88-31	15551-15554	and	_	
88-32	15555-15563	anterior	_	
88-33	15564-15573	cingulate	_	
88-34	15574-15580	cortex	_	
88-35	15580-15581	,	_	
88-36	15582-15593	coordinates	_	
88-37	15594-15598	from	_	
88-38	15599-15603	Kuhn	_	
88-39	15604-15605	&	_	
88-40	15606-15614	Gallinat	_	
88-41	15615-15616	(	_	
88-42	15616-15620	2011	_	
88-43	15620-15621	)	_	
88-44	15621-15622	,	_	
88-45	15623-15625	as	_	
88-46	15626-15635	displayed	_	
88-47	15636-15638	in	_	
88-48	15639-15642	Fig	_	
88-49	15642-15643	.	_	
88-50	15643-15644	 	_	
88-51	15644-15645	3	_	
88-52	15645-15646	.	_	

#Text=Mean drug cue‐neutral session contrast estimates were extracted from each of the six ROIs using the Easy ROI toolbox implemented in SPM (http://www.sbirc.ed.ac.uk/LCL/LCL_M1.html) and entered into mixed ANOVAs in SPSS (version 20) to investigate effects of time and group on drug cue‐neutral session BOLD signal.
89-1	15647-15651	Mean	_	
89-2	15652-15656	drug	_	
89-3	15657-15668	cue‐neutral	_	
89-4	15669-15676	session	_	
89-5	15677-15685	contrast	_	
89-6	15686-15695	estimates	_	
89-7	15696-15700	were	_	
89-8	15701-15710	extracted	_	
89-9	15711-15715	from	_	
89-10	15716-15720	each	_	
89-11	15721-15723	of	_	
89-12	15724-15727	the	_	
89-13	15728-15731	six	_	
89-14	15732-15736	ROIs	_	
89-15	15737-15742	using	_	
89-16	15743-15746	the	_	
89-17	15747-15751	Easy	_	
89-18	15752-15755	ROI	_	
89-19	15756-15763	toolbox	_	
89-20	15764-15775	implemented	_	
89-21	15776-15778	in	_	
89-22	15779-15782	SPM	_	
89-23	15783-15784	(	_	
89-24	15784-15788	http	_	
89-25	15788-15789	:	_	
89-26	15789-15790	/	_	
89-27	15790-15791	/	_	
89-28	15791-15809	www.sbirc.ed.ac.uk	_	
89-29	15809-15810	/	_	
89-30	15810-15813	LCL	_	
89-31	15813-15814	/	_	
89-32	15814-15820	LCL_M1	_	
89-33	15820-15821	.	_	
89-34	15821-15825	html	_	
89-35	15825-15826	)	_	
89-36	15827-15830	and	_	
89-37	15831-15838	entered	_	
89-38	15839-15843	into	_	
89-39	15844-15849	mixed	_	
89-40	15850-15856	ANOVAs	_	
89-41	15857-15859	in	_	
89-42	15860-15864	SPSS	_	
89-43	15865-15866	(	_	
89-44	15866-15873	version	_	
89-45	15874-15876	20	_	
89-46	15876-15877	)	_	
89-47	15878-15880	to	_	
89-48	15881-15892	investigate	_	
89-49	15893-15900	effects	_	
89-50	15901-15903	of	_	
89-51	15904-15908	time	_	
89-52	15909-15912	and	_	
89-53	15913-15918	group	_	
89-54	15919-15921	on	_	
89-55	15922-15926	drug	_	
89-56	15927-15938	cue‐neutral	_	
89-57	15939-15946	session	_	
89-58	15947-15951	BOLD	_	
89-59	15952-15958	signal	_	
89-60	15958-15959	.	_	

#Text=Investigations were carried out for the whole session (T0 to T15) and for the video time‐bins (T1–T10) and post‐video time‐bins separately (T11 to T15) with session order included as a covariate.
90-1	15960-15974	Investigations	_	
90-2	15975-15979	were	_	
90-3	15980-15987	carried	_	
90-4	15988-15991	out	_	
90-5	15992-15995	for	_	
90-6	15996-15999	the	_	
90-7	16000-16005	whole	_	
90-8	16006-16013	session	_	
90-9	16014-16015	(	_	
90-10	16015-16017	T0	_	
90-11	16018-16020	to	_	
90-12	16021-16024	T15	_	
90-13	16024-16025	)	_	
90-14	16026-16029	and	_	
90-15	16030-16033	for	_	
90-16	16034-16037	the	_	
90-17	16038-16043	video	_	
90-18	16044-16053	time‐bins	_	
90-19	16054-16055	(	_	
90-20	16055-16057	T1	_	
90-21	16057-16058	–	_	
90-22	16058-16061	T10	_	
90-23	16061-16062	)	_	
90-24	16063-16066	and	_	
90-25	16067-16077	post‐video	_	
90-26	16078-16087	time‐bins	_	
90-27	16088-16098	separately	_	
90-28	16099-16100	(	_	
90-29	16100-16103	T11	_	
90-30	16104-16106	to	_	
90-31	16107-16110	T15	_	
90-32	16110-16111	)	_	
90-33	16112-16116	with	_	
90-34	16117-16124	session	_	
90-35	16125-16130	order	_	
90-36	16131-16139	included	_	
90-37	16140-16142	as	_	
90-38	16143-16144	a	_	
90-39	16145-16154	covariate	_	
90-40	16154-16155	.	_	

#Text=A Greenhouse‐Geisser correction was applied when Mauchley's assumption of sphericity was violated.
91-1	16156-16157	A	_	
91-2	16158-16176	Greenhouse‐Geisser	_	
91-3	16177-16187	correction	_	
91-4	16188-16191	was	_	
91-5	16192-16199	applied	_	
91-6	16200-16204	when	_	
91-7	16205-16215	Mauchley's	_	
91-8	16216-16226	assumption	_	
91-9	16227-16229	of	_	
91-10	16230-16240	sphericity	_	
91-11	16241-16244	was	_	
91-12	16245-16253	violated	_	
91-13	16253-16254	.	_	

#Text=A Bonferroni correction for the six separate ROIs results in a significance value of p < 0.008 for this analysis.
92-1	16255-16256	A	_	
92-2	16257-16267	Bonferroni	_	
92-3	16268-16278	correction	_	
92-4	16279-16282	for	_	
92-5	16283-16286	the	_	
92-6	16287-16290	six	_	
92-7	16291-16299	separate	_	
92-8	16300-16304	ROIs	_	
92-9	16305-16312	results	_	
92-10	16313-16315	in	_	
92-11	16316-16317	a	_	
92-12	16318-16330	significance	_	
92-13	16331-16336	value	_	
92-14	16337-16339	of	_	
92-15	16340-16341	p	_	
92-16	16341-16342	 	_	
92-17	16342-16343	<	_	
92-18	16343-16344	 	_	
92-19	16344-16349	0.008	_	
92-20	16350-16353	for	_	
92-21	16354-16358	this	_	
92-22	16359-16367	analysis	_	
92-23	16367-16368	.	_	

#Text=However, this is a conservative approach, which may result in false negatives.
93-1	16369-16376	However	_	
93-2	16376-16377	,	_	
93-3	16378-16382	this	_	
93-4	16383-16385	is	_	
93-5	16386-16387	a	_	
93-6	16388-16400	conservative	_	
93-7	16401-16409	approach	_	
93-8	16409-16410	,	_	
93-9	16411-16416	which	_	
93-10	16417-16420	may	_	
93-11	16421-16427	result	_	
93-12	16428-16430	in	_	
93-13	16431-16436	false	_	
93-14	16437-16446	negatives	_	
93-15	16446-16447	.	_	

#Text=Results are therefore reported significant at p < 0.05 with results surviving Bonferroni correction highlighted.
94-1	16448-16455	Results	_	
94-2	16456-16459	are	_	
94-3	16460-16469	therefore	_	
94-4	16470-16478	reported	_	
94-5	16479-16490	significant	_	
94-6	16491-16493	at	_	
94-7	16494-16495	p	_	
94-8	16495-16496	 	_	
94-9	16496-16497	<	_	
94-10	16497-16498	 	_	
94-11	16498-16502	0.05	_	
94-12	16503-16507	with	_	
94-13	16508-16515	results	_	
94-14	16516-16525	surviving	_	
94-15	16526-16536	Bonferroni	_	
94-16	16537-16547	correction	_	
94-17	16548-16559	highlighted	_	
94-18	16559-16560	.	_	

#Text=ROI BOLD signal time course and subjective rating time course temporal correlation analysis
#Text=In participants reporting a subjective rating change in response to the drug cue session, we investigated whether their subjective rating time course was temporally correlated with fMRI signal in the ROIs.
95-1	16562-16565	ROI	_	
95-2	16566-16570	BOLD	_	
95-3	16571-16577	signal	_	
95-4	16578-16582	time	_	
95-5	16583-16589	course	_	
95-6	16590-16593	and	_	
95-7	16594-16604	subjective	_	
95-8	16605-16611	rating	_	
95-9	16612-16616	time	_	
95-10	16617-16623	course	_	
95-11	16624-16632	temporal	_	
95-12	16633-16644	correlation	_	
95-13	16645-16653	analysis	_	
95-14	16654-16656	In	_	
95-15	16657-16669	participants	_	
95-16	16670-16679	reporting	_	
95-17	16680-16681	a	_	
95-18	16682-16692	subjective	_	
95-19	16693-16699	rating	_	
95-20	16700-16706	change	_	
95-21	16707-16709	in	_	
95-22	16710-16718	response	_	
95-23	16719-16721	to	_	
95-24	16722-16725	the	_	
95-25	16726-16730	drug	_	
95-26	16731-16734	cue	_	
95-27	16735-16742	session	_	
95-28	16742-16743	,	_	
95-29	16744-16746	we	_	
95-30	16747-16759	investigated	_	
95-31	16760-16767	whether	_	
95-32	16768-16773	their	_	
95-33	16774-16784	subjective	_	
95-34	16785-16791	rating	_	
95-35	16792-16796	time	_	
95-36	16797-16803	course	_	
95-37	16804-16807	was	_	
95-38	16808-16818	temporally	_	
95-39	16819-16829	correlated	_	
95-40	16830-16834	with	_	
95-41	16835-16839	fMRI	_	
95-42	16840-16846	signal	_	
95-43	16847-16849	in	_	
95-44	16850-16853	the	_	
95-45	16854-16858	ROIs	_	
95-46	16858-16859	.	_	

#Text=Analyses were restricted to subjective ratings and ROI BOLD signal time courses, demonstrating significant effects in the ANOVAs.
96-1	16860-16868	Analyses	_	
96-2	16869-16873	were	_	
96-3	16874-16884	restricted	_	
96-4	16885-16887	to	_	
96-5	16888-16898	subjective	_	
96-6	16899-16906	ratings	_	
96-7	16907-16910	and	_	
96-8	16911-16914	ROI	_	
96-9	16915-16919	BOLD	_	
96-10	16920-16926	signal	_	
96-11	16927-16931	time	_	
96-12	16932-16939	courses	_	
96-13	16939-16940	,	_	
96-14	16941-16954	demonstrating	_	
96-15	16955-16966	significant	_	
96-16	16967-16974	effects	_	
96-17	16975-16977	in	_	
96-18	16978-16981	the	_	
96-19	16982-16988	ANOVAs	_	
96-20	16988-16989	.	_	

#Text=Before correlations were carried out, the pre‐video baseline subjective rating was subtracted from each video and post‐video rating for each session.
97-1	16990-16996	Before	_	
97-2	16997-17009	correlations	_	
97-3	17010-17014	were	_	
97-4	17015-17022	carried	_	
97-5	17023-17026	out	_	
97-6	17026-17027	,	_	
97-7	17028-17031	the	_	
97-8	17032-17041	pre‐video	_	
97-9	17042-17050	baseline	_	
97-10	17051-17061	subjective	_	
97-11	17062-17068	rating	_	
97-12	17069-17072	was	_	
97-13	17073-17083	subtracted	_	
97-14	17084-17088	from	_	
97-15	17089-17093	each	_	
97-16	17094-17099	video	_	
97-17	17100-17103	and	_	
97-18	17104-17114	post‐video	_	
97-19	17115-17121	rating	_	
97-20	17122-17125	for	_	
97-21	17126-17130	each	_	
97-22	17131-17138	session	_	
97-23	17138-17139	.	_	

#Text=The neutral session ratings were then subtracted from the drug cue session ratings.
98-1	17140-17143	The	_	
98-2	17144-17151	neutral	_	
98-3	17152-17159	session	_	
98-4	17160-17167	ratings	_	
98-5	17168-17172	were	_	
98-6	17173-17177	then	_	
98-7	17178-17188	subtracted	_	
98-8	17189-17193	from	_	
98-9	17194-17197	the	_	
98-10	17198-17202	drug	_	
98-11	17203-17206	cue	_	
98-12	17207-17214	session	_	
98-13	17215-17222	ratings	_	
98-14	17222-17223	.	_	

#Text=This was to ensure both the fMRI and subjective rating data reflected drug cue session changes from baseline minus neutral session changes from baseline (fMRI data already in this format after first‐level analysis).
99-1	17224-17228	This	_	
99-2	17229-17232	was	_	
99-3	17233-17235	to	_	
99-4	17236-17242	ensure	_	
99-5	17243-17247	both	_	
99-6	17248-17251	the	_	
99-7	17252-17256	fMRI	_	
99-8	17257-17260	and	_	
99-9	17261-17271	subjective	_	
99-10	17272-17278	rating	_	
99-11	17279-17283	data	_	
99-12	17284-17293	reflected	_	
99-13	17294-17298	drug	_	
99-14	17299-17302	cue	_	
99-15	17303-17310	session	_	
99-16	17311-17318	changes	_	
99-17	17319-17323	from	_	
99-18	17324-17332	baseline	_	
99-19	17333-17338	minus	_	
99-20	17339-17346	neutral	_	
99-21	17347-17354	session	_	
99-22	17355-17362	changes	_	
99-23	17363-17367	from	_	
99-24	17368-17376	baseline	_	
99-25	17377-17378	(	_	
99-26	17378-17382	fMRI	_	
99-27	17383-17387	data	_	
99-28	17388-17395	already	_	
99-29	17396-17398	in	_	
99-30	17399-17403	this	_	
99-31	17404-17410	format	_	
99-32	17411-17416	after	_	
99-33	17417-17428	first‐level	_	
99-34	17429-17437	analysis	_	
99-35	17437-17438	)	_	
99-36	17438-17439	.	_	

#Text=Finally, the fMRI BOLD signal data were averaged over 3‐minute intervals to reflect the 3‐minute interval of subjective rating presentation during each session.
100-1	17440-17447	Finally	_	
100-2	17447-17448	,	_	
100-3	17449-17452	the	_	
100-4	17453-17457	fMRI	_	
100-5	17458-17462	BOLD	_	
100-6	17463-17469	signal	_	
100-7	17470-17474	data	_	
100-8	17475-17479	were	_	
100-9	17480-17488	averaged	_	
100-10	17489-17493	over	_	
100-11	17494-17495	3	_	
100-12	17495-17496	‐	_	
100-13	17496-17502	minute	_	
100-14	17503-17512	intervals	_	
100-15	17513-17515	to	_	
100-16	17516-17523	reflect	_	
100-17	17524-17527	the	_	
100-18	17528-17529	3	_	
100-19	17529-17530	‐	_	
100-20	17530-17536	minute	_	
100-21	17537-17545	interval	_	
100-22	17546-17548	of	_	
100-23	17549-17559	subjective	_	
100-24	17560-17566	rating	_	
100-25	17567-17579	presentation	_	
100-26	17580-17586	during	_	
100-27	17587-17591	each	_	
100-28	17592-17599	session	_	
100-29	17599-17600	.	_	

#Text=Correlational analyses were carried out between each individual's subjective rating and ROI BOLD signal time courses using Pearson's product moment correlation coefficient.
101-1	17601-17614	Correlational	_	
101-2	17615-17623	analyses	_	
101-3	17624-17628	were	_	
101-4	17629-17636	carried	_	
101-5	17637-17640	out	_	
101-6	17641-17648	between	_	
101-7	17649-17653	each	_	
101-8	17654-17666	individual's	_	
101-9	17667-17677	subjective	_	
101-10	17678-17684	rating	_	
101-11	17685-17688	and	_	
101-12	17689-17692	ROI	_	
101-13	17693-17697	BOLD	_	
101-14	17698-17704	signal	_	
101-15	17705-17709	time	_	
101-16	17710-17717	courses	_	
101-17	17718-17723	using	_	
101-18	17724-17733	Pearson's	_	
101-19	17734-17741	product	_	
101-20	17742-17748	moment	_	
101-21	17749-17760	correlation	_	
101-22	17761-17772	coefficient	_	
101-23	17772-17773	.	_	

#Text=Resultant correlation coefficients were Fisher's z‐transformed and entered into one‐sample t‐tests to determine group level significance.
102-1	17774-17783	Resultant	_	
102-2	17784-17795	correlation	_	
102-3	17796-17808	coefficients	_	
102-4	17809-17813	were	_	
102-5	17814-17822	Fisher's	_	
102-6	17823-17836	z‐transformed	_	
102-7	17837-17840	and	_	
102-8	17841-17848	entered	_	
102-9	17849-17853	into	_	
102-10	17854-17864	one‐sample	_	
102-11	17865-17872	t‐tests	_	
102-12	17873-17875	to	_	
102-13	17876-17885	determine	_	
102-14	17886-17891	group	_	
102-15	17892-17897	level	_	
102-16	17898-17910	significance	_	
102-17	17910-17911	.	_	

#Text=Results
#Text=Subjective ratings
#Text=Craving
#Text=All main effects and two‐way interactions were significant (p < 0.001) as was the time × session × group interaction [F(3.54, 123.93) = 7.54, p < 0.001].
103-1	17912-17919	Results	_	
103-2	17920-17930	Subjective	_	
103-3	17931-17938	ratings	_	
103-4	17939-17946	Craving	_	
103-5	17947-17950	All	_	
103-6	17951-17955	main	_	
103-7	17956-17963	effects	_	
103-8	17964-17967	and	_	
103-9	17968-17975	two‐way	_	
103-10	17976-17988	interactions	_	
103-11	17989-17993	were	_	
103-12	17994-18005	significant	_	
103-13	18006-18007	(	_	
103-14	18007-18008	p	_	
103-15	18008-18009	 	_	
103-16	18009-18010	<	_	
103-17	18010-18011	 	_	
103-18	18011-18016	0.001	_	
103-19	18016-18017	)	_	
103-20	18018-18020	as	_	
103-21	18021-18024	was	_	
103-22	18025-18028	the	_	
103-23	18029-18033	time	_	
103-24	18033-18034	 	_	
103-25	18034-18035	×	_	
103-26	18035-18036	 	_	
103-27	18036-18043	session	_	
103-28	18043-18044	 	_	
103-29	18044-18045	×	_	
103-30	18045-18046	 	_	
103-31	18046-18051	group	_	
103-32	18052-18063	interaction	_	
103-33	18064-18065	[	_	
103-34	18065-18066	F	_	
103-35	18066-18067	(	_	
103-36	18067-18071	3.54	_	
103-37	18071-18072	,	_	
103-38	18073-18079	123.93	_	
103-39	18079-18080	)	_	
103-40	18080-18081	 	_	
103-41	18081-18082	=	_	
103-42	18082-18083	 	_	
103-43	18083-18087	7.54	_	
103-44	18087-18088	,	_	
103-45	18089-18090	p	_	
103-46	18090-18091	 	_	
103-47	18091-18092	<	_	
103-48	18092-18093	 	_	
103-49	18093-18098	0.001	_	
103-50	18098-18099	]	_	
103-51	18099-18100	.	_	

#Text=Subjective craving increased significantly during the drug session in the OD group only as shown in Fig. 2.
104-1	18101-18111	Subjective	_	
104-2	18112-18119	craving	_	
104-3	18120-18129	increased	_	
104-4	18130-18143	significantly	_	
104-5	18144-18150	during	_	
104-6	18151-18154	the	_	
104-7	18155-18159	drug	_	
104-8	18160-18167	session	_	
104-9	18168-18170	in	_	
104-10	18171-18174	the	_	
104-11	18175-18177	OD	_	
104-12	18178-18183	group	_	
104-13	18184-18188	only	_	
104-14	18189-18191	as	_	
104-15	18192-18197	shown	_	
104-16	18198-18200	in	_	
104-17	18201-18204	Fig	_	
104-18	18204-18205	.	_	
104-19	18205-18206	 	_	
104-20	18206-18207	2	_	
104-21	18207-18208	.	_	

#Text=Subjective ratings taken during both the drug cue and neutral session in ODs (n = 18) and HCs (n = 20).
105-1	18209-18219	Subjective	_	
105-2	18220-18227	ratings	_	
105-3	18228-18233	taken	_	
105-4	18234-18240	during	_	
105-5	18241-18245	both	_	
105-6	18246-18249	the	_	
105-7	18250-18254	drug	_	
105-8	18255-18258	cue	_	
105-9	18259-18262	and	_	
105-10	18263-18270	neutral	_	
105-11	18271-18278	session	_	
105-12	18279-18281	in	_	
105-13	18282-18285	ODs	_	
105-14	18286-18287	(	_	
105-15	18287-18288	n	_	
105-16	18288-18289	 	_	
105-17	18289-18290	=	_	
105-18	18290-18291	 	_	
105-19	18291-18293	18	_	
105-20	18293-18294	)	_	
105-21	18295-18298	and	_	
105-22	18299-18302	HCs	_	
105-23	18303-18304	(	_	
105-24	18304-18305	n	_	
105-25	18305-18306	 	_	
105-26	18306-18307	=	_	
105-27	18307-18308	 	_	
105-28	18308-18310	20	_	
105-29	18310-18311	)	_	
105-30	18311-18312	.	_	

#Text=Ratings were taken every 3 minutes throughout each session: 1 (not at all), 2 (slight), 3 (moderate) and 4 (extreme).
106-1	18313-18320	Ratings	_	
106-2	18321-18325	were	_	
106-3	18326-18331	taken	_	
106-4	18332-18337	every	_	
106-5	18338-18339	3	_	
106-6	18339-18340	 	_	
106-7	18340-18347	minutes	_	
106-8	18348-18358	throughout	_	
106-9	18359-18363	each	_	
106-10	18364-18371	session	_	
106-11	18371-18372	:	_	
106-12	18373-18374	1	_	
106-13	18375-18376	(	_	
106-14	18376-18379	not	_	
106-15	18380-18382	at	_	
106-16	18383-18386	all	_	
106-17	18386-18387	)	_	
106-18	18387-18388	,	_	
106-19	18389-18390	2	_	
106-20	18391-18392	(	_	
106-21	18392-18398	slight	_	
106-22	18398-18399	)	_	
106-23	18399-18400	,	_	
106-24	18401-18402	3	_	
106-25	18403-18404	(	_	
106-26	18404-18412	moderate	_	
106-27	18412-18413	)	_	
106-28	18414-18417	and	_	
106-29	18418-18419	4	_	
106-30	18420-18421	(	_	
106-31	18421-18428	extreme	_	
106-32	18428-18429	)	_	
106-33	18429-18430	.	_	

#Text=The video started at 0 minute and ended at 10 minutes (grey bar).
107-1	18431-18434	The	_	
107-2	18435-18440	video	_	
107-3	18441-18448	started	_	
107-4	18449-18451	at	_	
107-5	18452-18453	0	_	
107-6	18453-18454	 	_	
107-7	18454-18460	minute	_	
107-8	18461-18464	and	_	
107-9	18465-18470	ended	_	
107-10	18471-18473	at	_	
107-11	18474-18476	10	_	
107-12	18476-18477	 	_	
107-13	18477-18484	minutes	_	
107-14	18485-18486	(	_	
107-15	18486-18490	grey	_	
107-16	18491-18494	bar	_	
107-17	18494-18495	)	_	
107-18	18495-18496	.	_	

#Text=Error bars show standard error of the mean (SEM)
#Text=Anxiety
#Text=No significant main effect of time or session was revealed, although an overall main effect of group was found [F(1,34) = 23.45, p < 0.001] indicating higher anxiety in the OD than HC group (Fig. 2).
108-1	18497-18502	Error	_	
108-2	18503-18507	bars	_	
108-3	18508-18512	show	_	
108-4	18513-18521	standard	_	
108-5	18522-18527	error	_	
108-6	18528-18530	of	_	
108-7	18531-18534	the	_	
108-8	18535-18539	mean	_	
108-9	18540-18541	(	_	
108-10	18541-18544	SEM	_	
108-11	18544-18545	)	_	
108-12	18546-18553	Anxiety	_	
108-13	18554-18556	No	_	
108-14	18557-18568	significant	_	
108-15	18569-18573	main	_	
108-16	18574-18580	effect	_	
108-17	18581-18583	of	_	
108-18	18584-18588	time	_	
108-19	18589-18591	or	_	
108-20	18592-18599	session	_	
108-21	18600-18603	was	_	
108-22	18604-18612	revealed	_	
108-23	18612-18613	,	_	
108-24	18614-18622	although	_	
108-25	18623-18625	an	_	
108-26	18626-18633	overall	_	
108-27	18634-18638	main	_	
108-28	18639-18645	effect	_	
108-29	18646-18648	of	_	
108-30	18649-18654	group	_	
108-31	18655-18658	was	_	
108-32	18659-18664	found	_	
108-33	18665-18666	[	_	
108-34	18666-18667	F	_	
108-35	18667-18668	(	_	
108-36	18668-18672	1,34	_	
108-37	18672-18673	)	_	
108-38	18673-18674	 	_	
108-39	18674-18675	=	_	
108-40	18675-18676	 	_	
108-41	18676-18681	23.45	_	
108-42	18681-18682	,	_	
108-43	18683-18684	p	_	
108-44	18684-18685	 	_	
108-45	18685-18686	<	_	
108-46	18686-18687	 	_	
108-47	18687-18692	0.001	_	
108-48	18692-18693	]	_	
108-49	18694-18704	indicating	_	
108-50	18705-18711	higher	_	
108-51	18712-18719	anxiety	_	
108-52	18720-18722	in	_	
108-53	18723-18726	the	_	
108-54	18727-18729	OD	_	
108-55	18730-18734	than	_	
108-56	18735-18737	HC	_	
108-57	18738-18743	group	_	
108-58	18744-18745	(	_	
108-59	18745-18748	Fig	_	
108-60	18748-18749	.	_	
108-61	18749-18750	 	_	
108-62	18750-18751	2	_	
108-63	18751-18752	)	_	
108-64	18752-18753	.	_	

#Text=A significant time × session interaction was found [F(3.53, 119.97) = 2.87, p = 0.03], but no three‐way interaction (p > 0.05); anxiety increased in both the OD and HC groups during the craving compared with neutral videos.
109-1	18754-18755	A	_	
109-2	18756-18767	significant	_	
109-3	18768-18772	time	_	
109-4	18772-18773	 	_	
109-5	18773-18774	×	_	
109-6	18774-18775	 	_	
109-7	18775-18782	session	_	
109-8	18783-18794	interaction	_	
109-9	18795-18798	was	_	
109-10	18799-18804	found	_	
109-11	18805-18806	[	_	
109-12	18806-18807	F	_	
109-13	18807-18808	(	_	
109-14	18808-18812	3.53	_	
109-15	18812-18813	,	_	
109-16	18814-18820	119.97	_	
109-17	18820-18821	)	_	
109-18	18822-18823	=	_	
109-19	18824-18828	2.87	_	
109-20	18828-18829	,	_	
109-21	18830-18831	p	_	
109-22	18832-18833	=	_	
109-23	18834-18838	0.03	_	
109-24	18838-18839	]	_	
109-25	18839-18840	,	_	
109-26	18841-18844	but	_	
109-27	18845-18847	no	_	
109-28	18848-18857	three‐way	_	
109-29	18858-18869	interaction	_	
109-30	18870-18871	(	_	
109-31	18871-18872	p	_	
109-32	18872-18873	 	_	
109-33	18873-18874	>	_	
109-34	18874-18875	 	_	
109-35	18875-18879	0.05	_	
109-36	18879-18880	)	_	
109-37	18880-18881	;	_	
109-38	18882-18889	anxiety	_	
109-39	18890-18899	increased	_	
109-40	18900-18902	in	_	
109-41	18903-18907	both	_	
109-42	18908-18911	the	_	
109-43	18912-18914	OD	_	
109-44	18915-18918	and	_	
109-45	18919-18921	HC	_	
109-46	18922-18928	groups	_	
109-47	18929-18935	during	_	
109-48	18936-18939	the	_	
109-49	18940-18947	craving	_	
109-50	18948-18956	compared	_	
109-51	18957-18961	with	_	
109-52	18962-18969	neutral	_	
109-53	18970-18976	videos	_	
109-54	18976-18977	.	_	

#Text=High
#Text=No significant main effects or interactions were found (Fig. 2).
110-1	18978-18982	High	_	
110-2	18983-18985	No	_	
110-3	18986-18997	significant	_	
110-4	18998-19002	main	_	
110-5	19003-19010	effects	_	
110-6	19011-19013	or	_	
110-7	19014-19026	interactions	_	
110-8	19027-19031	were	_	
110-9	19032-19037	found	_	
110-10	19038-19039	(	_	
110-11	19039-19042	Fig	_	
110-12	19042-19043	.	_	
110-13	19043-19044	 	_	
110-14	19044-19045	2	_	
110-15	19045-19046	)	_	
110-16	19046-19047	.	_	

#Text=Withdrawal
#Text=There was a significant main effect of group [F(1, 34) = 10.47, p = 0.003], but no other significant main effects or interactions.
111-1	19048-19058	Withdrawal	_	
111-2	19059-19064	There	_	
111-3	19065-19068	was	_	
111-4	19069-19070	a	_	
111-5	19071-19082	significant	_	
111-6	19083-19087	main	_	
111-7	19088-19094	effect	_	
111-8	19095-19097	of	_	
111-9	19098-19103	group	_	
111-10	19104-19105	[	_	
111-11	19105-19106	F	_	
111-12	19106-19107	(	_	
111-13	19107-19108	1	_	
111-14	19108-19109	,	_	
111-15	19110-19112	34	_	
111-16	19112-19113	)	_	
111-17	19113-19114	 	_	
111-18	19114-19115	=	_	
111-19	19115-19116	 	_	
111-20	19116-19121	10.47	_	
111-21	19121-19122	,	_	
111-22	19123-19124	p	_	
111-23	19124-19125	 	_	
111-24	19125-19126	=	_	
111-25	19126-19127	 	_	
111-26	19127-19132	0.003	_	
111-27	19132-19133	]	_	
111-28	19133-19134	,	_	
111-29	19135-19138	but	_	
111-30	19139-19141	no	_	
111-31	19142-19147	other	_	
111-32	19148-19159	significant	_	
111-33	19160-19164	main	_	
111-34	19165-19172	effects	_	
111-35	19173-19175	or	_	
111-36	19176-19188	interactions	_	
111-37	19188-19189	.	_	

#Text=Higher withdrawal symptoms were reported in the OD group compared with HC group throughout both sessions (Fig. 2).
112-1	19190-19196	Higher	_	
112-2	19197-19207	withdrawal	_	
112-3	19208-19216	symptoms	_	
112-4	19217-19221	were	_	
112-5	19222-19230	reported	_	
112-6	19231-19233	in	_	
112-7	19234-19237	the	_	
112-8	19238-19240	OD	_	
112-9	19241-19246	group	_	
112-10	19247-19255	compared	_	
112-11	19256-19260	with	_	
112-12	19261-19263	HC	_	
112-13	19264-19269	group	_	
112-14	19270-19280	throughout	_	
112-15	19281-19285	both	_	
112-16	19286-19294	sessions	_	
112-17	19295-19296	(	_	
112-18	19296-19299	Fig	_	
112-19	19299-19300	.	_	
112-20	19300-19301	 	_	
112-21	19301-19302	2	_	
112-22	19302-19303	)	_	
112-23	19303-19304	.	_	

#Text=Effects of group and time on ROI BOLD signal
#Text=Significant effects were observed only in the left amygdala and dACC (see Supporting Information Tables S2–S4 for F‐values and p‐values for all of the regions of interest).
113-1	19305-19312	Effects	_	
113-2	19313-19315	of	_	
113-3	19316-19321	group	_	
113-4	19322-19325	and	_	
113-5	19326-19330	time	_	
113-6	19331-19333	on	_	
113-7	19334-19337	ROI	_	
113-8	19338-19342	BOLD	_	
113-9	19343-19349	signal	_	
113-10	19350-19361	Significant	_	
113-11	19362-19369	effects	_	
113-12	19370-19374	were	_	
113-13	19375-19383	observed	_	
113-14	19384-19388	only	_	
113-15	19389-19391	in	_	
113-16	19392-19395	the	_	
113-17	19396-19400	left	_	
113-18	19401-19409	amygdala	_	
113-19	19410-19413	and	_	
113-20	19414-19418	dACC	_	
113-21	19419-19420	(	_	
113-22	19420-19423	see	_	
113-23	19424-19434	Supporting	_	
113-24	19435-19446	Information	_	
113-25	19446-19447	 	_	
113-26	19447-19453	Tables	_	
113-27	19454-19456	S2	_	
113-28	19456-19457	–	_	
113-29	19457-19459	S4	_	
113-30	19460-19463	for	_	
113-31	19464-19472	F‐values	_	
113-32	19473-19476	and	_	
113-33	19477-19485	p‐values	_	
113-34	19486-19489	for	_	
113-35	19490-19493	all	_	
113-36	19494-19496	of	_	
113-37	19497-19500	the	_	
113-38	19501-19508	regions	_	
113-39	19509-19511	of	_	
113-40	19512-19520	interest	_	
113-41	19520-19521	)	_	
113-42	19521-19522	.	_	

#Text=Within the left amygdala, there was an overall main effect of group (OD > HC, p = 0.014).
114-1	19523-19529	Within	_	
114-2	19530-19533	the	_	
114-3	19534-19538	left	_	
114-4	19539-19547	amygdala	_	
114-5	19547-19548	,	_	
114-6	19549-19554	there	_	
114-7	19555-19558	was	_	
114-8	19559-19561	an	_	
114-9	19562-19569	overall	_	
114-10	19570-19574	main	_	
114-11	19575-19581	effect	_	
114-12	19582-19584	of	_	
114-13	19585-19590	group	_	
114-14	19591-19592	(	_	
114-15	19592-19594	OD	_	
114-16	19594-19595	 	_	
114-17	19595-19596	>	_	
114-18	19596-19597	 	_	
114-19	19597-19599	HC	_	
114-20	19599-19600	,	_	
114-21	19601-19602	p	_	
114-22	19602-19603	 	_	
114-23	19603-19604	=	_	
114-24	19604-19605	 	_	
114-25	19605-19610	0.014	_	
114-26	19610-19611	)	_	
114-27	19611-19612	.	_	

#Text=Focusing on the video period only, there was a significant time × group interaction (p = 0.017) and a significant effect of group surviving Bonferroni correction for the six ROIs (p = 0.007).
115-1	19613-19621	Focusing	_	
115-2	19622-19624	on	_	
115-3	19625-19628	the	_	
115-4	19629-19634	video	_	
115-5	19635-19641	period	_	
115-6	19642-19646	only	_	
115-7	19646-19647	,	_	
115-8	19648-19653	there	_	
115-9	19654-19657	was	_	
115-10	19658-19659	a	_	
115-11	19660-19671	significant	_	
115-12	19672-19676	time	_	
115-13	19676-19677	 	_	
115-14	19677-19678	×	_	
115-15	19678-19679	 	_	
115-16	19679-19684	group	_	
115-17	19685-19696	interaction	_	
115-18	19697-19698	(	_	
115-19	19698-19699	p	_	
115-20	19699-19700	 	_	
115-21	19700-19701	=	_	
115-22	19701-19702	 	_	
115-23	19702-19707	0.017	_	
115-24	19707-19708	)	_	
115-25	19709-19712	and	_	
115-26	19713-19714	a	_	
115-27	19715-19726	significant	_	
115-28	19727-19733	effect	_	
115-29	19734-19736	of	_	
115-30	19737-19742	group	_	
115-31	19743-19752	surviving	_	
115-32	19753-19763	Bonferroni	_	
115-33	19764-19774	correction	_	
115-34	19775-19778	for	_	
115-35	19779-19782	the	_	
115-36	19783-19786	six	_	
115-37	19787-19791	ROIs	_	
115-38	19792-19793	(	_	
115-39	19793-19794	p	_	
115-40	19794-19795	 	_	
115-41	19795-19796	=	_	
115-42	19796-19797	 	_	
115-43	19797-19802	0.007	_	
115-44	19802-19803	)	_	
115-45	19803-19804	.	_	

#Text=Figure 3 shows that these effects were due to amygdala BOLD signal increasing during the video in the OD group only.
116-1	19805-19811	Figure	_	
116-2	19811-19812	 	_	
116-3	19812-19813	3	_	
116-4	19814-19819	shows	_	
116-5	19820-19824	that	_	
116-6	19825-19830	these	_	
116-7	19831-19838	effects	_	
116-8	19839-19843	were	_	
116-9	19844-19847	due	_	
116-10	19848-19850	to	_	
116-11	19851-19859	amygdala	_	
116-12	19860-19864	BOLD	_	
116-13	19865-19871	signal	_	
116-14	19872-19882	increasing	_	
116-15	19883-19889	during	_	
116-16	19890-19893	the	_	
116-17	19894-19899	video	_	
116-18	19900-19902	in	_	
116-19	19903-19906	the	_	
116-20	19907-19909	OD	_	
116-21	19910-19915	group	_	
116-22	19916-19920	only	_	
116-23	19920-19921	.	_	

#Text=There was a significant effect of time (p = 0.041) and time × group interaction (p = 0.018) during the 5‐minute period after the end of the video.
117-1	19922-19927	There	_	
117-2	19928-19931	was	_	
117-3	19932-19933	a	_	
117-4	19934-19945	significant	_	
117-5	19946-19952	effect	_	
117-6	19953-19955	of	_	
117-7	19956-19960	time	_	
117-8	19961-19962	(	_	
117-9	19962-19963	p	_	
117-10	19963-19964	 	_	
117-11	19964-19965	=	_	
117-12	19965-19966	 	_	
117-13	19966-19971	0.041	_	
117-14	19971-19972	)	_	
117-15	19973-19976	and	_	
117-16	19977-19981	time	_	
117-17	19981-19982	 	_	
117-18	19982-19983	×	_	
117-19	19983-19984	 	_	
117-20	19984-19989	group	_	
117-21	19990-20001	interaction	_	
117-22	20002-20003	(	_	
117-23	20003-20004	p	_	
117-24	20004-20005	 	_	
117-25	20005-20006	=	_	
117-26	20006-20007	 	_	
117-27	20007-20012	0.018	_	
117-28	20012-20013	)	_	
117-29	20014-20020	during	_	
117-30	20021-20024	the	_	
117-31	20025-20026	5	_	
117-32	20026-20027	‐	_	
117-33	20027-20033	minute	_	
117-34	20034-20040	period	_	
117-35	20041-20046	after	_	
117-36	20047-20050	the	_	
117-37	20051-20054	end	_	
117-38	20055-20057	of	_	
117-39	20058-20061	the	_	
117-40	20062-20067	video	_	
117-41	20067-20068	.	_	

#Text=The effect of group was no longer significant during this period.
118-1	20069-20072	The	_	
118-2	20073-20079	effect	_	
118-3	20080-20082	of	_	
118-4	20083-20088	group	_	
118-5	20089-20092	was	_	
118-6	20093-20095	no	_	
118-7	20096-20102	longer	_	
118-8	20103-20114	significant	_	
118-9	20115-20121	during	_	
118-10	20122-20126	this	_	
118-11	20127-20133	period	_	
118-12	20133-20134	.	_	

#Text=Figure 3 illustrates that these effects were due to BOLD signal dropping in the OD group only after the end of the video session.
119-1	20135-20141	Figure	_	
119-2	20141-20142	 	_	
119-3	20142-20143	3	_	
119-4	20144-20155	illustrates	_	
119-5	20156-20160	that	_	
119-6	20161-20166	these	_	
119-7	20167-20174	effects	_	
119-8	20175-20179	were	_	
119-9	20180-20183	due	_	
119-10	20184-20186	to	_	
119-11	20187-20191	BOLD	_	
119-12	20192-20198	signal	_	
119-13	20199-20207	dropping	_	
119-14	20208-20210	in	_	
119-15	20211-20214	the	_	
119-16	20215-20217	OD	_	
119-17	20218-20223	group	_	
119-18	20224-20228	only	_	
119-19	20229-20234	after	_	
119-20	20235-20238	the	_	
119-21	20239-20242	end	_	
119-22	20243-20245	of	_	
119-23	20246-20249	the	_	
119-24	20250-20255	video	_	
119-25	20256-20263	session	_	
119-26	20263-20264	.	_	

#Text=Regions of interest and average BOLD signal time course of each region.
120-1	20265-20272	Regions	_	
120-2	20273-20275	of	_	
120-3	20276-20284	interest	_	
120-4	20285-20288	and	_	
120-5	20289-20296	average	_	
120-6	20297-20301	BOLD	_	
120-7	20302-20308	signal	_	
120-8	20309-20313	time	_	
120-9	20314-20320	course	_	
120-10	20321-20323	of	_	
120-11	20324-20328	each	_	
120-12	20329-20335	region	_	
120-13	20335-20336	.	_	

#Text=Time courses show the BOLD signal difference between drug cue‐neutral session in the bilateral amygdala, dorsal anterior cingulate and ventral medial prefrontal cortex.
121-1	20337-20341	Time	_	
121-2	20342-20349	courses	_	
121-3	20350-20354	show	_	
121-4	20355-20358	the	_	
121-5	20359-20363	BOLD	_	
121-6	20364-20370	signal	_	
121-7	20371-20381	difference	_	
121-8	20382-20389	between	_	
121-9	20390-20394	drug	_	
121-10	20395-20406	cue‐neutral	_	
121-11	20407-20414	session	_	
121-12	20415-20417	in	_	
121-13	20418-20421	the	_	
121-14	20422-20431	bilateral	_	
121-15	20432-20440	amygdala	_	
121-16	20440-20441	,	_	
121-17	20442-20448	dorsal	_	
121-18	20449-20457	anterior	_	
121-19	20458-20467	cingulate	_	
121-20	20468-20471	and	_	
121-21	20472-20479	ventral	_	
121-22	20480-20486	medial	_	
121-23	20487-20497	prefrontal	_	
121-24	20498-20504	cortex	_	
121-25	20504-20505	.	_	

#Text=The videos were displayed from 0 to 10 minutes (grey bar).
122-1	20506-20509	The	_	
122-2	20510-20516	videos	_	
122-3	20517-20521	were	_	
122-4	20522-20531	displayed	_	
122-5	20532-20536	from	_	
122-6	20537-20538	0	_	
122-7	20539-20541	to	_	
122-8	20542-20544	10	_	
122-9	20544-20545	 	_	
122-10	20545-20552	minutes	_	
122-11	20553-20554	(	_	
122-12	20554-20558	grey	_	
122-13	20559-20562	bar	_	
122-14	20562-20563	)	_	
122-15	20563-20564	.	_	

#Text=The last 5 minutes are the post‐video period.
123-1	20565-20568	The	_	
123-2	20569-20573	last	_	
123-3	20574-20575	5	_	
123-4	20575-20576	 	_	
123-5	20576-20583	minutes	_	
123-6	20584-20587	are	_	
123-7	20588-20591	the	_	
123-8	20592-20602	post‐video	_	
123-9	20603-20609	period	_	
123-10	20609-20610	.	_	

#Text=The solid blue bars demonstrate the average time course of the OD group (n = 18), and the red dotted line shows the average time course of the HC group (n = 20).
124-1	20611-20614	The	_	
124-2	20615-20620	solid	_	
124-3	20621-20625	blue	_	
124-4	20626-20630	bars	_	
124-5	20631-20642	demonstrate	_	
124-6	20643-20646	the	_	
124-7	20647-20654	average	_	
124-8	20655-20659	time	_	
124-9	20660-20666	course	_	
124-10	20667-20669	of	_	
124-11	20670-20673	the	_	
124-12	20674-20676	OD	_	
124-13	20677-20682	group	_	
124-14	20683-20684	(	_	
124-15	20684-20685	n	_	
124-16	20685-20686	 	_	
124-17	20686-20687	=	_	
124-18	20687-20688	 	_	
124-19	20688-20690	18	_	
124-20	20690-20691	)	_	
124-21	20691-20692	,	_	
124-22	20693-20696	and	_	
124-23	20697-20700	the	_	
124-24	20701-20704	red	_	
124-25	20705-20711	dotted	_	
124-26	20712-20716	line	_	
124-27	20717-20722	shows	_	
124-28	20723-20726	the	_	
124-29	20727-20734	average	_	
124-30	20735-20739	time	_	
124-31	20740-20746	course	_	
124-32	20747-20749	of	_	
124-33	20750-20753	the	_	
124-34	20754-20756	HC	_	
124-35	20757-20762	group	_	
124-36	20763-20764	(	_	
124-37	20764-20765	n	_	
124-38	20765-20766	 	_	
124-39	20766-20767	=	_	
124-40	20767-20768	 	_	
124-41	20768-20770	20	_	
124-42	20770-20771	)	_	
124-43	20771-20772	.	_	

#Text=Error bars show standard error of the mean (SEM)
#Text=Within the dACC, there was a significant main effect of time for the entire drug cue‐neutral session time course, surviving Bonferroni correction for the six ROIs (p = 0.004).
125-1	20773-20778	Error	_	
125-2	20779-20783	bars	_	
125-3	20784-20788	show	_	
125-4	20789-20797	standard	_	
125-5	20798-20803	error	_	
125-6	20804-20806	of	_	
125-7	20807-20810	the	_	
125-8	20811-20815	mean	_	
125-9	20816-20817	(	_	
125-10	20817-20820	SEM	_	
125-11	20820-20821	)	_	
125-12	20822-20828	Within	_	
125-13	20829-20832	the	_	
125-14	20833-20837	dACC	_	
125-15	20837-20838	,	_	
125-16	20839-20844	there	_	
125-17	20845-20848	was	_	
125-18	20849-20850	a	_	
125-19	20851-20862	significant	_	
125-20	20863-20867	main	_	
125-21	20868-20874	effect	_	
125-22	20875-20877	of	_	
125-23	20878-20882	time	_	
125-24	20883-20886	for	_	
125-25	20887-20890	the	_	
125-26	20891-20897	entire	_	
125-27	20898-20902	drug	_	
125-28	20903-20914	cue‐neutral	_	
125-29	20915-20922	session	_	
125-30	20923-20927	time	_	
125-31	20928-20934	course	_	
125-32	20934-20935	,	_	
125-33	20936-20945	surviving	_	
125-34	20946-20956	Bonferroni	_	
125-35	20957-20967	correction	_	
125-36	20968-20971	for	_	
125-37	20972-20975	the	_	
125-38	20976-20979	six	_	
125-39	20980-20984	ROIs	_	
125-40	20985-20986	(	_	
125-41	20986-20987	p	_	
125-42	20987-20988	 	_	
125-43	20988-20989	=	_	
125-44	20989-20990	 	_	
125-45	20990-20995	0.004	_	
125-46	20995-20996	)	_	
125-47	20996-20997	.	_	

#Text=There was no time × group interaction, suggesting significant time course effects in both groups. dACC BOLD signal within the OD group was significantly higher than in the HC group within the post‐video period only (p = 0.046).
126-1	20998-21003	There	_	
126-2	21004-21007	was	_	
126-3	21008-21010	no	_	
126-4	21011-21015	time	_	
126-5	21015-21016	 	_	
126-6	21016-21017	×	_	
126-7	21017-21018	 	_	
126-8	21018-21023	group	_	
126-9	21024-21035	interaction	_	
126-10	21035-21036	,	_	
126-11	21037-21047	suggesting	_	
126-12	21048-21059	significant	_	
126-13	21060-21064	time	_	
126-14	21065-21071	course	_	
126-15	21072-21079	effects	_	
126-16	21080-21082	in	_	
126-17	21083-21087	both	_	
126-18	21088-21094	groups	_	
126-19	21094-21095	.	_	
126-20	21096-21100	dACC	_	
126-21	21101-21105	BOLD	_	
126-22	21106-21112	signal	_	
126-23	21113-21119	within	_	
126-24	21120-21123	the	_	
126-25	21124-21126	OD	_	
126-26	21127-21132	group	_	
126-27	21133-21136	was	_	
126-28	21137-21150	significantly	_	
126-29	21151-21157	higher	_	
126-30	21158-21162	than	_	
126-31	21163-21165	in	_	
126-32	21166-21169	the	_	
126-33	21170-21172	HC	_	
126-34	21173-21178	group	_	
126-35	21179-21185	within	_	
126-36	21186-21189	the	_	
126-37	21190-21200	post‐video	_	
126-38	21201-21207	period	_	
126-39	21208-21212	only	_	
126-40	21213-21214	(	_	
126-41	21214-21215	p	_	
126-42	21215-21216	 	_	
126-43	21216-21217	=	_	
126-44	21217-21218	 	_	
126-45	21218-21223	0.046	_	
126-46	21223-21224	)	_	
126-47	21224-21225	.	_	

#Text=Figure 3 illustrates that this effect is due to sustained recruitment of the dACC after the end of the video session in the OD group only.
127-1	21226-21232	Figure	_	
127-2	21232-21233	 	_	
127-3	21233-21234	3	_	
127-4	21235-21246	illustrates	_	
127-5	21247-21251	that	_	
127-6	21252-21256	this	_	
127-7	21257-21263	effect	_	
127-8	21264-21266	is	_	
127-9	21267-21270	due	_	
127-10	21271-21273	to	_	
127-11	21274-21283	sustained	_	
127-12	21284-21295	recruitment	_	
127-13	21296-21298	of	_	
127-14	21299-21302	the	_	
127-15	21303-21307	dACC	_	
127-16	21308-21313	after	_	
127-17	21314-21317	the	_	
127-18	21318-21321	end	_	
127-19	21322-21324	of	_	
127-20	21325-21328	the	_	
127-21	21329-21334	video	_	
127-22	21335-21342	session	_	
127-23	21343-21345	in	_	
127-24	21346-21349	the	_	
127-25	21350-21352	OD	_	
127-26	21353-21358	group	_	
127-27	21359-21363	only	_	
127-28	21363-21364	.	_	

#Text=There were no main effects or interactions for the four other ROIs examined.
128-1	21365-21370	There	_	
128-2	21371-21375	were	_	
128-3	21376-21378	no	_	
128-4	21379-21383	main	_	
128-5	21384-21391	effects	_	
128-6	21392-21394	or	_	
128-7	21395-21407	interactions	_	
128-8	21408-21411	for	_	
128-9	21412-21415	the	_	
128-10	21416-21420	four	_	
128-11	21421-21426	other	_	
128-12	21427-21431	ROIs	_	
128-13	21432-21440	examined	_	
128-14	21440-21441	.	_	

#Text=Temporal correlations between subjective ratings and ROI BOLD signal time courses
#Text=Analyses were restricted to craving/anxiety ratings and amygdala/dACC ROIs in the OD group, and anxiety ratings and dACC in the HC group, as these were the only ratings/ROI BOLD signal time courses that were significant in the ANOVAs.
129-1	21442-21450	Temporal	_	
129-2	21451-21463	correlations	_	
129-3	21464-21471	between	_	
129-4	21472-21482	subjective	_	
129-5	21483-21490	ratings	_	
129-6	21491-21494	and	_	
129-7	21495-21498	ROI	_	
129-8	21499-21503	BOLD	_	
129-9	21504-21510	signal	_	
129-10	21511-21515	time	_	
129-11	21516-21523	courses	_	
129-12	21524-21532	Analyses	_	
129-13	21533-21537	were	_	
129-14	21538-21548	restricted	_	
129-15	21549-21551	to	_	
129-16	21552-21559	craving	_	
129-17	21559-21560	/	_	
129-18	21560-21567	anxiety	_	
129-19	21568-21575	ratings	_	
129-20	21576-21579	and	_	
129-21	21580-21588	amygdala	_	
129-22	21588-21589	/	_	
129-23	21589-21593	dACC	_	
129-24	21594-21598	ROIs	_	
129-25	21599-21601	in	_	
129-26	21602-21605	the	_	
129-27	21606-21608	OD	_	
129-28	21609-21614	group	_	
129-29	21614-21615	,	_	
129-30	21616-21619	and	_	
129-31	21620-21627	anxiety	_	
129-32	21628-21635	ratings	_	
129-33	21636-21639	and	_	
129-34	21640-21644	dACC	_	
129-35	21645-21647	in	_	
129-36	21648-21651	the	_	
129-37	21652-21654	HC	_	
129-38	21655-21660	group	_	
129-39	21660-21661	,	_	
129-40	21662-21664	as	_	
129-41	21665-21670	these	_	
129-42	21671-21675	were	_	
129-43	21676-21679	the	_	
129-44	21680-21684	only	_	
129-45	21685-21692	ratings	_	
129-46	21692-21693	/	_	
129-47	21693-21696	ROI	_	
129-48	21697-21701	BOLD	_	
129-49	21702-21708	signal	_	
129-50	21709-21713	time	_	
129-51	21714-21721	courses	_	
129-52	21722-21726	that	_	
129-53	21727-21731	were	_	
129-54	21732-21743	significant	_	
129-55	21744-21746	in	_	
129-56	21747-21750	the	_	
129-57	21751-21757	ANOVAs	_	
129-58	21757-21758	.	_	

#Text=As some participants did not report a drug cue‐neutral session change in their subjective ratings (5 in OD group for craving, 4 in OD group for anxiety and 10 in HC group for anxiety), subjective rating‐BOLD signal correlations could not be conducted for these individuals for these rating scales.
130-1	21759-21761	As	_	
130-2	21762-21766	some	_	
130-3	21767-21779	participants	_	
130-4	21780-21783	did	_	
130-5	21784-21787	not	_	
130-6	21788-21794	report	_	
130-7	21795-21796	a	_	
130-8	21797-21801	drug	_	
130-9	21802-21813	cue‐neutral	_	
130-10	21814-21821	session	_	
130-11	21822-21828	change	_	
130-12	21829-21831	in	_	
130-13	21832-21837	their	_	
130-14	21838-21848	subjective	_	
130-15	21849-21856	ratings	_	
130-16	21857-21858	(	_	
130-17	21858-21859	5	_	
130-18	21860-21862	in	_	
130-19	21863-21865	OD	_	
130-20	21866-21871	group	_	
130-21	21872-21875	for	_	
130-22	21876-21883	craving	_	
130-23	21883-21884	,	_	
130-24	21885-21886	4	_	
130-25	21887-21889	in	_	
130-26	21890-21892	OD	_	
130-27	21893-21898	group	_	
130-28	21899-21902	for	_	
130-29	21903-21910	anxiety	_	
130-30	21911-21914	and	_	
130-31	21915-21917	10	_	
130-32	21918-21920	in	_	
130-33	21921-21923	HC	_	
130-34	21924-21929	group	_	
130-35	21930-21933	for	_	
130-36	21934-21941	anxiety	_	
130-37	21941-21942	)	_	
130-38	21942-21943	,	_	
130-39	21944-21954	subjective	_	
130-40	21955-21966	rating‐BOLD	_	
130-41	21967-21973	signal	_	
130-42	21974-21986	correlations	_	
130-43	21987-21992	could	_	
130-44	21993-21996	not	_	
130-45	21997-21999	be	_	
130-46	22000-22009	conducted	_	
130-47	22010-22013	for	_	
130-48	22014-22019	these	_	
130-49	22020-22031	individuals	_	
130-50	22032-22035	for	_	
130-51	22036-22041	these	_	
130-52	22042-22048	rating	_	
130-53	22049-22055	scales	_	
130-54	22055-22056	.	_	

#Text=The only correlation that was significant was between craving and left amygdala time courses in the OD group [mean (SD) Fisher's z‐score = 0.44(66), t(12)=2.40, p = 0.034) (Table 2).
131-1	22057-22060	The	_	
131-2	22061-22065	only	_	
131-3	22066-22077	correlation	_	
131-4	22078-22082	that	_	
131-5	22083-22086	was	_	
131-6	22087-22098	significant	_	
131-7	22099-22102	was	_	
131-8	22103-22110	between	_	
131-9	22111-22118	craving	_	
131-10	22119-22122	and	_	
131-11	22123-22127	left	_	
131-12	22128-22136	amygdala	_	
131-13	22137-22141	time	_	
131-14	22142-22149	courses	_	
131-15	22150-22152	in	_	
131-16	22153-22156	the	_	
131-17	22157-22159	OD	_	
131-18	22160-22165	group	_	
131-19	22166-22167	[	_	
131-20	22167-22171	mean	_	
131-21	22172-22173	(	_	
131-22	22173-22175	SD	_	
131-23	22175-22176	)	_	
131-24	22177-22185	Fisher's	_	
131-25	22186-22193	z‐score	_	
131-26	22193-22194	 	_	
131-27	22194-22195	=	_	
131-28	22195-22196	 	_	
131-29	22196-22200	0.44	_	
131-30	22200-22201	(	_	
131-31	22201-22203	66	_	
131-32	22203-22204	)	_	
131-33	22204-22205	,	_	
131-34	22206-22207	t	_	
131-35	22207-22208	(	_	
131-36	22208-22210	12	_	
131-37	22210-22211	)	_	
131-38	22211-22212	=	_	
131-39	22212-22216	2.40	_	
131-40	22216-22217	,	_	
131-41	22218-22219	p	_	
131-42	22219-22220	 	_	
131-43	22220-22221	=	_	
131-44	22221-22222	 	_	
131-45	22222-22227	0.034	_	
131-46	22227-22228	)	_	
131-47	22229-22230	(	_	
131-48	22230-22235	Table	_	
131-49	22235-22236	 	_	
131-50	22236-22237	2	_	
131-51	22237-22238	)	_	
131-52	22238-22239	.	_	

#Text=Mean and standard deviation of the z‐scores derived from Fisher's z‐transformation of correlation coefficients obtained from the ROI/subjective rating time course correlational analysis.
132-1	22240-22244	Mean	_	
132-2	22245-22248	and	_	
132-3	22249-22257	standard	_	
132-4	22258-22267	deviation	_	
132-5	22268-22270	of	_	
132-6	22271-22274	the	_	
132-7	22275-22283	z‐scores	_	
132-8	22284-22291	derived	_	
132-9	22292-22296	from	_	
132-10	22297-22305	Fisher's	_	
132-11	22306-22322	z‐transformation	_	
132-12	22323-22325	of	_	
132-13	22326-22337	correlation	_	
132-14	22338-22350	coefficients	_	
132-15	22351-22359	obtained	_	
132-16	22360-22364	from	_	
132-17	22365-22368	the	_	
132-18	22369-22372	ROI	_	
132-19	22372-22373	/	_	
132-20	22373-22383	subjective	_	
132-21	22384-22390	rating	_	
132-22	22391-22395	time	_	
132-23	22396-22402	course	_	
132-24	22403-22416	correlational	_	
132-25	22417-22425	analysis	_	
132-26	22425-22426	.	_	

#Text=Correlations (scale‐ROI)\tMean (SD) z‐score\tt(df)\tp‐value\t \tOD: Craving‐left amygdala\t0.44 (0.66)\t2.40(12)\t0.034*\t \tOD: Craving‐dACC\t0.32 (0.71)\t1.64(12)\t0.126\t \tOD: Anxiety‐left amygdala\t0.15 (0.34)\t1.56(13)\t0.143\t \tOD: Anxiety‐dACC\t0.34 (0.99)\t1.29(13)\t0.220\t \tHC: Anxiety‐dACC\t0.006 (0.92)\t0.02(8)\t0.99\t \t
#Text=Table shows the t‐values obtained from one‐sample t‐tests and corresponding statistical significance.
133-1	22427-22439	Correlations	_	
133-2	22440-22441	(	_	
133-3	22441-22450	scale‐ROI	_	
133-4	22450-22451	)	_	
133-5	22452-22456	Mean	_	
133-6	22457-22458	(	_	
133-7	22458-22460	SD	_	
133-8	22460-22461	)	_	
133-9	22462-22469	z‐score	_	
133-10	22470-22471	t	_	
133-11	22471-22472	(	_	
133-12	22472-22474	df	_	
133-13	22474-22475	)	_	
133-14	22476-22483	p‐value	_	
133-15	22486-22488	OD	_	
133-16	22488-22489	:	_	
133-17	22490-22502	Craving‐left	_	
133-18	22503-22511	amygdala	_	
133-19	22512-22516	0.44	_	
133-20	22517-22518	(	_	
133-21	22518-22522	0.66	_	
133-22	22522-22523	)	_	
133-23	22524-22528	2.40	_	
133-24	22528-22529	(	_	
133-25	22529-22531	12	_	
133-26	22531-22532	)	_	
133-27	22533-22538	0.034	_	
133-28	22538-22539	*	_	
133-29	22542-22544	OD	_	
133-30	22544-22545	:	_	
133-31	22546-22558	Craving‐dACC	_	
133-32	22559-22563	0.32	_	
133-33	22564-22565	(	_	
133-34	22565-22569	0.71	_	
133-35	22569-22570	)	_	
133-36	22571-22575	1.64	_	
133-37	22575-22576	(	_	
133-38	22576-22578	12	_	
133-39	22578-22579	)	_	
133-40	22580-22585	0.126	_	
133-41	22588-22590	OD	_	
133-42	22590-22591	:	_	
133-43	22592-22604	Anxiety‐left	_	
133-44	22605-22613	amygdala	_	
133-45	22614-22618	0.15	_	
133-46	22619-22620	(	_	
133-47	22620-22624	0.34	_	
133-48	22624-22625	)	_	
133-49	22626-22630	1.56	_	
133-50	22630-22631	(	_	
133-51	22631-22633	13	_	
133-52	22633-22634	)	_	
133-53	22635-22640	0.143	_	
133-54	22643-22645	OD	_	
133-55	22645-22646	:	_	
133-56	22647-22659	Anxiety‐dACC	_	
133-57	22660-22664	0.34	_	
133-58	22665-22666	(	_	
133-59	22666-22670	0.99	_	
133-60	22670-22671	)	_	
133-61	22672-22676	1.29	_	
133-62	22676-22677	(	_	
133-63	22677-22679	13	_	
133-64	22679-22680	)	_	
133-65	22681-22686	0.220	_	
133-66	22689-22691	HC	_	
133-67	22691-22692	:	_	
133-68	22693-22705	Anxiety‐dACC	_	
133-69	22706-22711	0.006	_	
133-70	22712-22713	(	_	
133-71	22713-22717	0.92	_	
133-72	22717-22718	)	_	
133-73	22719-22723	0.02	_	
133-74	22723-22724	(	_	
133-75	22724-22725	8	_	
133-76	22725-22726	)	_	
133-77	22727-22731	0.99	_	
133-78	22735-22740	Table	_	
133-79	22741-22746	shows	_	
133-80	22747-22750	the	_	
133-81	22751-22759	t‐values	_	
133-82	22760-22768	obtained	_	
133-83	22769-22773	from	_	
133-84	22774-22784	one‐sample	_	
133-85	22785-22792	t‐tests	_	
133-86	22793-22796	and	_	
133-87	22797-22810	corresponding	_	
133-88	22811-22822	statistical	_	
133-89	22823-22835	significance	_	
133-90	22835-22836	.	_	

#Text=Significant at p < 0.05.
134-1	22838-22849	Significant	_	
134-2	22850-22852	at	_	
134-3	22853-22854	p	_	
134-4	22854-22855	 	_	
134-5	22855-22856	<	_	
134-6	22856-22857	 	_	
134-7	22857-22861	0.05	_	
134-8	22861-22862	.	_	

#Text=Discussion
#Text=In this study, we demonstrated that a drug cue video increased craving in 13 of 18 recently detoxified opioid‐dependent participants, with a time course that correlated with BOLD signal time course within the left amygdala but not the dACC.
135-1	22863-22873	Discussion	_	
135-2	22874-22876	In	_	
135-3	22877-22881	this	_	
135-4	22882-22887	study	_	
135-5	22887-22888	,	_	
135-6	22889-22891	we	_	
135-7	22892-22904	demonstrated	_	
135-8	22905-22909	that	_	
135-9	22910-22911	a	_	
135-10	22912-22916	drug	_	
135-11	22917-22920	cue	_	
135-12	22921-22926	video	_	
135-13	22927-22936	increased	_	
135-14	22937-22944	craving	_	
135-15	22945-22947	in	_	
135-16	22948-22950	13	_	
135-17	22951-22953	of	_	
135-18	22954-22956	18	_	
135-19	22957-22965	recently	_	
135-20	22966-22976	detoxified	_	
135-21	22977-22993	opioid‐dependent	_	
135-22	22994-23006	participants	_	
135-23	23006-23007	,	_	
135-24	23008-23012	with	_	
135-25	23013-23014	a	_	
135-26	23015-23019	time	_	
135-27	23020-23026	course	_	
135-28	23027-23031	that	_	
135-29	23032-23042	correlated	_	
135-30	23043-23047	with	_	
135-31	23048-23052	BOLD	_	
135-32	23053-23059	signal	_	
135-33	23060-23064	time	_	
135-34	23065-23071	course	_	
135-35	23072-23078	within	_	
135-36	23079-23082	the	_	
135-37	23083-23087	left	_	
135-38	23088-23096	amygdala	_	
135-39	23097-23100	but	_	
135-40	23101-23104	not	_	
135-41	23105-23108	the	_	
135-42	23109-23113	dACC	_	
135-43	23113-23114	.	_	

#Text=Peak amygdala response occurred during the drug cue video in the OD group, whereas dACC BOLD responses peaked in the 5 minutes following the drug cue video (when craving levels were decreasing).
136-1	23115-23119	Peak	_	
136-2	23120-23128	amygdala	_	
136-3	23129-23137	response	_	
136-4	23138-23146	occurred	_	
136-5	23147-23153	during	_	
136-6	23154-23157	the	_	
136-7	23158-23162	drug	_	
136-8	23163-23166	cue	_	
136-9	23167-23172	video	_	
136-10	23173-23175	in	_	
136-11	23176-23179	the	_	
136-12	23180-23182	OD	_	
136-13	23183-23188	group	_	
136-14	23188-23189	,	_	
136-15	23190-23197	whereas	_	
136-16	23198-23202	dACC	_	
136-17	23203-23207	BOLD	_	
136-18	23208-23217	responses	_	
136-19	23218-23224	peaked	_	
136-20	23225-23227	in	_	
136-21	23228-23231	the	_	
136-22	23232-23233	5	_	
136-23	23233-23234	 	_	
136-24	23234-23241	minutes	_	
136-25	23242-23251	following	_	
136-26	23252-23255	the	_	
136-27	23256-23260	drug	_	
136-28	23261-23264	cue	_	
136-29	23265-23270	video	_	
136-30	23271-23272	(	_	
136-31	23272-23276	when	_	
136-32	23277-23284	craving	_	
136-33	23285-23291	levels	_	
136-34	23292-23296	were	_	
136-35	23297-23307	decreasing	_	
136-36	23307-23308	)	_	
136-37	23308-23309	.	_	

#Text=Although anxiety ratings increased in response to the drug cue video, no correlations were found with either the amygdala or dACC.
137-1	23310-23318	Although	_	
137-2	23319-23326	anxiety	_	
137-3	23327-23334	ratings	_	
137-4	23335-23344	increased	_	
137-5	23345-23347	in	_	
137-6	23348-23356	response	_	
137-7	23357-23359	to	_	
137-8	23360-23363	the	_	
137-9	23364-23368	drug	_	
137-10	23369-23372	cue	_	
137-11	23373-23378	video	_	
137-12	23378-23379	,	_	
137-13	23380-23382	no	_	
137-14	23383-23395	correlations	_	
137-15	23396-23400	were	_	
137-16	23401-23406	found	_	
137-17	23407-23411	with	_	
137-18	23412-23418	either	_	
137-19	23419-23422	the	_	
137-20	23423-23431	amygdala	_	
137-21	23432-23434	or	_	
137-22	23435-23439	dACC	_	
137-23	23439-23440	.	_	

#Text=Against expectations, the ventral striatum was not recruited by the drug cue paradigm.
138-1	23441-23448	Against	_	
138-2	23449-23461	expectations	_	
138-3	23461-23462	,	_	
138-4	23463-23466	the	_	
138-5	23467-23474	ventral	_	
138-6	23475-23483	striatum	_	
138-7	23484-23487	was	_	
138-8	23488-23491	not	_	
138-9	23492-23501	recruited	_	
138-10	23502-23504	by	_	
138-11	23505-23508	the	_	
138-12	23509-23513	drug	_	
138-13	23514-23517	cue	_	
138-14	23518-23526	paradigm	_	
138-15	23526-23527	.	_	

#Text=The amygdala and craving
#Text=The significant correlation between amygdala BOLD signal and the time course of craving (but not anxiety) suggests the amygdala has a key role in the generation of cue‐elicited craving.
139-1	23528-23531	The	_	
139-2	23532-23540	amygdala	_	
139-3	23541-23544	and	_	
139-4	23545-23552	craving	_	
139-5	23553-23556	The	_	
139-6	23557-23568	significant	_	
139-7	23569-23580	correlation	_	
139-8	23581-23588	between	_	
139-9	23589-23597	amygdala	_	
139-10	23598-23602	BOLD	_	
139-11	23603-23609	signal	_	
139-12	23610-23613	and	_	
139-13	23614-23617	the	_	
139-14	23618-23622	time	_	
139-15	23623-23629	course	_	
139-16	23630-23632	of	_	
139-17	23633-23640	craving	_	
139-18	23641-23642	(	_	
139-19	23642-23645	but	_	
139-20	23646-23649	not	_	
139-21	23650-23657	anxiety	_	
139-22	23657-23658	)	_	
139-23	23659-23667	suggests	_	
139-24	23668-23671	the	_	
139-25	23672-23680	amygdala	_	
139-26	23681-23684	has	_	
139-27	23685-23686	a	_	
139-28	23687-23690	key	_	
139-29	23691-23695	role	_	
139-30	23696-23698	in	_	
139-31	23699-23702	the	_	
139-32	23703-23713	generation	_	
139-33	23714-23716	of	_	
139-34	23717-23729	cue‐elicited	_	
139-35	23730-23737	craving	_	
139-36	23737-23738	.	_	

#Text=This finding is in agreement with evidence demonstrating the amygdala to be important for Pavlovian‐conditioned behaviour and motivation (Janak & Tye 2015).
140-1	23739-23743	This	_	
140-2	23744-23751	finding	_	
140-3	23752-23754	is	_	
140-4	23755-23757	in	_	
140-5	23758-23767	agreement	_	
140-6	23768-23772	with	_	
140-7	23773-23781	evidence	_	
140-8	23782-23795	demonstrating	_	
140-9	23796-23799	the	_	
140-10	23800-23808	amygdala	_	
140-11	23809-23811	to	_	
140-12	23812-23814	be	_	
140-13	23815-23824	important	_	
140-14	23825-23828	for	_	
140-15	23829-23850	Pavlovian‐conditioned	_	
140-16	23851-23860	behaviour	_	
140-17	23861-23864	and	_	
140-18	23865-23875	motivation	_	
140-19	23876-23877	(	_	
140-20	23877-23882	Janak	_	
140-21	23883-23884	&	_	
140-22	23885-23888	Tye	_	
140-23	23889-23893	2015	_	
140-24	23893-23894	)	_	
140-25	23894-23895	.	_	

#Text=Preclinical findings demonstrate both the basolateral and central amygdala to be crucial for generating drug‐seeking responses to drug cues (Li et al. 2008; Buffalari & See 2010).
141-1	23896-23907	Preclinical	_	
141-2	23908-23916	findings	_	
141-3	23917-23928	demonstrate	_	
141-4	23929-23933	both	_	
141-5	23934-23937	the	_	
141-6	23938-23949	basolateral	_	
141-7	23950-23953	and	_	
141-8	23954-23961	central	_	
141-9	23962-23970	amygdala	_	
141-10	23971-23973	to	_	
141-11	23974-23976	be	_	
141-12	23977-23984	crucial	_	
141-13	23985-23988	for	_	
141-14	23989-23999	generating	_	
141-15	24000-24012	drug‐seeking	_	
141-16	24013-24022	responses	_	
141-17	24023-24025	to	_	
141-18	24026-24030	drug	_	
141-19	24031-24035	cues	_	
141-20	24036-24037	(	_	
141-21	24037-24039	Li	_	
141-22	24040-24042	et	_	
141-23	24043-24045	al	_	
141-24	24045-24046	.	_	
141-25	24047-24051	2008	_	
141-26	24051-24052	;	_	
141-27	24053-24062	Buffalari	_	
141-28	24063-24064	&	_	
141-29	24065-24068	See	_	
141-30	24069-24073	2010	_	
141-31	24073-24074	)	_	
141-32	24074-24075	.	_	

#Text=Human fMRI studies similarly report amygdala activation in response to heroin cues (Langleben et al. 2008; Mei, Zhang, & Xiao 2010; Li et al. 2012; Langleben et al. 2014), and pharmacological agents used to manage OD attenuate both amygdala activation and craving (Langleben et al. 2008; Mei et al. 2010; Langleben et al. 2014).
142-1	24076-24081	Human	_	
142-2	24082-24086	fMRI	_	
142-3	24087-24094	studies	_	
142-4	24095-24104	similarly	_	
142-5	24105-24111	report	_	
142-6	24112-24120	amygdala	_	
142-7	24121-24131	activation	_	
142-8	24132-24134	in	_	
142-9	24135-24143	response	_	
142-10	24144-24146	to	_	
142-11	24147-24153	heroin	_	
142-12	24154-24158	cues	_	
142-13	24159-24160	(	_	
142-14	24160-24169	Langleben	_	
142-15	24170-24172	et	_	
142-16	24173-24175	al	_	
142-17	24175-24176	.	_	
142-18	24177-24181	2008	_	
142-19	24181-24182	;	_	
142-20	24183-24186	Mei	_	
142-21	24186-24187	,	_	
142-22	24188-24193	Zhang	_	
142-23	24193-24194	,	_	
142-24	24195-24196	&	_	
142-25	24197-24201	Xiao	_	
142-26	24202-24206	2010	_	
142-27	24206-24207	;	_	
142-28	24208-24210	Li	_	
142-29	24211-24213	et	_	
142-30	24214-24216	al	_	
142-31	24216-24217	.	_	
142-32	24218-24222	2012	_	
142-33	24222-24223	;	_	
142-34	24224-24233	Langleben	_	
142-35	24234-24236	et	_	
142-36	24237-24239	al	_	
142-37	24239-24240	.	_	
142-38	24241-24245	2014	_	
142-39	24245-24246	)	_	
142-40	24246-24247	,	_	
142-41	24248-24251	and	_	
142-42	24252-24267	pharmacological	_	
142-43	24268-24274	agents	_	
142-44	24275-24279	used	_	
142-45	24280-24282	to	_	
142-46	24283-24289	manage	_	
142-47	24290-24292	OD	_	
142-48	24293-24302	attenuate	_	
142-49	24303-24307	both	_	
142-50	24308-24316	amygdala	_	
142-51	24317-24327	activation	_	
142-52	24328-24331	and	_	
142-53	24332-24339	craving	_	
142-54	24340-24341	(	_	
142-55	24341-24350	Langleben	_	
142-56	24351-24353	et	_	
142-57	24354-24356	al	_	
142-58	24356-24357	.	_	
142-59	24358-24362	2008	_	
142-60	24362-24363	;	_	
142-61	24364-24367	Mei	_	
142-62	24368-24370	et	_	
142-63	24371-24373	al	_	
142-64	24373-24374	.	_	
142-65	24375-24379	2010	_	
142-66	24379-24380	;	_	
142-67	24381-24390	Langleben	_	
142-68	24391-24393	et	_	
142-69	24394-24396	al	_	
142-70	24396-24397	.	_	
142-71	24398-24402	2014	_	
142-72	24402-24403	)	_	
142-73	24403-24404	.	_	

#Text=However, whilst one recent meta‐analysis of cue‐elicited craving paradigms did identify an association between amygdala activation and subjective craving (Chase et al. 2011), another meta‐analysis did not (Kuhn & Gallinat 2011).
143-1	24405-24412	However	_	
143-2	24412-24413	,	_	
143-3	24414-24420	whilst	_	
143-4	24421-24424	one	_	
143-5	24425-24431	recent	_	
143-6	24432-24445	meta‐analysis	_	
143-7	24446-24448	of	_	
143-8	24449-24461	cue‐elicited	_	
143-9	24462-24469	craving	_	
143-10	24470-24479	paradigms	_	
143-11	24480-24483	did	_	
143-12	24484-24492	identify	_	
143-13	24493-24495	an	_	
143-14	24496-24507	association	_	
143-15	24508-24515	between	_	
143-16	24516-24524	amygdala	_	
143-17	24525-24535	activation	_	
143-18	24536-24539	and	_	
143-19	24540-24550	subjective	_	
143-20	24551-24558	craving	_	
143-21	24559-24560	(	_	
143-22	24560-24565	Chase	_	
143-23	24566-24568	et	_	
143-24	24569-24571	al	_	
143-25	24571-24572	.	_	
143-26	24573-24577	2011	_	
143-27	24577-24578	)	_	
143-28	24578-24579	,	_	
143-29	24580-24587	another	_	
143-30	24588-24601	meta‐analysis	_	
143-31	24602-24605	did	_	
143-32	24606-24609	not	_	
143-33	24610-24611	(	_	
143-34	24611-24615	Kuhn	_	
143-35	24616-24617	&	_	
143-36	24618-24626	Gallinat	_	
143-37	24627-24631	2011	_	
143-38	24631-24632	)	_	
143-39	24632-24633	.	_	

#Text=One potential reason for this discrepancy may relate to differences in the methodology employed to examine brain‐craving relationships.
144-1	24634-24637	One	_	
144-2	24638-24647	potential	_	
144-3	24648-24654	reason	_	
144-4	24655-24658	for	_	
144-5	24659-24663	this	_	
144-6	24664-24675	discrepancy	_	
144-7	24676-24679	may	_	
144-8	24680-24686	relate	_	
144-9	24687-24689	to	_	
144-10	24690-24701	differences	_	
144-11	24702-24704	in	_	
144-12	24705-24708	the	_	
144-13	24709-24720	methodology	_	
144-14	24721-24729	employed	_	
144-15	24730-24732	to	_	
144-16	24733-24740	examine	_	
144-17	24741-24754	brain‐craving	_	
144-18	24755-24768	relationships	_	
144-19	24768-24769	.	_	

#Text=Traditional fMRI designs correlate average magnitude of BOLD signal during cue presentation with mean craving scores.
145-1	24770-24781	Traditional	_	
145-2	24782-24786	fMRI	_	
145-3	24787-24794	designs	_	
145-4	24795-24804	correlate	_	
145-5	24805-24812	average	_	
145-6	24813-24822	magnitude	_	
145-7	24823-24825	of	_	
145-8	24826-24830	BOLD	_	
145-9	24831-24837	signal	_	
145-10	24838-24844	during	_	
145-11	24845-24848	cue	_	
145-12	24849-24861	presentation	_	
145-13	24862-24866	with	_	
145-14	24867-24871	mean	_	
145-15	24872-24879	craving	_	
145-16	24880-24886	scores	_	
145-17	24886-24887	.	_	

#Text=This approach may be problematic given the non‐quantitative nature of BOLD, and the variation of craving over time.
146-1	24888-24892	This	_	
146-2	24893-24901	approach	_	
146-3	24902-24905	may	_	
146-4	24906-24908	be	_	
146-5	24909-24920	problematic	_	
146-6	24921-24926	given	_	
146-7	24927-24930	the	_	
146-8	24931-24947	non‐quantitative	_	
146-9	24948-24954	nature	_	
146-10	24955-24957	of	_	
146-11	24958-24962	BOLD	_	
146-12	24962-24963	,	_	
146-13	24964-24967	and	_	
146-14	24968-24971	the	_	
146-15	24972-24981	variation	_	
146-16	24982-24984	of	_	
146-17	24985-24992	craving	_	
146-18	24993-24997	over	_	
146-19	24998-25002	time	_	
146-20	25002-25003	.	_	

#Text=The current time course study allowed us to investigate how the shape of the BOLD signal related to subjective craving over time.
147-1	25004-25007	The	_	
147-2	25008-25015	current	_	
147-3	25016-25020	time	_	
147-4	25021-25027	course	_	
147-5	25028-25033	study	_	
147-6	25034-25041	allowed	_	
147-7	25042-25044	us	_	
147-8	25045-25047	to	_	
147-9	25048-25059	investigate	_	
147-10	25060-25063	how	_	
147-11	25064-25067	the	_	
147-12	25068-25073	shape	_	
147-13	25074-25076	of	_	
147-14	25077-25080	the	_	
147-15	25081-25085	BOLD	_	
147-16	25086-25092	signal	_	
147-17	25093-25100	related	_	
147-18	25101-25103	to	_	
147-19	25104-25114	subjective	_	
147-20	25115-25122	craving	_	
147-21	25123-25127	over	_	
147-22	25128-25132	time	_	
147-23	25132-25133	.	_	

#Text=Unlike a number of previous studies, we did observe a significant correlation, suggesting that this approach may be more reliable, and/or sensitive, in detecting a biomarker of subjective craving.
148-1	25134-25140	Unlike	_	
148-2	25141-25142	a	_	
148-3	25143-25149	number	_	
148-4	25150-25152	of	_	
148-5	25153-25161	previous	_	
148-6	25162-25169	studies	_	
148-7	25169-25170	,	_	
148-8	25171-25173	we	_	
148-9	25174-25177	did	_	
148-10	25178-25185	observe	_	
148-11	25186-25187	a	_	
148-12	25188-25199	significant	_	
148-13	25200-25211	correlation	_	
148-14	25211-25212	,	_	
148-15	25213-25223	suggesting	_	
148-16	25224-25228	that	_	
148-17	25229-25233	this	_	
148-18	25234-25242	approach	_	
148-19	25243-25246	may	_	
148-20	25247-25249	be	_	
148-21	25250-25254	more	_	
148-22	25255-25263	reliable	_	
148-23	25263-25264	,	_	
148-24	25265-25268	and	_	
148-25	25268-25269	/	_	
148-26	25269-25271	or	_	
148-27	25272-25281	sensitive	_	
148-28	25281-25282	,	_	
148-29	25283-25285	in	_	
148-30	25286-25295	detecting	_	
148-31	25296-25297	a	_	
148-32	25298-25307	biomarker	_	
148-33	25308-25310	of	_	
148-34	25311-25321	subjective	_	
148-35	25322-25329	craving	_	
148-36	25329-25330	.	_	

#Text=The effects within the amygdala were unilateral, possibly suggesting a left‐sided laterality for craving.
149-1	25331-25334	The	_	
149-2	25335-25342	effects	_	
149-3	25343-25349	within	_	
149-4	25350-25353	the	_	
149-5	25354-25362	amygdala	_	
149-6	25363-25367	were	_	
149-7	25368-25378	unilateral	_	
149-8	25378-25379	,	_	
149-9	25380-25388	possibly	_	
149-10	25389-25399	suggesting	_	
149-11	25400-25401	a	_	
149-12	25402-25412	left‐sided	_	
149-13	25413-25423	laterality	_	
149-14	25424-25427	for	_	
149-15	25428-25435	craving	_	
149-16	25435-25436	.	_	

#Text=Previous meta‐analyses of cue‐elicited craving studies have demonstrated a different lateralisation dependent upon the substance of dependence (Kuhn & Gallinat 2011) or the contrast investigated (Chase et al. 2011).
150-1	25437-25445	Previous	_	
150-2	25446-25459	meta‐analyses	_	
150-3	25460-25462	of	_	
150-4	25463-25475	cue‐elicited	_	
150-5	25476-25483	craving	_	
150-6	25484-25491	studies	_	
150-7	25492-25496	have	_	
150-8	25497-25509	demonstrated	_	
150-9	25510-25511	a	_	
150-10	25512-25521	different	_	
150-11	25522-25536	lateralisation	_	
150-12	25537-25546	dependent	_	
150-13	25547-25551	upon	_	
150-14	25552-25555	the	_	
150-15	25556-25565	substance	_	
150-16	25566-25568	of	_	
150-17	25569-25579	dependence	_	
150-18	25580-25581	(	_	
150-19	25581-25585	Kuhn	_	
150-20	25586-25587	&	_	
150-21	25588-25596	Gallinat	_	
150-22	25597-25601	2011	_	
150-23	25601-25602	)	_	
150-24	25603-25605	or	_	
150-25	25606-25609	the	_	
150-26	25610-25618	contrast	_	
150-27	25619-25631	investigated	_	
150-28	25632-25633	(	_	
150-29	25633-25638	Chase	_	
150-30	25639-25641	et	_	
150-31	25642-25644	al	_	
150-32	25644-25645	.	_	
150-33	25646-25650	2011	_	
150-34	25650-25651	)	_	
150-35	25651-25652	.	_	

#Text=Study design may also influence lateralisation, as the left amygdala is more commonly recruited in block designs rather than event‐related designs (Sergerie, Chochol, & Armony 2008), which may reflect different temporal dynamics (i.e. the right amygdala rapidly and automatically detects emotional stimuli, whilst the left amygdala engages in a more sustained evaluation) (Wright et al. 2001; Sergerie et al. 2008).
151-1	25653-25658	Study	_	
151-2	25659-25665	design	_	
151-3	25666-25669	may	_	
151-4	25670-25674	also	_	
151-5	25675-25684	influence	_	
151-6	25685-25699	lateralisation	_	
151-7	25699-25700	,	_	
151-8	25701-25703	as	_	
151-9	25704-25707	the	_	
151-10	25708-25712	left	_	
151-11	25713-25721	amygdala	_	
151-12	25722-25724	is	_	
151-13	25725-25729	more	_	
151-14	25730-25738	commonly	_	
151-15	25739-25748	recruited	_	
151-16	25749-25751	in	_	
151-17	25752-25757	block	_	
151-18	25758-25765	designs	_	
151-19	25766-25772	rather	_	
151-20	25773-25777	than	_	
151-21	25778-25791	event‐related	_	
151-22	25792-25799	designs	_	
151-23	25800-25801	(	_	
151-24	25801-25809	Sergerie	_	
151-25	25809-25810	,	_	
151-26	25811-25818	Chochol	_	
151-27	25818-25819	,	_	
151-28	25820-25821	&	_	
151-29	25822-25828	Armony	_	
151-30	25829-25833	2008	_	
151-31	25833-25834	)	_	
151-32	25834-25835	,	_	
151-33	25836-25841	which	_	
151-34	25842-25845	may	_	
151-35	25846-25853	reflect	_	
151-36	25854-25863	different	_	
151-37	25864-25872	temporal	_	
151-38	25873-25881	dynamics	_	
151-39	25882-25883	(	_	
151-40	25883-25886	i.e	_	
151-41	25886-25887	.	_	
151-42	25888-25891	the	_	
151-43	25892-25897	right	_	
151-44	25898-25906	amygdala	_	
151-45	25907-25914	rapidly	_	
151-46	25915-25918	and	_	
151-47	25919-25932	automatically	_	
151-48	25933-25940	detects	_	
151-49	25941-25950	emotional	_	
151-50	25951-25958	stimuli	_	
151-51	25958-25959	,	_	
151-52	25960-25966	whilst	_	
151-53	25967-25970	the	_	
151-54	25971-25975	left	_	
151-55	25976-25984	amygdala	_	
151-56	25985-25992	engages	_	
151-57	25993-25995	in	_	
151-58	25996-25997	a	_	
151-59	25998-26002	more	_	
151-60	26003-26012	sustained	_	
151-61	26013-26023	evaluation	_	
151-62	26023-26024	)	_	
151-63	26025-26026	(	_	
151-64	26026-26032	Wright	_	
151-65	26033-26035	et	_	
151-66	26036-26038	al	_	
151-67	26038-26039	.	_	
151-68	26040-26044	2001	_	
151-69	26044-26045	;	_	
151-70	26046-26054	Sergerie	_	
151-71	26055-26057	et	_	
151-72	26058-26060	al	_	
151-73	26060-26061	.	_	
151-74	26062-26066	2008	_	
151-75	26066-26067	)	_	
151-76	26067-26068	.	_	

#Text=Our sustained video stimulus would thus plausibly lead to a left‐lateralised response.
152-1	26069-26072	Our	_	
152-2	26073-26082	sustained	_	
152-3	26083-26088	video	_	
152-4	26089-26097	stimulus	_	
152-5	26098-26103	would	_	
152-6	26104-26108	thus	_	
152-7	26109-26118	plausibly	_	
152-8	26119-26123	lead	_	
152-9	26124-26126	to	_	
152-10	26127-26128	a	_	
152-11	26129-26145	left‐lateralised	_	
152-12	26146-26154	response	_	
152-13	26154-26155	.	_	

#Text=Dorsal ACC and craving
#Text=The dorsal ACC region is involved in both affective processing and higher order cognitive and behavioural control (Yucel & Lubman 2007; Etkin, Egner, & Kalisch 2011; Sheth et al. 2012; Shenhav et al. 2013).
153-1	26156-26162	Dorsal	_	
153-2	26163-26166	ACC	_	
153-3	26167-26170	and	_	
153-4	26171-26178	craving	_	
153-5	26179-26182	The	_	
153-6	26183-26189	dorsal	_	
153-7	26190-26193	ACC	_	
153-8	26194-26200	region	_	
153-9	26201-26203	is	_	
153-10	26204-26212	involved	_	
153-11	26213-26215	in	_	
153-12	26216-26220	both	_	
153-13	26221-26230	affective	_	
153-14	26231-26241	processing	_	
153-15	26242-26245	and	_	
153-16	26246-26252	higher	_	
153-17	26253-26258	order	_	
153-18	26259-26268	cognitive	_	
153-19	26269-26272	and	_	
153-20	26273-26284	behavioural	_	
153-21	26285-26292	control	_	
153-22	26293-26294	(	_	
153-23	26294-26299	Yucel	_	
153-24	26300-26301	&	_	
153-25	26302-26308	Lubman	_	
153-26	26309-26313	2007	_	
153-27	26313-26314	;	_	
153-28	26315-26320	Etkin	_	
153-29	26320-26321	,	_	
153-30	26322-26327	Egner	_	
153-31	26327-26328	,	_	
153-32	26329-26330	&	_	
153-33	26331-26338	Kalisch	_	
153-34	26339-26343	2011	_	
153-35	26343-26344	;	_	
153-36	26345-26350	Sheth	_	
153-37	26351-26353	et	_	
153-38	26354-26356	al	_	
153-39	26356-26357	.	_	
153-40	26358-26362	2012	_	
153-41	26362-26363	;	_	
153-42	26364-26371	Shenhav	_	
153-43	26372-26374	et	_	
153-44	26375-26377	al	_	
153-45	26377-26378	.	_	
153-46	26379-26383	2013	_	
153-47	26383-26384	)	_	
153-48	26384-26385	.	_	

#Text=Cue‐elicited ACC response has previously been observed in cocaine‐dependent individuals viewing a short (<5 minutes) cocaine video (Wexler et al. 2001), and positive correlations between ACC activity and craving have been reported (Kuhn & Gallinat 2011; Li et al. 2012).
154-1	26386-26398	Cue‐elicited	_	
154-2	26399-26402	ACC	_	
154-3	26403-26411	response	_	
154-4	26412-26415	has	_	
154-5	26416-26426	previously	_	
154-6	26427-26431	been	_	
154-7	26432-26440	observed	_	
154-8	26441-26443	in	_	
154-9	26444-26461	cocaine‐dependent	_	
154-10	26462-26473	individuals	_	
154-11	26474-26481	viewing	_	
154-12	26482-26483	a	_	
154-13	26484-26489	short	_	
154-14	26490-26491	(	_	
154-15	26491-26492	<	_	
154-16	26492-26493	5	_	
154-17	26493-26494	 	_	
154-18	26494-26501	minutes	_	
154-19	26501-26502	)	_	
154-20	26503-26510	cocaine	_	
154-21	26511-26516	video	_	
154-22	26517-26518	(	_	
154-23	26518-26524	Wexler	_	
154-24	26525-26527	et	_	
154-25	26528-26530	al	_	
154-26	26530-26531	.	_	
154-27	26532-26536	2001	_	
154-28	26536-26537	)	_	
154-29	26537-26538	,	_	
154-30	26539-26542	and	_	
154-31	26543-26551	positive	_	
154-32	26552-26564	correlations	_	
154-33	26565-26572	between	_	
154-34	26573-26576	ACC	_	
154-35	26577-26585	activity	_	
154-36	26586-26589	and	_	
154-37	26590-26597	craving	_	
154-38	26598-26602	have	_	
154-39	26603-26607	been	_	
154-40	26608-26616	reported	_	
154-41	26617-26618	(	_	
154-42	26618-26622	Kuhn	_	
154-43	26623-26624	&	_	
154-44	26625-26633	Gallinat	_	
154-45	26634-26638	2011	_	
154-46	26638-26639	;	_	
154-47	26640-26642	Li	_	
154-48	26643-26645	et	_	
154-49	26646-26648	al	_	
154-50	26648-26649	.	_	
154-51	26650-26654	2012	_	
154-52	26654-26655	)	_	
154-53	26655-26656	.	_	

#Text=However, traditional fMRI designs typically do not allow separation of the generation of craving from attempts to control craving (Goldstein & Volkow 2011).
155-1	26657-26664	However	_	
155-2	26664-26665	,	_	
155-3	26666-26677	traditional	_	
155-4	26678-26682	fMRI	_	
155-5	26683-26690	designs	_	
155-6	26691-26700	typically	_	
155-7	26701-26703	do	_	
155-8	26704-26707	not	_	
155-9	26708-26713	allow	_	
155-10	26714-26724	separation	_	
155-11	26725-26727	of	_	
155-12	26728-26731	the	_	
155-13	26732-26742	generation	_	
155-14	26743-26745	of	_	
155-15	26746-26753	craving	_	
155-16	26754-26758	from	_	
155-17	26759-26767	attempts	_	
155-18	26768-26770	to	_	
155-19	26771-26778	control	_	
155-20	26779-26786	craving	_	
155-21	26787-26788	(	_	
155-22	26788-26797	Goldstein	_	
155-23	26798-26799	&	_	
155-24	26800-26806	Volkow	_	
155-25	26807-26811	2011	_	
155-26	26811-26812	)	_	
155-27	26812-26813	.	_	

#Text=Here, our time course analysis showed that the dACC was not significantly recruited during the video when craving was at its peak, but was engaged after the end of the video whilst craving was declining.
156-1	26814-26818	Here	_	
156-2	26818-26819	,	_	
156-3	26820-26823	our	_	
156-4	26824-26828	time	_	
156-5	26829-26835	course	_	
156-6	26836-26844	analysis	_	
156-7	26845-26851	showed	_	
156-8	26852-26856	that	_	
156-9	26857-26860	the	_	
156-10	26861-26865	dACC	_	
156-11	26866-26869	was	_	
156-12	26870-26873	not	_	
156-13	26874-26887	significantly	_	
156-14	26888-26897	recruited	_	
156-15	26898-26904	during	_	
156-16	26905-26908	the	_	
156-17	26909-26914	video	_	
156-18	26915-26919	when	_	
156-19	26920-26927	craving	_	
156-20	26928-26931	was	_	
156-21	26932-26934	at	_	
156-22	26935-26938	its	_	
156-23	26939-26943	peak	_	
156-24	26943-26944	,	_	
156-25	26945-26948	but	_	
156-26	26949-26952	was	_	
156-27	26953-26960	engaged	_	
156-28	26961-26966	after	_	
156-29	26967-26970	the	_	
156-30	26971-26974	end	_	
156-31	26975-26977	of	_	
156-32	26978-26981	the	_	
156-33	26982-26987	video	_	
156-34	26988-26994	whilst	_	
156-35	26995-27002	craving	_	
156-36	27003-27006	was	_	
156-37	27007-27016	declining	_	
156-38	27016-27017	.	_	

#Text=This suggests that the dACC is not involved in the generation of craving, but may be recruited as newly abstinent individuals consciously attempt to bring craving under control.
157-1	27018-27022	This	_	
157-2	27023-27031	suggests	_	
157-3	27032-27036	that	_	
157-4	27037-27040	the	_	
157-5	27041-27045	dACC	_	
157-6	27046-27048	is	_	
157-7	27049-27052	not	_	
157-8	27053-27061	involved	_	
157-9	27062-27064	in	_	
157-10	27065-27068	the	_	
157-11	27069-27079	generation	_	
157-12	27080-27082	of	_	
157-13	27083-27090	craving	_	
157-14	27090-27091	,	_	
157-15	27092-27095	but	_	
157-16	27096-27099	may	_	
157-17	27100-27102	be	_	
157-18	27103-27112	recruited	_	
157-19	27113-27115	as	_	
157-20	27116-27121	newly	_	
157-21	27122-27131	abstinent	_	
157-22	27132-27143	individuals	_	
157-23	27144-27155	consciously	_	
157-24	27156-27163	attempt	_	
157-25	27164-27166	to	_	
157-26	27167-27172	bring	_	
157-27	27173-27180	craving	_	
157-28	27181-27186	under	_	
157-29	27187-27194	control	_	
157-30	27194-27195	.	_	

#Text=Indeed, nicotine craving studies have demonstrated that the dACC is recruited when participants ‘resist’ (Brody et al. 2007), or cognitively reappraise (Zhao et al. 2012), craving.
158-1	27196-27202	Indeed	_	
158-2	27202-27203	,	_	
158-3	27204-27212	nicotine	_	
158-4	27213-27220	craving	_	
158-5	27221-27228	studies	_	
158-6	27229-27233	have	_	
158-7	27234-27246	demonstrated	_	
158-8	27247-27251	that	_	
158-9	27252-27255	the	_	
158-10	27256-27260	dACC	_	
158-11	27261-27263	is	_	
158-12	27264-27273	recruited	_	
158-13	27274-27278	when	_	
158-14	27279-27291	participants	_	
158-15	27292-27293	‘	_	
158-16	27293-27299	resist	_	
158-17	27299-27300	’	_	
158-18	27301-27302	(	_	
158-19	27302-27307	Brody	_	
158-20	27308-27310	et	_	
158-21	27311-27313	al	_	
158-22	27313-27314	.	_	
158-23	27315-27319	2007	_	
158-24	27319-27320	)	_	
158-25	27320-27321	,	_	
158-26	27322-27324	or	_	
158-27	27325-27336	cognitively	_	
158-28	27337-27347	reappraise	_	
158-29	27348-27349	(	_	
158-30	27349-27353	Zhao	_	
158-31	27354-27356	et	_	
158-32	27357-27359	al	_	
158-33	27359-27360	.	_	
158-34	27361-27365	2012	_	
158-35	27365-27366	)	_	
158-36	27366-27367	,	_	
158-37	27368-27375	craving	_	
158-38	27375-27376	.	_	

#Text=Of particular interest here, it has been demonstrated previously that opioid users show inefficient dACC activation during inhibitory control (Yucel et al. 2007), which may reduce their ability to resist craving, and increase risk of relapse following detoxification.
159-1	27377-27379	Of	_	
159-2	27380-27390	particular	_	
159-3	27391-27399	interest	_	
159-4	27400-27404	here	_	
159-5	27404-27405	,	_	
159-6	27406-27408	it	_	
159-7	27409-27412	has	_	
159-8	27413-27417	been	_	
159-9	27418-27430	demonstrated	_	
159-10	27431-27441	previously	_	
159-11	27442-27446	that	_	
159-12	27447-27453	opioid	_	
159-13	27454-27459	users	_	
159-14	27460-27464	show	_	
159-15	27465-27476	inefficient	_	
159-16	27477-27481	dACC	_	
159-17	27482-27492	activation	_	
159-18	27493-27499	during	_	
159-19	27500-27510	inhibitory	_	
159-20	27511-27518	control	_	
159-21	27519-27520	(	_	
159-22	27520-27525	Yucel	_	
159-23	27526-27528	et	_	
159-24	27529-27531	al	_	
159-25	27531-27532	.	_	
159-26	27533-27537	2007	_	
159-27	27537-27538	)	_	
159-28	27538-27539	,	_	
159-29	27540-27545	which	_	
159-30	27546-27549	may	_	
159-31	27550-27556	reduce	_	
159-32	27557-27562	their	_	
159-33	27563-27570	ability	_	
159-34	27571-27573	to	_	
159-35	27574-27580	resist	_	
159-36	27581-27588	craving	_	
159-37	27588-27589	,	_	
159-38	27590-27593	and	_	
159-39	27594-27602	increase	_	
159-40	27603-27607	risk	_	
159-41	27608-27610	of	_	
159-42	27611-27618	relapse	_	
159-43	27619-27628	following	_	
159-44	27629-27643	detoxification	_	
159-45	27643-27644	.	_	

#Text=Future research should explore the relationship between dACC response in a newly abstinent group and duration of abstinence.
160-1	27645-27651	Future	_	
160-2	27652-27660	research	_	
160-3	27661-27667	should	_	
160-4	27668-27675	explore	_	
160-5	27676-27679	the	_	
160-6	27680-27692	relationship	_	
160-7	27693-27700	between	_	
160-8	27701-27705	dACC	_	
160-9	27706-27714	response	_	
160-10	27715-27717	in	_	
160-11	27718-27719	a	_	
160-12	27720-27725	newly	_	
160-13	27726-27735	abstinent	_	
160-14	27736-27741	group	_	
160-15	27742-27745	and	_	
160-16	27746-27754	duration	_	
160-17	27755-27757	of	_	
160-18	27758-27768	abstinence	_	
160-19	27768-27769	.	_	

#Text=Ventral medial prefrontal cortex, the ventral striatum and craving
#Text=Against expectations, we did not observe significant group or time effects for BOLD signal within the VmPFC and ventral striatum.
161-1	27770-27777	Ventral	_	
161-2	27778-27784	medial	_	
161-3	27785-27795	prefrontal	_	
161-4	27796-27802	cortex	_	
161-5	27802-27803	,	_	
161-6	27804-27807	the	_	
161-7	27808-27815	ventral	_	
161-8	27816-27824	striatum	_	
161-9	27825-27828	and	_	
161-10	27829-27836	craving	_	
161-11	27837-27844	Against	_	
161-12	27845-27857	expectations	_	
161-13	27857-27858	,	_	
161-14	27859-27861	we	_	
161-15	27862-27865	did	_	
161-16	27866-27869	not	_	
161-17	27870-27877	observe	_	
161-18	27878-27889	significant	_	
161-19	27890-27895	group	_	
161-20	27896-27898	or	_	
161-21	27899-27903	time	_	
161-22	27904-27911	effects	_	
161-23	27912-27915	for	_	
161-24	27916-27920	BOLD	_	
161-25	27921-27927	signal	_	
161-26	27928-27934	within	_	
161-27	27935-27938	the	_	
161-28	27939-27944	VmPFC	_	
161-29	27945-27948	and	_	
161-30	27949-27956	ventral	_	
161-31	27957-27965	striatum	_	
161-32	27965-27966	.	_	

#Text=The VmPFC is involved in the valuation of conditioned stimuli, signalling the subjective value of associated rewards (Elliott et al. 2008; Schoenbaum et al. 2009).
162-1	27967-27970	The	_	
162-2	27971-27976	VmPFC	_	
162-3	27977-27979	is	_	
162-4	27980-27988	involved	_	
162-5	27989-27991	in	_	
162-6	27992-27995	the	_	
162-7	27996-28005	valuation	_	
162-8	28006-28008	of	_	
162-9	28009-28020	conditioned	_	
162-10	28021-28028	stimuli	_	
162-11	28028-28029	,	_	
162-12	28030-28040	signalling	_	
162-13	28041-28044	the	_	
162-14	28045-28055	subjective	_	
162-15	28056-28061	value	_	
162-16	28062-28064	of	_	
162-17	28065-28075	associated	_	
162-18	28076-28083	rewards	_	
162-19	28084-28085	(	_	
162-20	28085-28092	Elliott	_	
162-21	28093-28095	et	_	
162-22	28096-28098	al	_	
162-23	28098-28099	.	_	
162-24	28100-28104	2008	_	
162-25	28104-28105	;	_	
162-26	28106-28116	Schoenbaum	_	
162-27	28117-28119	et	_	
162-28	28120-28122	al	_	
162-29	28122-28123	.	_	
162-30	28124-28128	2009	_	
162-31	28128-28129	)	_	
162-32	28129-28130	.	_	

#Text=VmPFC activation to drug cues has previously been observed, but typically in non‐treatment‐seeking individuals (Chase et al. 2011), suggesting that the lack of significant VmPFC recruitment in the current study may reflect altered motivational salience of drug cues in this newly abstinent group.
163-1	28131-28136	VmPFC	_	
163-2	28137-28147	activation	_	
163-3	28148-28150	to	_	
163-4	28151-28155	drug	_	
163-5	28156-28160	cues	_	
163-6	28161-28164	has	_	
163-7	28165-28175	previously	_	
163-8	28176-28180	been	_	
163-9	28181-28189	observed	_	
163-10	28189-28190	,	_	
163-11	28191-28194	but	_	
163-12	28195-28204	typically	_	
163-13	28205-28207	in	_	
163-14	28208-28229	non‐treatment‐seeking	_	
163-15	28230-28241	individuals	_	
163-16	28242-28243	(	_	
163-17	28243-28248	Chase	_	
163-18	28249-28251	et	_	
163-19	28252-28254	al	_	
163-20	28254-28255	.	_	
163-21	28256-28260	2011	_	
163-22	28260-28261	)	_	
163-23	28261-28262	,	_	
163-24	28263-28273	suggesting	_	
163-25	28274-28278	that	_	
163-26	28279-28282	the	_	
163-27	28283-28287	lack	_	
163-28	28288-28290	of	_	
163-29	28291-28302	significant	_	
163-30	28303-28308	VmPFC	_	
163-31	28309-28320	recruitment	_	
163-32	28321-28323	in	_	
163-33	28324-28327	the	_	
163-34	28328-28335	current	_	
163-35	28336-28341	study	_	
163-36	28342-28345	may	_	
163-37	28346-28353	reflect	_	
163-38	28354-28361	altered	_	
163-39	28362-28374	motivational	_	
163-40	28375-28383	salience	_	
163-41	28384-28386	of	_	
163-42	28387-28391	drug	_	
163-43	28392-28396	cues	_	
163-44	28397-28399	in	_	
163-45	28400-28404	this	_	
163-46	28405-28410	newly	_	
163-47	28411-28420	abstinent	_	
163-48	28421-28426	group	_	
163-49	28426-28427	.	_	

#Text=It may also be possible that the vulnerability of the VmPFC to susceptibility artefact precluded the detection of significant VmPFC findings.
164-1	28428-28430	It	_	
164-2	28431-28434	may	_	
164-3	28435-28439	also	_	
164-4	28440-28442	be	_	
164-5	28443-28451	possible	_	
164-6	28452-28456	that	_	
164-7	28457-28460	the	_	
164-8	28461-28474	vulnerability	_	
164-9	28475-28477	of	_	
164-10	28478-28481	the	_	
164-11	28482-28487	VmPFC	_	
164-12	28488-28490	to	_	
164-13	28491-28505	susceptibility	_	
164-14	28506-28514	artefact	_	
164-15	28515-28524	precluded	_	
164-16	28525-28528	the	_	
164-17	28529-28538	detection	_	
164-18	28539-28541	of	_	
164-19	28542-28553	significant	_	
164-20	28554-28559	VmPFC	_	
164-21	28560-28568	findings	_	
164-22	28568-28569	.	_	

#Text=Extensive evidence implicates the ventral striatum in various aspects of reward processing (Haber & Knutson 2010) including reward prediction (O'Doherty et al. 2004) and goal‐directed action based on salient affective information (Corbit, Muir, & Balleine 2001; Corbit & Balleine 2011).
165-1	28570-28579	Extensive	_	
165-2	28580-28588	evidence	_	
165-3	28589-28599	implicates	_	
165-4	28600-28603	the	_	
165-5	28604-28611	ventral	_	
165-6	28612-28620	striatum	_	
165-7	28621-28623	in	_	
165-8	28624-28631	various	_	
165-9	28632-28639	aspects	_	
165-10	28640-28642	of	_	
165-11	28643-28649	reward	_	
165-12	28650-28660	processing	_	
165-13	28661-28662	(	_	
165-14	28662-28667	Haber	_	
165-15	28668-28669	&	_	
165-16	28670-28677	Knutson	_	
165-17	28678-28682	2010	_	
165-18	28682-28683	)	_	
165-19	28684-28693	including	_	
165-20	28694-28700	reward	_	
165-21	28701-28711	prediction	_	
165-22	28712-28713	(	_	
165-23	28713-28722	O'Doherty	_	
165-24	28723-28725	et	_	
165-25	28726-28728	al	_	
165-26	28728-28729	.	_	
165-27	28730-28734	2004	_	
165-28	28734-28735	)	_	
165-29	28736-28739	and	_	
165-30	28740-28753	goal‐directed	_	
165-31	28754-28760	action	_	
165-32	28761-28766	based	_	
165-33	28767-28769	on	_	
165-34	28770-28777	salient	_	
165-35	28778-28787	affective	_	
165-36	28788-28799	information	_	
165-37	28800-28801	(	_	
165-38	28801-28807	Corbit	_	
165-39	28807-28808	,	_	
165-40	28809-28813	Muir	_	
165-41	28813-28814	,	_	
165-42	28815-28816	&	_	
165-43	28817-28825	Balleine	_	
165-44	28826-28830	2001	_	
165-45	28830-28831	;	_	
165-46	28832-28838	Corbit	_	
165-47	28839-28840	&	_	
165-48	28841-28849	Balleine	_	
165-49	28850-28854	2011	_	
165-50	28854-28855	)	_	
165-51	28855-28856	.	_	

#Text=It is therefore considered an important substrate of substance dependence, and we hypothesized that we would observe ventral striatum responses to the drug cue video; however, no such response was observed.
166-1	28857-28859	It	_	
166-2	28860-28862	is	_	
166-3	28863-28872	therefore	_	
166-4	28873-28883	considered	_	
166-5	28884-28886	an	_	
166-6	28887-28896	important	_	
166-7	28897-28906	substrate	_	
166-8	28907-28909	of	_	
166-9	28910-28919	substance	_	
166-10	28920-28930	dependence	_	
166-11	28930-28931	,	_	
166-12	28932-28935	and	_	
166-13	28936-28938	we	_	
166-14	28939-28951	hypothesized	_	
166-15	28952-28956	that	_	
166-16	28957-28959	we	_	
166-17	28960-28965	would	_	
166-18	28966-28973	observe	_	
166-19	28974-28981	ventral	_	
166-20	28982-28990	striatum	_	
166-21	28991-29000	responses	_	
166-22	29001-29003	to	_	
166-23	29004-29007	the	_	
166-24	29008-29012	drug	_	
166-25	29013-29016	cue	_	
166-26	29017-29022	video	_	
166-27	29022-29023	;	_	
166-28	29024-29031	however	_	
166-29	29031-29032	,	_	
166-30	29033-29035	no	_	
166-31	29036-29040	such	_	
166-32	29041-29049	response	_	
166-33	29050-29053	was	_	
166-34	29054-29062	observed	_	
166-35	29062-29063	.	_	

#Text=As we argued for the VmPFC, this may relate to reduced motivational salience of cues in actively treated individuals in combination with increased engagement of cognitive control processes that have been shown to inhibit both VmPFC and ventral striatal response to drug cues (Volkow et al. 2010).
167-1	29064-29066	As	_	
167-2	29067-29069	we	_	
167-3	29070-29076	argued	_	
167-4	29077-29080	for	_	
167-5	29081-29084	the	_	
167-6	29085-29090	VmPFC	_	
167-7	29090-29091	,	_	
167-8	29092-29096	this	_	
167-9	29097-29100	may	_	
167-10	29101-29107	relate	_	
167-11	29108-29110	to	_	
167-12	29111-29118	reduced	_	
167-13	29119-29131	motivational	_	
167-14	29132-29140	salience	_	
167-15	29141-29143	of	_	
167-16	29144-29148	cues	_	
167-17	29149-29151	in	_	
167-18	29152-29160	actively	_	
167-19	29161-29168	treated	_	
167-20	29169-29180	individuals	_	
167-21	29181-29183	in	_	
167-22	29184-29195	combination	_	
167-23	29196-29200	with	_	
167-24	29201-29210	increased	_	
167-25	29211-29221	engagement	_	
167-26	29222-29224	of	_	
167-27	29225-29234	cognitive	_	
167-28	29235-29242	control	_	
167-29	29243-29252	processes	_	
167-30	29253-29257	that	_	
167-31	29258-29262	have	_	
167-32	29263-29267	been	_	
167-33	29268-29273	shown	_	
167-34	29274-29276	to	_	
167-35	29277-29284	inhibit	_	
167-36	29285-29289	both	_	
167-37	29290-29295	VmPFC	_	
167-38	29296-29299	and	_	
167-39	29300-29307	ventral	_	
167-40	29308-29316	striatal	_	
167-41	29317-29325	response	_	
167-42	29326-29328	to	_	
167-43	29329-29333	drug	_	
167-44	29334-29338	cues	_	
167-45	29339-29340	(	_	
167-46	29340-29346	Volkow	_	
167-47	29347-29349	et	_	
167-48	29350-29352	al	_	
167-49	29352-29353	.	_	
167-50	29354-29358	2010	_	
167-51	29358-29359	)	_	
167-52	29359-29360	.	_	

#Text=However, meta‐analyses of previous fMRI studies report ventral striatum responses to drug cues in both treatment and non‐treatment‐seeking cohorts (Chase et al. 2011).
168-1	29361-29368	However	_	
168-2	29368-29369	,	_	
168-3	29370-29383	meta‐analyses	_	
168-4	29384-29386	of	_	
168-5	29387-29395	previous	_	
168-6	29396-29400	fMRI	_	
168-7	29401-29408	studies	_	
168-8	29409-29415	report	_	
168-9	29416-29423	ventral	_	
168-10	29424-29432	striatum	_	
168-11	29433-29442	responses	_	
168-12	29443-29445	to	_	
168-13	29446-29450	drug	_	
168-14	29451-29455	cues	_	
168-15	29456-29458	in	_	
168-16	29459-29463	both	_	
168-17	29464-29473	treatment	_	
168-18	29474-29477	and	_	
168-19	29478-29499	non‐treatment‐seeking	_	
168-20	29500-29507	cohorts	_	
168-21	29508-29509	(	_	
168-22	29509-29514	Chase	_	
168-23	29515-29517	et	_	
168-24	29518-29520	al	_	
168-25	29520-29521	.	_	
168-26	29522-29526	2011	_	
168-27	29526-29527	)	_	
168-28	29527-29528	.	_	

#Text=Ventral striatal response to craving cues has also been observed in another study of inpatient detoxified opioid‐dependent individuals (Li et al. 2012).
169-1	29529-29536	Ventral	_	
169-2	29537-29545	striatal	_	
169-3	29546-29554	response	_	
169-4	29555-29557	to	_	
169-5	29558-29565	craving	_	
169-6	29566-29570	cues	_	
169-7	29571-29574	has	_	
169-8	29575-29579	also	_	
169-9	29580-29584	been	_	
169-10	29585-29593	observed	_	
169-11	29594-29596	in	_	
169-12	29597-29604	another	_	
169-13	29605-29610	study	_	
169-14	29611-29613	of	_	
169-15	29614-29623	inpatient	_	
169-16	29624-29634	detoxified	_	
169-17	29635-29651	opioid‐dependent	_	
169-18	29652-29663	individuals	_	
169-19	29664-29665	(	_	
169-20	29665-29667	Li	_	
169-21	29668-29670	et	_	
169-22	29671-29673	al	_	
169-23	29673-29674	.	_	
169-24	29675-29679	2012	_	
169-25	29679-29680	)	_	
169-26	29680-29681	.	_	

#Text=However, it is important to consider the reasons why people are in treatment.
170-1	29682-29689	However	_	
170-2	29689-29690	,	_	
170-3	29691-29693	it	_	
170-4	29694-29696	is	_	
170-5	29697-29706	important	_	
170-6	29707-29709	to	_	
170-7	29710-29718	consider	_	
170-8	29719-29722	the	_	
170-9	29723-29730	reasons	_	
170-10	29731-29734	why	_	
170-11	29735-29741	people	_	
170-12	29742-29745	are	_	
170-13	29746-29748	in	_	
170-14	29749-29758	treatment	_	
170-15	29758-29759	.	_	

#Text=Drug detoxification is often compulsory in some countries (Werb et al. 2016) or may be ‘coerced’ (e.g. treatment to reduce or avoid a prison sentence); therefore, being ‘in treatment’ does not necessarily equate to ‘treatment seeking’.
171-1	29760-29764	Drug	_	
171-2	29765-29779	detoxification	_	
171-3	29780-29782	is	_	
171-4	29783-29788	often	_	
171-5	29789-29799	compulsory	_	
171-6	29800-29802	in	_	
171-7	29803-29807	some	_	
171-8	29808-29817	countries	_	
171-9	29818-29819	(	_	
171-10	29819-29823	Werb	_	
171-11	29824-29826	et	_	
171-12	29827-29829	al	_	
171-13	29829-29830	.	_	
171-14	29831-29835	2016	_	
171-15	29835-29836	)	_	
171-16	29837-29839	or	_	
171-17	29840-29843	may	_	
171-18	29844-29846	be	_	
171-19	29847-29848	‘	_	
171-20	29848-29855	coerced	_	
171-21	29855-29856	’	_	
171-22	29857-29858	(	_	
171-23	29858-29861	e.g	_	
171-24	29861-29862	.	_	
171-25	29863-29872	treatment	_	
171-26	29873-29875	to	_	
171-27	29876-29882	reduce	_	
171-28	29883-29885	or	_	
171-29	29886-29891	avoid	_	
171-30	29892-29893	a	_	
171-31	29894-29900	prison	_	
171-32	29901-29909	sentence	_	
171-33	29909-29910	)	_	
171-34	29910-29911	;	_	
171-35	29912-29921	therefore	_	
171-36	29921-29922	,	_	
171-37	29923-29928	being	_	
171-38	29929-29930	‘	_	
171-39	29930-29932	in	_	
171-40	29933-29942	treatment	_	
171-41	29942-29943	’	_	
171-42	29944-29948	does	_	
171-43	29949-29952	not	_	
171-44	29953-29964	necessarily	_	
171-45	29965-29971	equate	_	
171-46	29972-29974	to	_	
171-47	29975-29976	‘	_	
171-48	29976-29985	treatment	_	
171-49	29986-29993	seeking	_	
171-50	29993-29994	’	_	
171-51	29994-29995	.	_	

#Text=Different responses to drug cues may be expected in those who have voluntarily chosen treatment compared with those who have been compelled or coerced to enter treatment programmes.
172-1	29996-30005	Different	_	
172-2	30006-30015	responses	_	
172-3	30016-30018	to	_	
172-4	30019-30023	drug	_	
172-5	30024-30028	cues	_	
172-6	30029-30032	may	_	
172-7	30033-30035	be	_	
172-8	30036-30044	expected	_	
172-9	30045-30047	in	_	
172-10	30048-30053	those	_	
172-11	30054-30057	who	_	
172-12	30058-30062	have	_	
172-13	30063-30074	voluntarily	_	
172-14	30075-30081	chosen	_	
172-15	30082-30091	treatment	_	
172-16	30092-30100	compared	_	
172-17	30101-30105	with	_	
172-18	30106-30111	those	_	
172-19	30112-30115	who	_	
172-20	30116-30120	have	_	
172-21	30121-30125	been	_	
172-22	30126-30135	compelled	_	
172-23	30136-30138	or	_	
172-24	30139-30146	coerced	_	
172-25	30147-30149	to	_	
172-26	30150-30155	enter	_	
172-27	30156-30165	treatment	_	
172-28	30166-30176	programmes	_	
172-29	30176-30177	.	_	

#Text=Furthermore, the exact stage of treatment may influence brain response to drug cues.
173-1	30178-30189	Furthermore	_	
173-2	30189-30190	,	_	
173-3	30191-30194	the	_	
173-4	30195-30200	exact	_	
173-5	30201-30206	stage	_	
173-6	30207-30209	of	_	
173-7	30210-30219	treatment	_	
173-8	30220-30223	may	_	
173-9	30224-30233	influence	_	
173-10	30234-30239	brain	_	
173-11	30240-30248	response	_	
173-12	30249-30251	to	_	
173-13	30252-30256	drug	_	
173-14	30257-30261	cues	_	
173-15	30261-30262	.	_	

#Text=In the current study, although 39 participants enrolled, approximately 50 percent self‐discharged from the detoxification unit before the fourth week of the residential stay when scanning took place.
174-1	30263-30265	In	_	
174-2	30266-30269	the	_	
174-3	30270-30277	current	_	
174-4	30278-30283	study	_	
174-5	30283-30284	,	_	
174-6	30285-30293	although	_	
174-7	30294-30296	39	_	
174-8	30297-30309	participants	_	
174-9	30310-30318	enrolled	_	
174-10	30318-30319	,	_	
174-11	30320-30333	approximately	_	
174-12	30334-30336	50	_	
174-13	30337-30344	percent	_	
174-14	30345-30360	self‐discharged	_	
174-15	30361-30365	from	_	
174-16	30366-30369	the	_	
174-17	30370-30384	detoxification	_	
174-18	30385-30389	unit	_	
174-19	30390-30396	before	_	
174-20	30397-30400	the	_	
174-21	30401-30407	fourth	_	
174-22	30408-30412	week	_	
174-23	30413-30415	of	_	
174-24	30416-30419	the	_	
174-25	30420-30431	residential	_	
174-26	30432-30436	stay	_	
174-27	30437-30441	when	_	
174-28	30442-30450	scanning	_	
174-29	30451-30455	took	_	
174-30	30456-30461	place	_	
174-31	30461-30462	.	_	

#Text=Therefore, it remains possible that our group, tested during the last week of a voluntary, recovery focussed inpatient treatment programme, represents a distinct ‘treatment‐seeking’ population maximally motivated to maintain abstinence.
175-1	30463-30472	Therefore	_	
175-2	30472-30473	,	_	
175-3	30474-30476	it	_	
175-4	30477-30484	remains	_	
175-5	30485-30493	possible	_	
175-6	30494-30498	that	_	
175-7	30499-30502	our	_	
175-8	30503-30508	group	_	
175-9	30508-30509	,	_	
175-10	30510-30516	tested	_	
175-11	30517-30523	during	_	
175-12	30524-30527	the	_	
175-13	30528-30532	last	_	
175-14	30533-30537	week	_	
175-15	30538-30540	of	_	
175-16	30541-30542	a	_	
175-17	30543-30552	voluntary	_	
175-18	30552-30553	,	_	
175-19	30554-30562	recovery	_	
175-20	30563-30571	focussed	_	
175-21	30572-30581	inpatient	_	
175-22	30582-30591	treatment	_	
175-23	30592-30601	programme	_	
175-24	30601-30602	,	_	
175-25	30603-30613	represents	_	
175-26	30614-30615	a	_	
175-27	30616-30624	distinct	_	
175-28	30625-30626	‘	_	
175-29	30626-30643	treatment‐seeking	_	
175-30	30643-30644	’	_	
175-31	30645-30655	population	_	
175-32	30656-30665	maximally	_	
175-33	30666-30675	motivated	_	
175-34	30676-30678	to	_	
175-35	30679-30687	maintain	_	
175-36	30688-30698	abstinence	_	
175-37	30698-30699	.	_	

#Text=Longitudinal studies are needed to test hypotheses about differential responses to drug cues at different stages of dependence, treatment and abstinence (Jasinska et al. 2014).
176-1	30700-30712	Longitudinal	_	
176-2	30713-30720	studies	_	
176-3	30721-30724	are	_	
176-4	30725-30731	needed	_	
176-5	30732-30734	to	_	
176-6	30735-30739	test	_	
176-7	30740-30750	hypotheses	_	
176-8	30751-30756	about	_	
176-9	30757-30769	differential	_	
176-10	30770-30779	responses	_	
176-11	30780-30782	to	_	
176-12	30783-30787	drug	_	
176-13	30788-30792	cues	_	
176-14	30793-30795	at	_	
176-15	30796-30805	different	_	
176-16	30806-30812	stages	_	
176-17	30813-30815	of	_	
176-18	30816-30826	dependence	_	
176-19	30826-30827	,	_	
176-20	30828-30837	treatment	_	
176-21	30838-30841	and	_	
176-22	30842-30852	abstinence	_	
176-23	30853-30854	(	_	
176-24	30854-30862	Jasinska	_	
176-25	30863-30865	et	_	
176-26	30866-30868	al	_	
176-27	30868-30869	.	_	
176-28	30870-30874	2014	_	
176-29	30874-30875	)	_	
176-30	30875-30876	.	_	

#Text=Limitations
#Text=There are a number of limitations of this study.
177-1	30877-30888	Limitations	_	
177-2	30889-30894	There	_	
177-3	30895-30898	are	_	
177-4	30899-30900	a	_	
177-5	30901-30907	number	_	
177-6	30908-30910	of	_	
177-7	30911-30922	limitations	_	
177-8	30923-30925	of	_	
177-9	30926-30930	this	_	
177-10	30931-30936	study	_	
177-11	30936-30937	.	_	

#Text=Most of the OD group were still receiving psychoactive medications (Supporting Information Table S1).
178-1	30938-30942	Most	_	
178-2	30943-30945	of	_	
178-3	30946-30949	the	_	
178-4	30950-30952	OD	_	
178-5	30953-30958	group	_	
178-6	30959-30963	were	_	
178-7	30964-30969	still	_	
178-8	30970-30979	receiving	_	
178-9	30980-30992	psychoactive	_	
178-10	30993-31004	medications	_	
178-11	31005-31006	(	_	
178-12	31006-31016	Supporting	_	
178-13	31017-31028	Information	_	
178-14	31029-31034	Table	_	
178-15	31035-31037	S1	_	
178-16	31037-31038	)	_	
178-17	31038-31039	.	_	

#Text=The limited numbers of participants did not allow exploration of the influence of medication; however, given its high prevalence within this population (Torrens, Gilchrist, & Domingo‐Salvany 2011; Vogel et al. 2013), inclusion of these individuals allows for a more representative study sample.
179-1	31040-31043	The	_	
179-2	31044-31051	limited	_	
179-3	31052-31059	numbers	_	
179-4	31060-31062	of	_	
179-5	31063-31075	participants	_	
179-6	31076-31079	did	_	
179-7	31080-31083	not	_	
179-8	31084-31089	allow	_	
179-9	31090-31101	exploration	_	
179-10	31102-31104	of	_	
179-11	31105-31108	the	_	
179-12	31109-31118	influence	_	
179-13	31119-31121	of	_	
179-14	31122-31132	medication	_	
179-15	31132-31133	;	_	
179-16	31134-31141	however	_	
179-17	31141-31142	,	_	
179-18	31143-31148	given	_	
179-19	31149-31152	its	_	
179-20	31153-31157	high	_	
179-21	31158-31168	prevalence	_	
179-22	31169-31175	within	_	
179-23	31176-31180	this	_	
179-24	31181-31191	population	_	
179-25	31192-31193	(	_	
179-26	31193-31200	Torrens	_	
179-27	31200-31201	,	_	
179-28	31202-31211	Gilchrist	_	
179-29	31211-31212	,	_	
179-30	31213-31214	&	_	
179-31	31215-31230	Domingo‐Salvany	_	
179-32	31231-31235	2011	_	
179-33	31235-31236	;	_	
179-34	31237-31242	Vogel	_	
179-35	31243-31245	et	_	
179-36	31246-31248	al	_	
179-37	31248-31249	.	_	
179-38	31250-31254	2013	_	
179-39	31254-31255	)	_	
179-40	31255-31256	,	_	
179-41	31257-31266	inclusion	_	
179-42	31267-31269	of	_	
179-43	31270-31275	these	_	
179-44	31276-31287	individuals	_	
179-45	31288-31294	allows	_	
179-46	31295-31298	for	_	
179-47	31299-31300	a	_	
179-48	31301-31305	more	_	
179-49	31306-31320	representative	_	
179-50	31321-31326	study	_	
179-51	31327-31333	sample	_	
179-52	31333-31334	.	_	

#Text=Half of the OD participants were still receiving the opioid withdrawal medication lofexidine, and one small study reported that high doses of lofexidine (2.4 mg twice daily) reduce craving (Sinha et al. 2007).
180-1	31335-31339	Half	_	
180-2	31340-31342	of	_	
180-3	31343-31346	the	_	
180-4	31347-31349	OD	_	
180-5	31350-31362	participants	_	
180-6	31363-31367	were	_	
180-7	31368-31373	still	_	
180-8	31374-31383	receiving	_	
180-9	31384-31387	the	_	
180-10	31388-31394	opioid	_	
180-11	31395-31405	withdrawal	_	
180-12	31406-31416	medication	_	
180-13	31417-31427	lofexidine	_	
180-14	31427-31428	,	_	
180-15	31429-31432	and	_	
180-16	31433-31436	one	_	
180-17	31437-31442	small	_	
180-18	31443-31448	study	_	
180-19	31449-31457	reported	_	
180-20	31458-31462	that	_	
180-21	31463-31467	high	_	
180-22	31468-31473	doses	_	
180-23	31474-31476	of	_	
180-24	31477-31487	lofexidine	_	
180-25	31488-31489	(	_	
180-26	31489-31492	2.4	_	
180-27	31492-31493	 	_	
180-28	31493-31495	mg	_	
180-29	31496-31501	twice	_	
180-30	31502-31507	daily	_	
180-31	31507-31508	)	_	
180-32	31509-31515	reduce	_	
180-33	31516-31523	craving	_	
180-34	31524-31525	(	_	
180-35	31525-31530	Sinha	_	
180-36	31531-31533	et	_	
180-37	31534-31536	al	_	
180-38	31536-31537	.	_	
180-39	31538-31542	2007	_	
180-40	31542-31543	)	_	
180-41	31543-31544	.	_	

#Text=However, lofexidine is not generally considered to suppress psychological cravings (Gish et al. 2010), and a much lower dose was administered to participants at the point of their participation in the present study (0.2 mg twice daily).
181-1	31545-31552	However	_	
181-2	31552-31553	,	_	
181-3	31554-31564	lofexidine	_	
181-4	31565-31567	is	_	
181-5	31568-31571	not	_	
181-6	31572-31581	generally	_	
181-7	31582-31592	considered	_	
181-8	31593-31595	to	_	
181-9	31596-31604	suppress	_	
181-10	31605-31618	psychological	_	
181-11	31619-31627	cravings	_	
181-12	31628-31629	(	_	
181-13	31629-31633	Gish	_	
181-14	31634-31636	et	_	
181-15	31637-31639	al	_	
181-16	31639-31640	.	_	
181-17	31641-31645	2010	_	
181-18	31645-31646	)	_	
181-19	31646-31647	,	_	
181-20	31648-31651	and	_	
181-21	31652-31653	a	_	
181-22	31654-31658	much	_	
181-23	31659-31664	lower	_	
181-24	31665-31669	dose	_	
181-25	31670-31673	was	_	
181-26	31674-31686	administered	_	
181-27	31687-31689	to	_	
181-28	31690-31702	participants	_	
181-29	31703-31705	at	_	
181-30	31706-31709	the	_	
181-31	31710-31715	point	_	
181-32	31716-31718	of	_	
181-33	31719-31724	their	_	
181-34	31725-31738	participation	_	
181-35	31739-31741	in	_	
181-36	31742-31745	the	_	
181-37	31746-31753	present	_	
181-38	31754-31759	study	_	
181-39	31760-31761	(	_	
181-40	31761-31764	0.2	_	
181-41	31764-31765	 	_	
181-42	31765-31767	mg	_	
181-43	31768-31773	twice	_	
181-44	31774-31779	daily	_	
181-45	31779-31780	)	_	
181-46	31780-31781	.	_	

#Text=Furthermore, differences in IQ and years of education between our groups may have influenced findings.
182-1	31782-31793	Furthermore	_	
182-2	31793-31794	,	_	
182-3	31795-31806	differences	_	
182-4	31807-31809	in	_	
182-5	31810-31812	IQ	_	
182-6	31813-31816	and	_	
182-7	31817-31822	years	_	
182-8	31823-31825	of	_	
182-9	31826-31835	education	_	
182-10	31836-31843	between	_	
182-11	31844-31847	our	_	
182-12	31848-31854	groups	_	
182-13	31855-31858	may	_	
182-14	31859-31863	have	_	
182-15	31864-31874	influenced	_	
182-16	31875-31883	findings	_	
182-17	31883-31884	.	_	

#Text=However, a particular strength to the study was our selection of healthy volunteers based upon occupational experience of drug use.
183-1	31885-31892	However	_	
183-2	31892-31893	,	_	
183-3	31894-31895	a	_	
183-4	31896-31906	particular	_	
183-5	31907-31915	strength	_	
183-6	31916-31918	to	_	
183-7	31919-31922	the	_	
183-8	31923-31928	study	_	
183-9	31929-31932	was	_	
183-10	31933-31936	our	_	
183-11	31937-31946	selection	_	
183-12	31947-31949	of	_	
183-13	31950-31957	healthy	_	
183-14	31958-31968	volunteers	_	
183-15	31969-31974	based	_	
183-16	31975-31979	upon	_	
183-17	31980-31992	occupational	_	
183-18	31993-32003	experience	_	
183-19	32004-32006	of	_	
183-20	32007-32011	drug	_	
183-21	32012-32015	use	_	
183-22	32015-32016	.	_	

#Text=We chose to prioritize this over matching for educational performance, which findings from our group suggest do not impact upon incentive motivation and reward processes (Bland et al. 2016).
184-1	32017-32019	We	_	
184-2	32020-32025	chose	_	
184-3	32026-32028	to	_	
184-4	32029-32039	prioritize	_	
184-5	32040-32044	this	_	
184-6	32045-32049	over	_	
184-7	32050-32058	matching	_	
184-8	32059-32062	for	_	
184-9	32063-32074	educational	_	
184-10	32075-32086	performance	_	
184-11	32086-32087	,	_	
184-12	32088-32093	which	_	
184-13	32094-32102	findings	_	
184-14	32103-32107	from	_	
184-15	32108-32111	our	_	
184-16	32112-32117	group	_	
184-17	32118-32125	suggest	_	
184-18	32126-32128	do	_	
184-19	32129-32132	not	_	
184-20	32133-32139	impact	_	
184-21	32140-32144	upon	_	
184-22	32145-32154	incentive	_	
184-23	32155-32165	motivation	_	
184-24	32166-32169	and	_	
184-25	32170-32176	reward	_	
184-26	32177-32186	processes	_	
184-27	32187-32188	(	_	
184-28	32188-32193	Bland	_	
184-29	32194-32196	et	_	
184-30	32197-32199	al	_	
184-31	32199-32200	.	_	
184-32	32201-32205	2016	_	
184-33	32205-32206	)	_	
184-34	32206-32207	.	_	

#Text=Another limitation was that study numbers were relatively small, largely because this is a difficult group to recruit, especially given recent changes in UK addiction service provision (the inpatient unit admission criteria changed during the period of recruitment such that only those with complex health needs were admitted, resulting in many patients being ineligible for the study).
185-1	32208-32215	Another	_	
185-2	32216-32226	limitation	_	
185-3	32227-32230	was	_	
185-4	32231-32235	that	_	
185-5	32236-32241	study	_	
185-6	32242-32249	numbers	_	
185-7	32250-32254	were	_	
185-8	32255-32265	relatively	_	
185-9	32266-32271	small	_	
185-10	32271-32272	,	_	
185-11	32273-32280	largely	_	
185-12	32281-32288	because	_	
185-13	32289-32293	this	_	
185-14	32294-32296	is	_	
185-15	32297-32298	a	_	
185-16	32299-32308	difficult	_	
185-17	32309-32314	group	_	
185-18	32315-32317	to	_	
185-19	32318-32325	recruit	_	
185-20	32325-32326	,	_	
185-21	32327-32337	especially	_	
185-22	32338-32343	given	_	
185-23	32344-32350	recent	_	
185-24	32351-32358	changes	_	
185-25	32359-32361	in	_	
185-26	32362-32364	UK	_	
185-27	32365-32374	addiction	_	
185-28	32375-32382	service	_	
185-29	32383-32392	provision	_	
185-30	32393-32394	(	_	
185-31	32394-32397	the	_	
185-32	32398-32407	inpatient	_	
185-33	32408-32412	unit	_	
185-34	32413-32422	admission	_	
185-35	32423-32431	criteria	_	
185-36	32432-32439	changed	_	
185-37	32440-32446	during	_	
185-38	32447-32450	the	_	
185-39	32451-32457	period	_	
185-40	32458-32460	of	_	
185-41	32461-32472	recruitment	_	
185-42	32473-32477	such	_	
185-43	32478-32482	that	_	
185-44	32483-32487	only	_	
185-45	32488-32493	those	_	
185-46	32494-32498	with	_	
185-47	32499-32506	complex	_	
185-48	32507-32513	health	_	
185-49	32514-32519	needs	_	
185-50	32520-32524	were	_	
185-51	32525-32533	admitted	_	
185-52	32533-32534	,	_	
185-53	32535-32544	resulting	_	
185-54	32545-32547	in	_	
185-55	32548-32552	many	_	
185-56	32553-32561	patients	_	
185-57	32562-32567	being	_	
185-58	32568-32578	ineligible	_	
185-59	32579-32582	for	_	
185-60	32583-32586	the	_	
185-61	32587-32592	study	_	
185-62	32592-32593	)	_	
185-63	32593-32594	.	_	

#Text=This may have had an impact on results; e.g. the time course in the VmPFC did not reach significance because of high variability in this region prone to signal dropout.
186-1	32595-32599	This	_	
186-2	32600-32603	may	_	
186-3	32604-32608	have	_	
186-4	32609-32612	had	_	
186-5	32613-32615	an	_	
186-6	32616-32622	impact	_	
186-7	32623-32625	on	_	
186-8	32626-32633	results	_	
186-9	32633-32634	;	_	
186-10	32635-32638	e.g	_	
186-11	32638-32639	.	_	
186-12	32640-32643	the	_	
186-13	32644-32648	time	_	
186-14	32649-32655	course	_	
186-15	32656-32658	in	_	
186-16	32659-32662	the	_	
186-17	32663-32668	VmPFC	_	
186-18	32669-32672	did	_	
186-19	32673-32676	not	_	
186-20	32677-32682	reach	_	
186-21	32683-32695	significance	_	
186-22	32696-32703	because	_	
186-23	32704-32706	of	_	
186-24	32707-32711	high	_	
186-25	32712-32723	variability	_	
186-26	32724-32726	in	_	
186-27	32727-32731	this	_	
186-28	32732-32738	region	_	
186-29	32739-32744	prone	_	
186-30	32745-32747	to	_	
186-31	32748-32754	signal	_	
186-32	32755-32762	dropout	_	
186-33	32762-32763	.	_	

#Text=In a larger sample, this finding might have reached significance.
187-1	32764-32766	In	_	
187-2	32767-32768	a	_	
187-3	32769-32775	larger	_	
187-4	32776-32782	sample	_	
187-5	32782-32783	,	_	
187-6	32784-32788	this	_	
187-7	32789-32796	finding	_	
187-8	32797-32802	might	_	
187-9	32803-32807	have	_	
187-10	32808-32815	reached	_	
187-11	32816-32828	significance	_	
187-12	32828-32829	.	_	

#Text=Conclusion and Clinical Implications
#Text=Using a novel paradigm investigating dynamic brain and craving responses, we have demonstrated a similar time course that links the left amygdala with the emergence of subjective craving, suggesting a craving generative role for the amygdala.
188-1	32830-32840	Conclusion	_	
188-2	32841-32844	and	_	
188-3	32845-32853	Clinical	_	
188-4	32854-32866	Implications	_	
188-5	32867-32872	Using	_	
188-6	32873-32874	a	_	
188-7	32875-32880	novel	_	
188-8	32881-32889	paradigm	_	
188-9	32890-32903	investigating	_	
188-10	32904-32911	dynamic	_	
188-11	32912-32917	brain	_	
188-12	32918-32921	and	_	
188-13	32922-32929	craving	_	
188-14	32930-32939	responses	_	
188-15	32939-32940	,	_	
188-16	32941-32943	we	_	
188-17	32944-32948	have	_	
188-18	32949-32961	demonstrated	_	
188-19	32962-32963	a	_	
188-20	32964-32971	similar	_	
188-21	32972-32976	time	_	
188-22	32977-32983	course	_	
188-23	32984-32988	that	_	
188-24	32989-32994	links	_	
188-25	32995-32998	the	_	
188-26	32999-33003	left	_	
188-27	33004-33012	amygdala	_	
188-28	33013-33017	with	_	
188-29	33018-33021	the	_	
188-30	33022-33031	emergence	_	
188-31	33032-33034	of	_	
188-32	33035-33045	subjective	_	
188-33	33046-33053	craving	_	
188-34	33053-33054	,	_	
188-35	33055-33065	suggesting	_	
188-36	33066-33067	a	_	
188-37	33068-33075	craving	_	
188-38	33076-33086	generative	_	
188-39	33087-33091	role	_	
188-40	33092-33095	for	_	
188-41	33096-33099	the	_	
188-42	33100-33108	amygdala	_	
188-43	33108-33109	.	_	

#Text=Amygdala response to drug cues may represent a persistent vulnerability to relapse within this cohort.
189-1	33110-33118	Amygdala	_	
189-2	33119-33127	response	_	
189-3	33128-33130	to	_	
189-4	33131-33135	drug	_	
189-5	33136-33140	cues	_	
189-6	33141-33144	may	_	
189-7	33145-33154	represent	_	
189-8	33155-33156	a	_	
189-9	33157-33167	persistent	_	
189-10	33168-33181	vulnerability	_	
189-11	33182-33184	to	_	
189-12	33185-33192	relapse	_	
189-13	33193-33199	within	_	
189-14	33200-33204	this	_	
189-15	33205-33211	cohort	_	
189-16	33211-33212	.	_	

#Text=By analysing brain and craving responses after the end of the craving video, we found increased dACC BOLD response only during the period of decreasing subjective craving.
190-1	33213-33215	By	_	
190-2	33216-33225	analysing	_	
190-3	33226-33231	brain	_	
190-4	33232-33235	and	_	
190-5	33236-33243	craving	_	
190-6	33244-33253	responses	_	
190-7	33254-33259	after	_	
190-8	33260-33263	the	_	
190-9	33264-33267	end	_	
190-10	33268-33270	of	_	
190-11	33271-33274	the	_	
190-12	33275-33282	craving	_	
190-13	33283-33288	video	_	
190-14	33288-33289	,	_	
190-15	33290-33292	we	_	
190-16	33293-33298	found	_	
190-17	33299-33308	increased	_	
190-18	33309-33313	dACC	_	
190-19	33314-33318	BOLD	_	
190-20	33319-33327	response	_	
190-21	33328-33332	only	_	
190-22	33333-33339	during	_	
190-23	33340-33343	the	_	
190-24	33344-33350	period	_	
190-25	33351-33353	of	_	
190-26	33354-33364	decreasing	_	
190-27	33365-33375	subjective	_	
190-28	33376-33383	craving	_	
190-29	33383-33384	.	_	

#Text=This suggests a role for the dACC in behavioural/cognitive control in recovering individuals following a period of cue‐induced craving.
191-1	33385-33389	This	_	
191-2	33390-33398	suggests	_	
191-3	33399-33400	a	_	
191-4	33401-33405	role	_	
191-5	33406-33409	for	_	
191-6	33410-33413	the	_	
191-7	33414-33418	dACC	_	
191-8	33419-33421	in	_	
191-9	33422-33433	behavioural	_	
191-10	33433-33434	/	_	
191-11	33434-33443	cognitive	_	
191-12	33444-33451	control	_	
191-13	33452-33454	in	_	
191-14	33455-33465	recovering	_	
191-15	33466-33477	individuals	_	
191-16	33478-33487	following	_	
191-17	33488-33489	a	_	
191-18	33490-33496	period	_	
191-19	33497-33499	of	_	
191-20	33500-33511	cue‐induced	_	
191-21	33512-33519	craving	_	
191-22	33519-33520	.	_	

#Text=Persistent amygdala activation and craving in response to drug cues, together with inefficient dACC‐mediated control, may contribute to relapse following treatment.
192-1	33521-33531	Persistent	_	
192-2	33532-33540	amygdala	_	
192-3	33541-33551	activation	_	
192-4	33552-33555	and	_	
192-5	33556-33563	craving	_	
192-6	33564-33566	in	_	
192-7	33567-33575	response	_	
192-8	33576-33578	to	_	
192-9	33579-33583	drug	_	
192-10	33584-33588	cues	_	
192-11	33588-33589	,	_	
192-12	33590-33598	together	_	
192-13	33599-33603	with	_	
192-14	33604-33615	inefficient	_	
192-15	33616-33629	dACC‐mediated	_	
192-16	33630-33637	control	_	
192-17	33637-33638	,	_	
192-18	33639-33642	may	_	
192-19	33643-33653	contribute	_	
192-20	33654-33656	to	_	
192-21	33657-33664	relapse	_	
192-22	33665-33674	following	_	
192-23	33675-33684	treatment	_	
192-24	33684-33685	.	_	

#Text=Promising cognitive and pharmacological treatments have been shown to reduce amygdala cue reactivity and increase dACC activity in both preclinical models and human tests of cognitive performance (Spence et al. 2005; Xue et al. 2012).
193-1	33686-33695	Promising	_	
193-2	33696-33705	cognitive	_	
193-3	33706-33709	and	_	
193-4	33710-33725	pharmacological	_	
193-5	33726-33736	treatments	_	
193-6	33737-33741	have	_	
193-7	33742-33746	been	_	
193-8	33747-33752	shown	_	
193-9	33753-33755	to	_	
193-10	33756-33762	reduce	_	
193-11	33763-33771	amygdala	_	
193-12	33772-33775	cue	_	
193-13	33776-33786	reactivity	_	
193-14	33787-33790	and	_	
193-15	33791-33799	increase	_	
193-16	33800-33804	dACC	_	
193-17	33805-33813	activity	_	
193-18	33814-33816	in	_	
193-19	33817-33821	both	_	
193-20	33822-33833	preclinical	_	
193-21	33834-33840	models	_	
193-22	33841-33844	and	_	
193-23	33845-33850	human	_	
193-24	33851-33856	tests	_	
193-25	33857-33859	of	_	
193-26	33860-33869	cognitive	_	
193-27	33870-33881	performance	_	
193-28	33882-33883	(	_	
193-29	33883-33889	Spence	_	
193-30	33890-33892	et	_	
193-31	33893-33895	al	_	
193-32	33895-33896	.	_	
193-33	33897-33901	2005	_	
193-34	33901-33902	;	_	
193-35	33903-33906	Xue	_	
193-36	33907-33909	et	_	
193-37	33910-33912	al	_	
193-38	33912-33913	.	_	
193-39	33914-33918	2012	_	
193-40	33918-33919	)	_	
193-41	33919-33920	.	_	

#Text=Our time course‐based approach may represent an important biomarker for evaluating these treatments in dependent individuals.
194-1	33921-33924	Our	_	
194-2	33925-33929	time	_	
194-3	33930-33942	course‐based	_	
194-4	33943-33951	approach	_	
194-5	33952-33955	may	_	
194-6	33956-33965	represent	_	
194-7	33966-33968	an	_	
194-8	33969-33978	important	_	
194-9	33979-33988	biomarker	_	
194-10	33989-33992	for	_	
194-11	33993-34003	evaluating	_	
194-12	34004-34009	these	_	
194-13	34010-34020	treatments	_	
194-14	34021-34023	in	_	
194-15	34024-34033	dependent	_	
194-16	34034-34045	individuals	_	
194-17	34045-34046	.	_	

#Text=Conflict of Interest
#Text=The authors declare no conflicts of interest
#Text=Authors Contribution
#Text=RE was responsible for study concept.
195-1	34047-34055	Conflict	_	
195-2	34056-34058	of	_	
195-3	34059-34067	Interest	_	
195-4	34068-34071	The	_	
195-5	34072-34079	authors	_	
195-6	34080-34087	declare	_	
195-7	34088-34090	no	_	
195-8	34091-34100	conflicts	_	
195-9	34101-34103	of	_	
195-10	34104-34112	interest	_	
195-11	34113-34120	Authors	_	
195-12	34121-34133	Contribution	_	
195-13	34134-34136	RE	_	
195-14	34137-34140	was	_	
195-15	34141-34152	responsible	_	
195-16	34153-34156	for	_	
195-17	34157-34162	study	_	
195-18	34163-34170	concept	_	
195-19	34170-34171	.	_	

#Text=RE, DIL, SM, IA, BD, PSB, LAP, AM and SH made an active contribution to the study design and concept.
196-1	34172-34174	RE	_	
196-2	34174-34175	,	_	
196-3	34176-34179	DIL	_	
196-4	34179-34180	,	_	
196-5	34181-34183	SM	_	
196-6	34183-34184	,	_	
196-7	34185-34187	IA	_	
196-8	34187-34188	,	_	
196-9	34189-34191	BD	_	
196-10	34191-34192	,	_	
196-11	34193-34196	PSB	_	
196-12	34196-34197	,	_	
196-13	34198-34201	LAP	_	
196-14	34201-34202	,	_	
196-15	34203-34205	AM	_	
196-16	34206-34209	and	_	
196-17	34210-34212	SH	_	
196-18	34213-34217	made	_	
196-19	34218-34220	an	_	
196-20	34221-34227	active	_	
196-21	34228-34240	contribution	_	
196-22	34241-34243	to	_	
196-23	34244-34247	the	_	
196-24	34248-34253	study	_	
196-25	34254-34260	design	_	
196-26	34261-34264	and	_	
196-27	34265-34272	concept	_	
196-28	34272-34273	.	_	

#Text=AM and QF recruited participants.
197-1	34274-34276	AM	_	
197-2	34277-34280	and	_	
197-3	34281-34283	QF	_	
197-4	34284-34293	recruited	_	
197-5	34294-34306	participants	_	
197-6	34306-34307	.	_	

#Text=AM collected the data.
198-1	34308-34310	AM	_	
198-2	34311-34320	collected	_	
198-3	34321-34324	the	_	
198-4	34325-34329	data	_	
198-5	34329-34330	.	_	

#Text=AM, SM and SH analysed the data.
199-1	34331-34333	AM	_	
199-2	34333-34334	,	_	
199-3	34335-34337	SM	_	
199-4	34338-34341	and	_	
199-5	34342-34344	SH	_	
199-6	34345-34353	analysed	_	
199-7	34354-34357	the	_	
199-8	34358-34362	data	_	
199-9	34362-34363	.	_	

#Text=AM drafted the manuscript.
200-1	34364-34366	AM	_	
200-2	34367-34374	drafted	_	
200-3	34375-34378	the	_	
200-4	34379-34389	manuscript	_	
200-5	34389-34390	.	_	

#Text=RE, DIL, IA and BD provided critical revision of the manuscript for important intellectual content.
201-1	34391-34393	RE	_	
201-2	34393-34394	,	_	
201-3	34395-34398	DIL	_	
201-4	34398-34399	,	_	
201-5	34400-34402	IA	_	
201-6	34403-34406	and	_	
201-7	34407-34409	BD	_	
201-8	34410-34418	provided	_	
201-9	34419-34427	critical	_	
201-10	34428-34436	revision	_	
201-11	34437-34439	of	_	
201-12	34440-34443	the	_	
201-13	34444-34454	manuscript	_	
201-14	34455-34458	for	_	
201-15	34459-34468	important	_	
201-16	34469-34481	intellectual	_	
201-17	34482-34489	content	_	
201-18	34489-34490	.	_	

#Text=All authors critically reviewed the content and approved the final version for publication.
202-1	34491-34494	All	_	
202-2	34495-34502	authors	_	
202-3	34503-34513	critically	_	
202-4	34514-34522	reviewed	_	
202-5	34523-34526	the	_	
202-6	34527-34534	content	_	
202-7	34535-34538	and	_	
202-8	34539-34547	approved	_	
202-9	34548-34551	the	_	
202-10	34552-34557	final	_	
202-11	34558-34565	version	_	
202-12	34566-34569	for	_	
202-13	34570-34581	publication	_	
202-14	34581-34582	.	_	

#Text=Supporting information
#Text=References
#Text=Unified segmentation
#Text=EMOTICOM: a neuropsychological test battery to evaluate emotion, motivation, impulsivity, and social cognition
#Text=Neural substrates of resisting craving during cigarette cue exposure
#Text=Amygdala mechanisms of Pavlovian psychostimulant conditioning and relapse
#Text=The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta‐analysis
#Text=Limbic activation during cue‐induced cocaine craving
#Text=The general and outcome‐specific forms of Pavlovian‐instrumental transfer are differentially mediated by the nucleus accumbens core and shell
#Text=The role of the nucleus accumbens in instrumental conditioning: Evidence of a functional dissociation between accumbens core and shell
#Text=Medial orbitofrontal cortex codes relative rather than absolute value of financial rewards in humans
#Text=Real‐time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use
#Text=Emotional processing in anterior cingulate and medial prefrontal cortex
#Text=Craving and substance use among patients with alcohol, tobacco, cannabis or heroin addiction: a comparison of substance‐ and person‐specific cues
#Text=Lofexidine, an {alpha}2‐receptor agonist for opioid detoxification
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Value, pleasure and choice in the ventral prefrontal cortex
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=
#Text=From circuits to behaviour in the amygdala
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Common biology of craving across legal and illegal drugs—a quantitative meta‐analysis of cue‐reactivity brain response
#Text=Acute effect of methadone maintenance dose on brain FMRI response to heroin‐related cues
#Text=Extended‐release naltrexone modulates brain response to drug cues in abstinent heroin‐dependent patients
#Text=Central amygdala extracellular signal‐regulated kinase signaling pathway is critical to incubation of opiate craving
#Text=Craving correlates with mesolimbic responses to heroin‐related cues in short‐term abstinence from heroin: an event‐related fMRI study
#Text=Addiction, a condition of compulsive behaviour?
203-1	34583-34593	Supporting	_	
203-2	34594-34605	information	_	
203-3	34606-34616	References	_	
203-4	34617-34624	Unified	_	
203-5	34625-34637	segmentation	_	
203-6	34638-34646	EMOTICOM	_	
203-7	34646-34647	:	_	
203-8	34648-34649	a	_	
203-9	34650-34668	neuropsychological	_	
203-10	34669-34673	test	_	
203-11	34674-34681	battery	_	
203-12	34682-34684	to	_	
203-13	34685-34693	evaluate	_	
203-14	34694-34701	emotion	_	
203-15	34701-34702	,	_	
203-16	34703-34713	motivation	_	
203-17	34713-34714	,	_	
203-18	34715-34726	impulsivity	_	
203-19	34726-34727	,	_	
203-20	34728-34731	and	_	
203-21	34732-34738	social	_	
203-22	34739-34748	cognition	_	
203-23	34749-34755	Neural	_	
203-24	34756-34766	substrates	_	
203-25	34767-34769	of	_	
203-26	34770-34779	resisting	_	
203-27	34780-34787	craving	_	
203-28	34788-34794	during	_	
203-29	34795-34804	cigarette	_	
203-30	34805-34808	cue	_	
203-31	34809-34817	exposure	_	
203-32	34818-34826	Amygdala	_	
203-33	34827-34837	mechanisms	_	
203-34	34838-34840	of	_	
203-35	34841-34850	Pavlovian	_	
203-36	34851-34866	psychostimulant	_	
203-37	34867-34879	conditioning	_	
203-38	34880-34883	and	_	
203-39	34884-34891	relapse	_	
203-40	34892-34895	The	_	
203-41	34896-34902	neural	_	
203-42	34903-34908	basis	_	
203-43	34909-34911	of	_	
203-44	34912-34916	drug	_	
203-45	34917-34925	stimulus	_	
203-46	34926-34936	processing	_	
203-47	34937-34940	and	_	
203-48	34941-34948	craving	_	
203-49	34948-34949	:	_	
203-50	34950-34952	an	_	
203-51	34953-34963	activation	_	
203-52	34964-34974	likelihood	_	
203-53	34975-34985	estimation	_	
203-54	34986-34999	meta‐analysis	_	
203-55	35000-35006	Limbic	_	
203-56	35007-35017	activation	_	
203-57	35018-35024	during	_	
203-58	35025-35036	cue‐induced	_	
203-59	35037-35044	cocaine	_	
203-60	35045-35052	craving	_	
203-61	35053-35056	The	_	
203-62	35057-35064	general	_	
203-63	35065-35068	and	_	
203-64	35069-35085	outcome‐specific	_	
203-65	35086-35091	forms	_	
203-66	35092-35094	of	_	
203-67	35095-35117	Pavlovian‐instrumental	_	
203-68	35118-35126	transfer	_	
203-69	35127-35130	are	_	
203-70	35131-35145	differentially	_	
203-71	35146-35154	mediated	_	
203-72	35155-35157	by	_	
203-73	35158-35161	the	_	
203-74	35162-35169	nucleus	_	
203-75	35170-35179	accumbens	_	
203-76	35180-35184	core	_	
203-77	35185-35188	and	_	
203-78	35189-35194	shell	_	
203-79	35195-35198	The	_	
203-80	35199-35203	role	_	
203-81	35204-35206	of	_	
203-82	35207-35210	the	_	
203-83	35211-35218	nucleus	_	
203-84	35219-35228	accumbens	_	
203-85	35229-35231	in	_	
203-86	35232-35244	instrumental	_	
203-87	35245-35257	conditioning	_	
203-88	35257-35258	:	_	
203-89	35259-35267	Evidence	_	
203-90	35268-35270	of	_	
203-91	35271-35272	a	_	
203-92	35273-35283	functional	_	
203-93	35284-35296	dissociation	_	
203-94	35297-35304	between	_	
203-95	35305-35314	accumbens	_	
203-96	35315-35319	core	_	
203-97	35320-35323	and	_	
203-98	35324-35329	shell	_	
203-99	35330-35336	Medial	_	
203-100	35337-35350	orbitofrontal	_	
203-101	35351-35357	cortex	_	
203-102	35358-35363	codes	_	
203-103	35364-35372	relative	_	
203-104	35373-35379	rather	_	
203-105	35380-35384	than	_	
203-106	35385-35393	absolute	_	
203-107	35394-35399	value	_	
203-108	35400-35402	of	_	
203-109	35403-35412	financial	_	
203-110	35413-35420	rewards	_	
203-111	35421-35423	in	_	
203-112	35424-35430	humans	_	
203-113	35431-35440	Real‐time	_	
203-114	35441-35451	electronic	_	
203-115	35452-35457	diary	_	
203-116	35458-35465	reports	_	
203-117	35466-35468	of	_	
203-118	35469-35472	cue	_	
203-119	35473-35481	exposure	_	
203-120	35482-35485	and	_	
203-121	35486-35490	mood	_	
203-122	35491-35493	in	_	
203-123	35494-35497	the	_	
203-124	35498-35503	hours	_	
203-125	35504-35510	before	_	
203-126	35511-35518	cocaine	_	
203-127	35519-35522	and	_	
203-128	35523-35529	heroin	_	
203-129	35530-35537	craving	_	
203-130	35538-35541	and	_	
203-131	35542-35545	use	_	
203-132	35546-35555	Emotional	_	
203-133	35556-35566	processing	_	
203-134	35567-35569	in	_	
203-135	35570-35578	anterior	_	
203-136	35579-35588	cingulate	_	
203-137	35589-35592	and	_	
203-138	35593-35599	medial	_	
203-139	35600-35610	prefrontal	_	
203-140	35611-35617	cortex	_	
203-141	35618-35625	Craving	_	
203-142	35626-35629	and	_	
203-143	35630-35639	substance	_	
203-144	35640-35643	use	_	
203-145	35644-35649	among	_	
203-146	35650-35658	patients	_	
203-147	35659-35663	with	_	
203-148	35664-35671	alcohol	_	
203-149	35671-35672	,	_	
203-150	35673-35680	tobacco	_	
203-151	35680-35681	,	_	
203-152	35682-35690	cannabis	_	
203-153	35691-35693	or	_	
203-154	35694-35700	heroin	_	
203-155	35701-35710	addiction	_	
203-156	35710-35711	:	_	
203-157	35712-35713	a	_	
203-158	35714-35724	comparison	_	
203-159	35725-35727	of	_	
203-160	35728-35737	substance	_	
203-161	35737-35738	‐	_	
203-162	35739-35742	and	_	
203-163	35743-35758	person‐specific	_	
203-164	35759-35763	cues	_	
203-165	35764-35774	Lofexidine	_	
203-166	35774-35775	,	_	
203-167	35776-35778	an	_	
203-168	35779-35780	{	_	
203-169	35780-35785	alpha	_	
203-170	35785-35786	}	_	
203-171	35786-35787	2	_	
203-172	35787-35788	‐	_	
203-173	35788-35796	receptor	_	
203-174	35797-35804	agonist	_	
203-175	35805-35808	for	_	
203-176	35809-35815	opioid	_	
203-177	35816-35830	detoxification	_	
203-178	35831-35842	Dysfunction	_	
203-179	35843-35845	of	_	
203-180	35846-35849	the	_	
203-181	35850-35860	prefrontal	_	
203-182	35861-35867	cortex	_	
203-183	35868-35870	in	_	
203-184	35871-35880	addiction	_	
203-185	35880-35881	:	_	
203-186	35882-35894	neuroimaging	_	
203-187	35895-35903	findings	_	
203-188	35904-35907	and	_	
203-189	35908-35916	clinical	_	
203-190	35917-35929	implications	_	
203-191	35930-35935	Value	_	
203-192	35935-35936	,	_	
203-193	35937-35945	pleasure	_	
203-194	35946-35949	and	_	
203-195	35950-35956	choice	_	
203-196	35957-35959	in	_	
203-197	35960-35963	the	_	
203-198	35964-35971	ventral	_	
203-199	35972-35982	prefrontal	_	
203-200	35983-35989	cortex	_	
203-201	35990-35993	The	_	
203-202	35994-36000	reward	_	
203-203	36001-36008	circuit	_	
203-204	36008-36009	:	_	
203-205	36010-36017	linking	_	
203-206	36018-36025	primate	_	
203-207	36026-36033	anatomy	_	
203-208	36034-36037	and	_	
203-209	36038-36043	human	_	
203-210	36044-36051	imaging	_	
203-211	36053-36057	From	_	
203-212	36058-36066	circuits	_	
203-213	36067-36069	to	_	
203-214	36070-36079	behaviour	_	
203-215	36080-36082	in	_	
203-216	36083-36086	the	_	
203-217	36087-36095	amygdala	_	
203-218	36096-36103	Factors	_	
203-219	36104-36114	modulating	_	
203-220	36115-36121	neural	_	
203-221	36122-36132	reactivity	_	
203-222	36133-36135	to	_	
203-223	36136-36140	drug	_	
203-224	36141-36145	cues	_	
203-225	36146-36148	in	_	
203-226	36149-36158	addiction	_	
203-227	36158-36159	:	_	
203-228	36160-36161	a	_	
203-229	36162-36168	survey	_	
203-230	36169-36171	of	_	
203-231	36172-36177	human	_	
203-232	36178-36190	neuroimaging	_	
203-233	36191-36198	studies	_	
203-234	36199-36205	Common	_	
203-235	36206-36213	biology	_	
203-236	36214-36216	of	_	
203-237	36217-36224	craving	_	
203-238	36225-36231	across	_	
203-239	36232-36237	legal	_	
203-240	36238-36241	and	_	
203-241	36242-36249	illegal	_	
203-242	36250-36257	drugs—a	_	
203-243	36258-36270	quantitative	_	
203-244	36271-36284	meta‐analysis	_	
203-245	36285-36287	of	_	
203-246	36288-36302	cue‐reactivity	_	
203-247	36303-36308	brain	_	
203-248	36309-36317	response	_	
203-249	36318-36323	Acute	_	
203-250	36324-36330	effect	_	
203-251	36331-36333	of	_	
203-252	36334-36343	methadone	_	
203-253	36344-36355	maintenance	_	
203-254	36356-36360	dose	_	
203-255	36361-36363	on	_	
203-256	36364-36369	brain	_	
203-257	36370-36374	FMRI	_	
203-258	36375-36383	response	_	
203-259	36384-36386	to	_	
203-260	36387-36401	heroin‐related	_	
203-261	36402-36406	cues	_	
203-262	36407-36423	Extended‐release	_	
203-263	36424-36434	naltrexone	_	
203-264	36435-36444	modulates	_	
203-265	36445-36450	brain	_	
203-266	36451-36459	response	_	
203-267	36460-36462	to	_	
203-268	36463-36467	drug	_	
203-269	36468-36472	cues	_	
203-270	36473-36475	in	_	
203-271	36476-36485	abstinent	_	
203-272	36486-36502	heroin‐dependent	_	
203-273	36503-36511	patients	_	
203-274	36512-36519	Central	_	
203-275	36520-36528	amygdala	_	
203-276	36529-36542	extracellular	_	
203-277	36543-36559	signal‐regulated	_	
203-278	36560-36566	kinase	_	
203-279	36567-36576	signaling	_	
203-280	36577-36584	pathway	_	
203-281	36585-36587	is	_	
203-282	36588-36596	critical	_	
203-283	36597-36599	to	_	
203-284	36600-36610	incubation	_	
203-285	36611-36613	of	_	
203-286	36614-36620	opiate	_	
203-287	36621-36628	craving	_	
203-288	36629-36636	Craving	_	
203-289	36637-36647	correlates	_	
203-290	36648-36652	with	_	
203-291	36653-36663	mesolimbic	_	
203-292	36664-36673	responses	_	
203-293	36674-36676	to	_	
203-294	36677-36691	heroin‐related	_	
203-295	36692-36696	cues	_	
203-296	36697-36699	in	_	
203-297	36700-36710	short‐term	_	
203-298	36711-36721	abstinence	_	
203-299	36722-36726	from	_	
203-300	36727-36733	heroin	_	
203-301	36733-36734	:	_	
203-302	36735-36737	an	_	
203-303	36738-36751	event‐related	_	
203-304	36752-36756	fMRI	_	
203-305	36757-36762	study	_	
203-306	36763-36772	Addiction	_	
203-307	36772-36773	,	_	
203-308	36774-36775	a	_	
203-309	36776-36785	condition	_	
203-310	36786-36788	of	_	
203-311	36789-36799	compulsive	_	
203-312	36800-36809	behaviour	_	
203-313	36809-36810	?	_	

#Text=Neuroimaging and neuropsychological evidence of inhibitory dysregulation
#Text=Assessing craving and its relationship to subsequent prescription opioid use among treatment‐seeking prescription opioid dependent patients
#Text=Acute effects of sublingual buprenorphine on brain responses to heroin‐related cues in early‐abstinent heroin addicts: an uncontrolled trial
#Text=Ecological momentary assessment of the effects of craving and affect on risk for relapse during substance abuse treatment
#Text=Dissociable roles of ventral and dorsal striatum in instrumental conditioning
#Text=The assessment and analysis of handedness: the Edinburgh inventory
#Text=A new perspective on the role of the orbitofrontal cortex in adaptive behaviour
#Text=The role of the amygdala in emotional processing: a quantitative meta‐analysis of functional neuroimaging studies
#Text=The Mini‐International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10
#Text=The expected value of control: an integrative theory of anterior cingulate cortex function
#Text=Human dorsal anterior cingulate cortex neurons mediate ongoing behavioural adaptation
#Text=Effects of lofexidine on stress‐induced and cue‐induced opioid craving and opioid abstinence rates: preliminary findings
#Text=Modafinil modulates anterior cingulate function in chronic schizophrenia
#Text=The clinical significance of drug craving
#Text=Smoking‐related videos for use in cue‐induced craving paradigms
#Text=Psychiatric comorbidity in illicit drug users: substance‐induced versus independent disorders
#Text=Treatment or “high”: benzodiazepine use in patients on injectable heroin or oral opioids
#Text=Cognitive control of drug craving inhibits brain reward regions in cocaine abusers
#Text=Brain fMRI and craving response to heroin‐related cues in patients on methadone maintenance treatment
#Text=The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use
#Text=The effectiveness of compulsory drug treatment: a systematic review
#Text=Functional magnetic resonance imaging of cocaine craving
#Text=Differential prefrontal cortex and amygdala habituation to repeatedly presented emotional stimuli
#Text=A memory retrieval‐extinction procedure to prevent drug craving and relapse
#Text=Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention
#Text=A combined spectroscopic and functional MRI investigation of the dorsal anterior cingulate region in opiate addiction
#Text=The role of dorsal anterior cingulate cortex in the regulation of craving by reappraisal in smokers
#Text=Neurobiological substrates of cue‐elicited craving and anhedonia in recently abstinent opioid‐dependent males
204-1	36811-36823	Neuroimaging	_	
204-2	36824-36827	and	_	
204-3	36828-36846	neuropsychological	_	
204-4	36847-36855	evidence	_	
204-5	36856-36858	of	_	
204-6	36859-36869	inhibitory	_	
204-7	36870-36883	dysregulation	_	
204-8	36884-36893	Assessing	_	
204-9	36894-36901	craving	_	
204-10	36902-36905	and	_	
204-11	36906-36909	its	_	
204-12	36910-36922	relationship	_	
204-13	36923-36925	to	_	
204-14	36926-36936	subsequent	_	
204-15	36937-36949	prescription	_	
204-16	36950-36956	opioid	_	
204-17	36957-36960	use	_	
204-18	36961-36966	among	_	
204-19	36967-36984	treatment‐seeking	_	
204-20	36985-36997	prescription	_	
204-21	36998-37004	opioid	_	
204-22	37005-37014	dependent	_	
204-23	37015-37023	patients	_	
204-24	37024-37029	Acute	_	
204-25	37030-37037	effects	_	
204-26	37038-37040	of	_	
204-27	37041-37051	sublingual	_	
204-28	37052-37065	buprenorphine	_	
204-29	37066-37068	on	_	
204-30	37069-37074	brain	_	
204-31	37075-37084	responses	_	
204-32	37085-37087	to	_	
204-33	37088-37102	heroin‐related	_	
204-34	37103-37107	cues	_	
204-35	37108-37110	in	_	
204-36	37111-37126	early‐abstinent	_	
204-37	37127-37133	heroin	_	
204-38	37134-37141	addicts	_	
204-39	37141-37142	:	_	
204-40	37143-37145	an	_	
204-41	37146-37158	uncontrolled	_	
204-42	37159-37164	trial	_	
204-43	37165-37175	Ecological	_	
204-44	37176-37185	momentary	_	
204-45	37186-37196	assessment	_	
204-46	37197-37199	of	_	
204-47	37200-37203	the	_	
204-48	37204-37211	effects	_	
204-49	37212-37214	of	_	
204-50	37215-37222	craving	_	
204-51	37223-37226	and	_	
204-52	37227-37233	affect	_	
204-53	37234-37236	on	_	
204-54	37237-37241	risk	_	
204-55	37242-37245	for	_	
204-56	37246-37253	relapse	_	
204-57	37254-37260	during	_	
204-58	37261-37270	substance	_	
204-59	37271-37276	abuse	_	
204-60	37277-37286	treatment	_	
204-61	37287-37298	Dissociable	_	
204-62	37299-37304	roles	_	
204-63	37305-37307	of	_	
204-64	37308-37315	ventral	_	
204-65	37316-37319	and	_	
204-66	37320-37326	dorsal	_	
204-67	37327-37335	striatum	_	
204-68	37336-37338	in	_	
204-69	37339-37351	instrumental	_	
204-70	37352-37364	conditioning	_	
204-71	37365-37368	The	_	
204-72	37369-37379	assessment	_	
204-73	37380-37383	and	_	
204-74	37384-37392	analysis	_	
204-75	37393-37395	of	_	
204-76	37396-37406	handedness	_	
204-77	37406-37407	:	_	
204-78	37408-37411	the	_	
204-79	37412-37421	Edinburgh	_	
204-80	37422-37431	inventory	_	
204-81	37432-37433	A	_	
204-82	37434-37437	new	_	
204-83	37438-37449	perspective	_	
204-84	37450-37452	on	_	
204-85	37453-37456	the	_	
204-86	37457-37461	role	_	
204-87	37462-37464	of	_	
204-88	37465-37468	the	_	
204-89	37469-37482	orbitofrontal	_	
204-90	37483-37489	cortex	_	
204-91	37490-37492	in	_	
204-92	37493-37501	adaptive	_	
204-93	37502-37511	behaviour	_	
204-94	37512-37515	The	_	
204-95	37516-37520	role	_	
204-96	37521-37523	of	_	
204-97	37524-37527	the	_	
204-98	37528-37536	amygdala	_	
204-99	37537-37539	in	_	
204-100	37540-37549	emotional	_	
204-101	37550-37560	processing	_	
204-102	37560-37561	:	_	
204-103	37562-37563	a	_	
204-104	37564-37576	quantitative	_	
204-105	37577-37590	meta‐analysis	_	
204-106	37591-37593	of	_	
204-107	37594-37604	functional	_	
204-108	37605-37617	neuroimaging	_	
204-109	37618-37625	studies	_	
204-110	37626-37629	The	_	
204-111	37630-37648	Mini‐International	_	
204-112	37649-37665	Neuropsychiatric	_	
204-113	37666-37675	Interview	_	
204-114	37676-37677	(	_	
204-115	37677-37684	M.I.N.I	_	
204-116	37684-37685	.	_	
204-117	37685-37686	)	_	
204-118	37686-37687	:	_	
204-119	37688-37691	the	_	
204-120	37692-37703	development	_	
204-121	37704-37707	and	_	
204-122	37708-37718	validation	_	
204-123	37719-37721	of	_	
204-124	37722-37723	a	_	
204-125	37724-37734	structured	_	
204-126	37735-37745	diagnostic	_	
204-127	37746-37757	psychiatric	_	
204-128	37758-37767	interview	_	
204-129	37768-37771	for	_	
204-130	37772-37778	DSM‐IV	_	
204-131	37779-37782	and	_	
204-132	37783-37786	ICD	_	
204-133	37786-37787	‐	_	
204-134	37787-37789	10	_	
204-135	37790-37793	The	_	
204-136	37794-37802	expected	_	
204-137	37803-37808	value	_	
204-138	37809-37811	of	_	
204-139	37812-37819	control	_	
204-140	37819-37820	:	_	
204-141	37821-37823	an	_	
204-142	37824-37835	integrative	_	
204-143	37836-37842	theory	_	
204-144	37843-37845	of	_	
204-145	37846-37854	anterior	_	
204-146	37855-37864	cingulate	_	
204-147	37865-37871	cortex	_	
204-148	37872-37880	function	_	
204-149	37881-37886	Human	_	
204-150	37887-37893	dorsal	_	
204-151	37894-37902	anterior	_	
204-152	37903-37912	cingulate	_	
204-153	37913-37919	cortex	_	
204-154	37920-37927	neurons	_	
204-155	37928-37935	mediate	_	
204-156	37936-37943	ongoing	_	
204-157	37944-37955	behavioural	_	
204-158	37956-37966	adaptation	_	
204-159	37967-37974	Effects	_	
204-160	37975-37977	of	_	
204-161	37978-37988	lofexidine	_	
204-162	37989-37991	on	_	
204-163	37992-38006	stress‐induced	_	
204-164	38007-38010	and	_	
204-165	38011-38022	cue‐induced	_	
204-166	38023-38029	opioid	_	
204-167	38030-38037	craving	_	
204-168	38038-38041	and	_	
204-169	38042-38048	opioid	_	
204-170	38049-38059	abstinence	_	
204-171	38060-38065	rates	_	
204-172	38065-38066	:	_	
204-173	38067-38078	preliminary	_	
204-174	38079-38087	findings	_	
204-175	38088-38097	Modafinil	_	
204-176	38098-38107	modulates	_	
204-177	38108-38116	anterior	_	
204-178	38117-38126	cingulate	_	
204-179	38127-38135	function	_	
204-180	38136-38138	in	_	
204-181	38139-38146	chronic	_	
204-182	38147-38160	schizophrenia	_	
204-183	38161-38164	The	_	
204-184	38165-38173	clinical	_	
204-185	38174-38186	significance	_	
204-186	38187-38189	of	_	
204-187	38190-38194	drug	_	
204-188	38195-38202	craving	_	
204-189	38203-38218	Smoking‐related	_	
204-190	38219-38225	videos	_	
204-191	38226-38229	for	_	
204-192	38230-38233	use	_	
204-193	38234-38236	in	_	
204-194	38237-38248	cue‐induced	_	
204-195	38249-38256	craving	_	
204-196	38257-38266	paradigms	_	
204-197	38267-38278	Psychiatric	_	
204-198	38279-38290	comorbidity	_	
204-199	38291-38293	in	_	
204-200	38294-38301	illicit	_	
204-201	38302-38306	drug	_	
204-202	38307-38312	users	_	
204-203	38312-38313	:	_	
204-204	38314-38331	substance‐induced	_	
204-205	38332-38338	versus	_	
204-206	38339-38350	independent	_	
204-207	38351-38360	disorders	_	
204-208	38361-38370	Treatment	_	
204-209	38371-38373	or	_	
204-210	38374-38375	“	_	
204-211	38375-38379	high	_	
204-212	38379-38380	”	_	
204-213	38380-38381	:	_	
204-214	38382-38396	benzodiazepine	_	
204-215	38397-38400	use	_	
204-216	38401-38403	in	_	
204-217	38404-38412	patients	_	
204-218	38413-38415	on	_	
204-219	38416-38426	injectable	_	
204-220	38427-38433	heroin	_	
204-221	38434-38436	or	_	
204-222	38437-38441	oral	_	
204-223	38442-38449	opioids	_	
204-224	38450-38459	Cognitive	_	
204-225	38460-38467	control	_	
204-226	38468-38470	of	_	
204-227	38471-38475	drug	_	
204-228	38476-38483	craving	_	
204-229	38484-38492	inhibits	_	
204-230	38493-38498	brain	_	
204-231	38499-38505	reward	_	
204-232	38506-38513	regions	_	
204-233	38514-38516	in	_	
204-234	38517-38524	cocaine	_	
204-235	38525-38532	abusers	_	
204-236	38533-38538	Brain	_	
204-237	38539-38543	fMRI	_	
204-238	38544-38547	and	_	
204-239	38548-38555	craving	_	
204-240	38556-38564	response	_	
204-241	38565-38567	to	_	
204-242	38568-38582	heroin‐related	_	
204-243	38583-38587	cues	_	
204-244	38588-38590	in	_	
204-245	38591-38599	patients	_	
204-246	38600-38602	on	_	
204-247	38603-38612	methadone	_	
204-248	38613-38624	maintenance	_	
204-249	38625-38634	treatment	_	
204-250	38635-38638	The	_	
204-251	38639-38651	relationship	_	
204-252	38652-38659	between	_	
204-253	38660-38667	cocaine	_	
204-254	38668-38675	craving	_	
204-255	38675-38676	,	_	
204-256	38677-38689	psychosocial	_	
204-257	38690-38699	treatment	_	
204-258	38699-38700	,	_	
204-259	38701-38704	and	_	
204-260	38705-38715	subsequent	_	
204-261	38716-38723	cocaine	_	
204-262	38724-38727	use	_	
204-263	38728-38731	The	_	
204-264	38732-38745	effectiveness	_	
204-265	38746-38748	of	_	
204-266	38749-38759	compulsory	_	
204-267	38760-38764	drug	_	
204-268	38765-38774	treatment	_	
204-269	38774-38775	:	_	
204-270	38776-38777	a	_	
204-271	38778-38788	systematic	_	
204-272	38789-38795	review	_	
204-273	38796-38806	Functional	_	
204-274	38807-38815	magnetic	_	
204-275	38816-38825	resonance	_	
204-276	38826-38833	imaging	_	
204-277	38834-38836	of	_	
204-278	38837-38844	cocaine	_	
204-279	38845-38852	craving	_	
204-280	38853-38865	Differential	_	
204-281	38866-38876	prefrontal	_	
204-282	38877-38883	cortex	_	
204-283	38884-38887	and	_	
204-284	38888-38896	amygdala	_	
204-285	38897-38908	habituation	_	
204-286	38909-38911	to	_	
204-287	38912-38922	repeatedly	_	
204-288	38923-38932	presented	_	
204-289	38933-38942	emotional	_	
204-290	38943-38950	stimuli	_	
204-291	38951-38952	A	_	
204-292	38953-38959	memory	_	
204-293	38960-38980	retrieval‐extinction	_	
204-294	38981-38990	procedure	_	
204-295	38991-38993	to	_	
204-296	38994-39001	prevent	_	
204-297	39002-39006	drug	_	
204-298	39007-39014	craving	_	
204-299	39015-39018	and	_	
204-300	39019-39026	relapse	_	
204-301	39027-39041	Neurocognitive	_	
204-302	39042-39045	and	_	
204-303	39046-39058	neuroimaging	_	
204-304	39059-39067	evidence	_	
204-305	39068-39070	of	_	
204-306	39071-39082	behavioural	_	
204-307	39083-39096	dysregulation	_	
204-308	39097-39099	in	_	
204-309	39100-39105	human	_	
204-310	39106-39110	drug	_	
204-311	39111-39120	addiction	_	
204-312	39120-39121	:	_	
204-313	39122-39134	implications	_	
204-314	39135-39138	for	_	
204-315	39139-39148	diagnosis	_	
204-316	39148-39149	,	_	
204-317	39150-39159	treatment	_	
204-318	39160-39163	and	_	
204-319	39164-39174	prevention	_	
204-320	39175-39176	A	_	
204-321	39177-39185	combined	_	
204-322	39186-39199	spectroscopic	_	
204-323	39200-39203	and	_	
204-324	39204-39214	functional	_	
204-325	39215-39218	MRI	_	
204-326	39219-39232	investigation	_	
204-327	39233-39235	of	_	
204-328	39236-39239	the	_	
204-329	39240-39246	dorsal	_	
204-330	39247-39255	anterior	_	
204-331	39256-39265	cingulate	_	
204-332	39266-39272	region	_	
204-333	39273-39275	in	_	
204-334	39276-39282	opiate	_	
204-335	39283-39292	addiction	_	
204-336	39293-39296	The	_	
204-337	39297-39301	role	_	
204-338	39302-39304	of	_	
204-339	39305-39311	dorsal	_	
204-340	39312-39320	anterior	_	
204-341	39321-39330	cingulate	_	
204-342	39331-39337	cortex	_	
204-343	39338-39340	in	_	
204-344	39341-39344	the	_	
204-345	39345-39355	regulation	_	
204-346	39356-39358	of	_	
204-347	39359-39366	craving	_	
204-348	39367-39369	by	_	
204-349	39370-39381	reappraisal	_	
204-350	39382-39384	in	_	
204-351	39385-39392	smokers	_	
204-352	39393-39408	Neurobiological	_	
204-353	39409-39419	substrates	_	
204-354	39420-39422	of	_	
204-355	39423-39435	cue‐elicited	_	
204-356	39436-39443	craving	_	
204-357	39444-39447	and	_	
204-358	39448-39457	anhedonia	_	
204-359	39458-39460	in	_	
204-360	39461-39469	recently	_	
204-361	39470-39479	abstinent	_	
204-362	39480-39496	opioid‐dependent	_	
204-363	39497-39502	males	_	
